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ABSTRACT 
 
Type II diabetes is fast becoming a growing problem in developed countries worldwide. 
Traditionally the median age for diagnosis was around sixty, but recent surveys have 
shown that the entire age distribution curve has shifted to the left. Western countries 
boast the worst statistics in which type II diabetes is being reported in children under the 
age of ten. At such a young age the disease often goes undiagnosed for long periods of 
time allowing considerable damage to occur. The incidence of type II diabetes is thought 
to be parallel with the growing rate of obesity associated with a characteristically 
unhealthy western diet. 
 
Type II diabetes is an extremely expensive disease to manage, and with the rapid growth 
of this pandemic our country will soon feel the economic burden of this disease. It is for 
this reason that cheaper medication needs to be investigated in the form of traditional 
plants, such as Sutherlandia frutescens. 
 
Prescription medication, such as tricyclic antidepressants, may also increase body weight 
or appetite thereby playing a role in obesity. The cause of weight gain in such cases may 
go unrecognized or lead to cessation of the medication with or without the practitioner’s 
knowledge or approval. It is therefore necessary to investigate the causative agents 
responsible for the excessive weight gain.  
 
Drinking water containing extracts of the S. frutescens, metformin (a well known type II 
diabetes medication) and amitriptyline (a common tricyclic antidepressant) was 
administered to three groups of ten male Wistar rats. The control group received water 
without any medication. The rat’s weight and food consumption was monitored 
throughout the trial and their oxygen consumption was also determined. Rats were 
sacrificed after four months of medicinal compliance and glucose uptake, in the presence 
and absence of insulin, was tested in epididymal fat, liver and muscle. Fasting plasma 
glucose levels, lipoprotein, cholesterol and triglyceride concentrations were also 
determined. 
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CHAPTER 1 
REVIEW OF LITERATURE 
 
1.1 OBESITY: A RISK FACTOR FOR LATE ONSET TYPE II DIABETES 
MELLITUS 
1.2 INSULIN: A CLOSER LOOK INTO THE FORMATION, 
STRUCTURE, FUNCTION, AND DEGRADATION OF THIS 
MULTIFUNCTIONAL HORMONE 
1.3 DIABETES MELLITUS: CLASSIFICATION, SYMPTOMS, 
PREVENTION, AND TRREATMENT OF THIS FAST GROWING 
PANDEMIC 
1.4 ATP SENSITIVE POTASSSIUM (KATP) CHANNELS: STRUCTURE, 
FUNCTION, AND REGULATION THEREOF 
1.5 DEPRESSION AND AMITRIPTYLINE: THE IMPORTANCE OF 
BIOGENIC AMINES AND THEORIES OF EXCESS WEIGHT GAIN 
ASSOCIATED WITH AMITRIPTYLINE COMPLIANCE 
1.6 TISSUES CONCENTRATED ON THROUGHOUT THE PROJECT: 
LIVER, MUSCLE, AND ADIPOSE TISSUE 
 
1.1. OBESITY: A RISK FACTOR FOR LATE ONSET TYPE II DIABETES 
MELLITUS 
 
1.1.1. Introduction 
 
The enormous economic and health cost associated with obesity places it among the 
most pressing health care problems facing the westernised world to date. The United 
States and many other countries are facing an epidemic of insulin resistance, an 
evolving cardiovascular disease risk factor. This arises in the setting of a marked 
increase in the number of individuals diagnosed with type II diabetes and a dramatic 
increase in obesity. These trends are expected to increase throughout the next half 
century if serious actions are not undertaken (Case et al., 2002). 
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1.1.2. Criteria for Obesity 
 
Body mass index (BMI) is the cornerstone of the current classification system for 
obesity and its advantages are widely exploited across disciplines ranging from 
international surveillance to individual patient assessment (Prentice and Jebb, 2001). 
Body mass index is a measure of an individuals weight (kg)/height (m2). Health risks 
associated with obesity begin in the range of 25 to 30kg/m2. Values above 40kg/m2  
indicate severe obesity (Williams, 1997). 
 
Body mass index is, however, only a surrogate measurement of body fatness while 
obesity is defined as an excess accumulation of body fat, and it is the amount of this 
excess fat that correlates with ill health. A wide range of conditions supporting this 
argument have been put forward which may provide misleading information about 
body fat content. These include infancy and childhood, ageing, racial differences, 
athletes, military and civil forces personnel, weight loss with or without exercise, 
physical training and special clinical circumstances (Prentice and Jebb, 2001).  
 
A more practical way of identifying obesity is through the use of the metabolic 
syndrome. The metabolic syndrome is a clustering of risk factors such as plasma 
triglycerides, high density lipoprotein cholesterol, blood pressure and abdominal 
obesity defined by the National Cholesterol Education Program (NCEP). These are 
serious cardiovascular risk factors and are closely associated with insulin resistance. 
Epidemiological studies have shown that individuals with the metabolic syndrome 
and insulin resistance have a threefold increase in cardiovascular disease and a 
significant increase in cardiovascular mortality (Case et al., 2002). 
 
Case et al. (2002) showed (in his studies) that individuals tend to be more obese as 
the number of metabolic syndrome components increased. They also showed that 
obesity and weight loss were statistically significantly related to the baseline and 
changes in components of the metabolic syndrome. The study suggested that a very 
low calorie diet induced weight loss in individuals with the metabolic syndrome 
resulted in substantial reductions of systolic and diastolic blood pressure, plasma 
glucose, triglycerides and total cholesterol after four weeks. These results occurred 
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despite the persistence of a significantly elevated body mass index. The weight loss 
continued along with further significant reductions in blood pressure and triglycerides 
until the individuals no longer met the criteria for the metabolic syndrome (Case et 
al., 2002). This study displayed that a very low calorie diet is associated with a 
greater initial weight loss and active weight maintenance programme. 
 
1.1.3. Who is to Blame? 
 
The factors that contribute to excessive weight gain in humans are widespread and 
mostly unknown. This accounts for the fact that present treatments intended to 
produce a long-term reduction in body weight are largely ineffective (Clement, 1999). 
Obesity is not considered to be the result of a single genetic anomaly but instead is 
thought to depend on interactions between the following: 
 
· Environmental and physiological factors  
 
This includes physical activity, eating habits, social and cultural habits. Increases 
in the rate of childhood overweight are of particular concern due to the negative 
health and physiological effects noted among overweight children. The 
development of childhood overweight involves a complex set of factors from 
multiple contexts that interact with each other to place a child at risk of 
overweight. This multifaceted system can be conceptualised using Ecological 
Systems Theory (EST).  This system highlights the importance of considering the 
context, or ecological niche, in which a person is located in order to understand 
the emergence of a particular characteristic.  In the case of a child this ecological 
niche includes the family and the school, which in turn are embedded in larger 
social contexts including the community and society at large (Davison and Birch, 
2001). 
 
Specific characteristics which place an individual at risk of the development of 
obesity include: dietary intake, lack of physical activity and sedentary behaviour. 
Increases in cases of obesity are also a reflection in lifestyle changes brought 
about by the mechanisation of modern life (Vass, 2002). Hanely et al. (2000) 
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showed that increased television viewing was associated with a significant higher 
risk of becoming overweight. 
 
It is evident that the fast pace of today’s society leaves no room for healthy living, 
or does it? It seems more likely that man is becoming lazy, preferring to consume 
fast foods, exercise less, and favouring to drive to his/her destination.      
 
· Genetic and hormonal factors 
 
Although overeating and a decreased physical activity all contribute to obesity 
recent research strongly indicates that hereditary factors could be of equal 
importance for the development of both obesity and obesity complications. 
During the last decade, a continuously increasing interest has been focused on 
identifying genes that contribute to obesity and type II diabetes in humans, and 
the mode of action of these genes (Lonnqvist et al., 1999). 
 
It has long been postulated that secondary to overeating, the storage of additional 
fat will give signals to the brain that the body is obese, which in turn makes the 
subject eat less and burn more fuel. The discovery of such a determinator, leptin, 
and its receptor has therefore opened new avenues for obesity research. Both are 
parts of a complex lipostatic hormonal feedback loop regulating body fat stores 
through effects on both satiety and energy expenditure (Lonnqvist et al., 1999). 
 
Leptin is encoded by the ob gene, which is expressed exclusively in white and 
brown adipose tissue. Under normal conditions leptin mRNA levels correlate with 
the amount of body fat. The ob gene contains three exons; the coding sequence 
spans the last two exons and is interrupted by a 2kb intronic sequence. The major 
transcription of the human ob gene is a 4.5kb mRNA containing a long 3’-
untranslated region. The 167 amino acid protein leptin is well conserved between 
species. The leptin receptor is, in turn encoded by the db gene (Clement, 1999). 
 
Except in very rare monogenic cases leading to disruption of the leptin axis in 
humans, genetic studies have shown that ob and db loci do not have a major role 
in common forms of human obesity for a large proportion of the population. 
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However, the results of linkage and association studies with the ob and db genes 
do not exclude a minor role for these genes in the development of obesity. The 
polygenic nature of human obesity means that the presence of susceptibility 
alleles of numerous genes could increase the probability that the bearer develops 
obesity. The presence of the genetic variation is not enough to explain the 
expression of the disorder, but rather interacts with other genetic, metabolic or 
environmental factors. Mutations associated with the peroxisome proliferator 
activated receptor (PPAR) family could also play a role in the development of 
human obesity  (Clement, 1999). 
 
1.1.4. Treatment of Obesity and Maintenance of a Desirable Weight 
 
The first goal of a patient with excess weight should be to prevent further weight 
increase, then to lose a modest amount on a twelve week structured programme which 
includes diets, physical activity, and behavioural modification followed by a further 
twelve week programme for weight maintenance to allow for stabilisation of the 
energy balance (MIMS, 2000). Weight management programs make use of one or 
more of the following criteria: 
 
Diet: 
 
Very low calorie diets, providing 400 to 800 kcal/day, have become less popular 
as many patients seem to regain all the weight they have lost shortly after the diet. 
The energy profile of any diet should obtain less than 35% of the energy from fat, 
and 10-15% from protein; however a protein intake of 70g/day in elderly 
individuals is desirable. When calorie intake exceeds that expended, excess fat 
intake is stored as fat, whereas excess carbohydrate is mainly oxidised in the short 
term but can lead to substantial gain in fat stores because of the reduced fat 
oxidation and considerable new fat formation in the long term (MIMS, 2000). 
 
Exercise: 
 
A more active life-style should be adopted, including a daily cumulative thirty 
minutes or more of moderate-intensity activity (MIMS, 2000). 
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Pharmacotherapy: 
 
This treatment is only recommended to patients with high risk obesity and who 
have not managed to reduce their body weight by adaptations to their lifestyle 
alone. If such drugs are required then their use should be considered for long-term 
administration, similar to the current practice with drugs used for other chronic 
diseases. Over the counter drugs are generally harmless, questionably ineffective, 
and best avoided (MIMS, 2000). 
 
Surgical options: 
 
Vertical banded gastroplast is recommended for the morbidly obese individuals 
(BMI>40) with high co-morbid risk factors (MIMS, 2000). 
 
1.1.5. Motivation 
 
Obesity is the gateway to many metabolic disorders including cardiovascular disease, 
type II diabetes, hypertension, gallbladder disease and stroke. This alone makes 
obesity an extremely expensive disorder, an economic burden many individuals 
cannot cope with.  
 
The rapid onset of obesity in South Africa is associated with a rapid increase in 
insulin resistance and cardiovascular disease brought about by the westernised way of 
living in rural areas. Although the adoption of a westernised culture is the main 
instigator certain genetic factors may be to blame, in some cases, and certain 
prescription medication may also cause excessive weight gain. The fact remains that 
insulin resistance associated with type II diabetes is a fast growing pandemic in 
Southern Africa, placing a large economic burden on the government for overpriced 
medication. It is for this reason that new avenues need to be investigated, including 
the potential use of traditional medicine. This may relieve the economic burden and 
open opportunities for export of an indigenous medication against type II diabetes. 
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1.2. INSULIN: A CLOSER LOOK INTO THE FORMATION, STRUCTURE, 
FUNCTION, AND DEGRADATION OF THIS MULTIFUNCTIONAL 
HORMONE 
 
1.2.1. Structural Detail of Insulin  
 
Insulin is a polypeptide hormone produced in the pancreatic beta cells in the islets of 
Langerhans. It is a small protein with a molecular weight of 5700, which is released 
in response to increased glucose levels in the blood. It consists of two polypeptide 
chains, namely A and B which are then joined by two disulfide bonds (Lehninger et 
al., 2000), see figure 1.1. 
 
 
Figure 1.1: The amino acid sequence of the two chains of human insulin, joined by disulfide 
bridges (taken from Ganong , 1993) 
 
The structures of mouse and rat insulins are identical, however, there is a slight 
divergence in comparison to the A and B chains of the human insulin structure. On 
the A chain it has been found that Glu has been replaced by Asp at position 4, for 
mouse insulin, while three changes are apparent on the B chain of human insulin at 
positions 3, 9, and 30, which are Lys replacing Asn, Phe replacing Ser, and Ser 
replacing Thr respectively (Beintema and Campagne, 1987). Despite these four 
changes setting these two almost identical hormones apart, their role and function 
within the body appears to be exactly the same.   
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1.2.2. Insulin, the Initiation of its Being 
 
In adult mammals the insulin gene is expressed solely in the pancreatic beta cells. The 
beta cells specific expression is controlled by transcriptional enhancer and promoter 
sequence elements in the 5' flanking DNA of the gene (Flatt, 1992). 
The initial translational product of this gene is pre-proinsulin, which consists of an N-
terminal signal peptide linked to proinsulin. Like most nascent secretory proteins, 
translocation of pre-proinsulin across the rough endoplasmic reticulum membrane 
commences by interaction of the signal sequence with the 54kDa polypeptide 
component of the signal recognition particle, an event which retards further 
elongation of the peptide chain  (Flatt, 1992). 
  
The association of this complex with the rough endoplasmic reticulum membrane is 
mediated by the affinity of the signal recognition particle for the signal recognition 
receptor, also known as the docking protein. This interaction then promotes the 
release of the signal recognition particle from both the ribosome and the signal 
sequence, which is then transferred to the signal sequence receptor, a glycosylated, 
integral membrane protein (Flatt, 1992).  
 
1.2.3. Formation and Packaging of Insulin  
 
Insulin is synthesized in the pancreatic beta cells as an inactive single-chain 
precursor, preproinsulin with an amino terminal “signal sequence” that directs its 
passage into secretory vesicles (Lehninger et al., 2000). The signal sequence, which 
consists of 23 amino acids, is proteolytically removed at the amino terminus of the 
pre-proinsulin and the formation of three disulfide bonds produces proinsulin, see 
figure 1.2. Proinsulin is then transported through the cisternae of the endoplasmic 
reticulum to the Golgi complex for packaging into secretory granules. The proinsulin 
is then converted into insulin, through the proteolytic cleavage of the C-peptide, all of 
which takes place in the secretory granule. The insulin is then stored as a hexamer 
which is stabilized by a zinc ion. The intact insulin, C-peptide, and some basic amino 
acids are all released into the extracellular fluid during insulin secretion. This allows 
an assessment of endogenous insulin, released from diabetic patients, receiving 
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insulin to be determined through measuring the concentration of C-peptide released in 
conjunction with the endogenous insulin  (Newsholme and Leech, 1994).  
 
 
Figure 1.2: A schematic representation of insulin formation (bp, base pairs; nt, nucleotides and 
INT, intron) (taken from Ganong, 1993) 
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The three exons, in figure 1.2, of the insulin gene are seperated by two introns (INT 1 
and INT 2). Exons 1 and 2 code for an untranslated part of the mRNA, exon 2 codes 
for the signal peptide (P) and the B chain (B), exons 2 and 3 code for the C peptide 
(C), and exon 3 codes for the A chain (A) plus an untranslated part of the mRNA. The 
signal peptide guides the polypeptide chain into the endoplasmic reticulum and is 
then removed. The molecule is next folded, with formation of the disulfide bonds. 
The C peptide is separated by one or more converting enzymes in the secretory 
granules. 
 
1.2.4. Secretion of Insulin  
 
The biosynthesis and secretion of insulin by the islets of Langerhans are regulated by 
many circulating factors including glucose, neurotransmitters and hormones. 
 
(a) As controlled through insulin gene transcription 
 
It has been demonstrated that in isolated islets there is an increase in the synthesis of 
insulin mRNA relative to other cellular mRNA, when the islets are induced with 
glucose. An experiment confirmed this by demonstrating that the insulin mRNA 
content of islets was reduced by culture in low glucose (0-3.3mM) compared with 
islets cultured in high glucose (17-20mM).  In addition, the rate of insulin gene 
transcription was approximately 3-fold higher in islets cultured in 17mM glucose 
compared with 3.3mM glucose. The experiment was also able to show that the half-
life of insulin mRNA was 2.6 fold greater in islets cultured in 17mM glucose 
compared to those cultured in 3.3mM glucose (Flatt, 1992). 
 
(b) As controlled through glucose concentrations  
 
Insulin is released from their granules, in the beta cells of the pancreas, through 
exocytosis in response to an elevated blood glucose level, usually above 5mM 
(Tortora and Grabowski, 2000). The movement of the granules to the cell membrane 
in response to stimulation is due to microfilaments and microtubules which are 
organized in a subcytosolic web with individual microfilaments inserting in the cell 
membrane and the microtubules. Insulin secretion can therefore be inhibited through 
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the depolymerization of tubulin, which results in the breakdown of the microtubules 
(Newsholme and Leech, 1994).  
 
It is thought that there is a link between a glycolytic intermediate and insulin 
secretion, which together is known as the coupling factor and is thought to involve 
calcium ions. Phosphoenolpyruvate is thought to be the intermediate involved. The 
intracellular protein that detects the change in concentration of calcium ions is 
probably calmodulin, a heat stable protein with a molecular mass of about 17 000. 
This protein is able to bind up to four calcium ions at a time thereby changing the 
three dimensional structure of the protein which in turn somehow controls the 
contractile activity of the microtubules  (Newsholme and Leech, 1994). 
 
The entire process is then thought to interact with one another to bring about insulin 
secretion as follows: when the glucose concentration increases to about 5mM, the rate 
of glycolysis increases proportionally, thereby raising the concentration of 
phosphoenol- pyruvate. The increased activity of the glycolytic pathway generates 
signals that close ATP-sensitive K+channels in the plasma membrane. The resulting 
decrease in K+ conductance leads to depolarization with subsequent opening of 
voltage dependent calcium channels. The calcium influx through these channels 
increases, causing a rise in free cytoplasmic calcium which serves as the triggering 
signal  (Shepard and Henquin, 1995).  
  
The triggering signal then functions via calmodulin which causes contraction of the 
microfilaments or microtubules, which may contain actin or myosin and hence 
contract in a similar way to skeletal muscles. This contraction then results in an 
increased rate of exocytosis and insulin secretion  (Newsholme and Leech, 1994). 
 
(c) As controlled through hormonal regulation 
 
It has also been demonstrated that endogeneous insulin itself is able to stimulate 
insulin secretion in pancreatic beta cells. Functional insulin receptors have been found 
on beta cells, and the insulin concentration necessary to activate these receptors to 
bring about insulin secretion is in the nanomolar range (Aspinwall et al., 1998). 
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The insulin-stimulated insulin secretion is not controlled by glucose or increased 
glucose utilization as the effect occurs even at 0mM glucose. Insulin does, however, 
cause a rise in the intracellular calcium concentration which subsequently initiates 
insulin secretion as described earlier, through the binding of the calcium to the  
calmodulin protein. The beta cell insulin system is a rare example of positive 
feedback on secretion as most autoreceptors mediate negative feedback on secretion 
(Aspinwall et al., 1998). 
 
This positive feedback mechanism would cause augmented secretion during the initial 
stages of elevated glucose levels giving rise to a greater bolus of insulin release, 
however, other mechanisms must eventually take over to suppress the release. This 
could therefore be the reason that a rapid increase is observed in the first phase 
insulin secretion and the sustained, lower secretion is observed during the second 
phase of secretion. It has also been discovered that type II diabetics have a reduction 
in first phase insulin secretion, which could be a result involving a lack of positive 
feedback from the beta cell insulin receptor (Aspinwall et al., 1998). 
 
Figure 1.3 illustrates the way in which insulin is secreted in its two peaks. The first 
peak is released approximately 3-10 minutes after the ingestion of glucose. This 
insulin has already been produced by the beta cells of the pancreas, and is in storage. 
Its main function is to stop the blood glucose from rising too high, as this could 
overstimulate, and thereby damage the pancreas. The second phase of insulin 
secretion occurs approximately 30 minutes later from the beta cells. This insulin is 
not from a stored reserve but has been produced for this specific task. The size of this 
phase is directly proportional to the elevation of glycaemia (Servier, 2001).       
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Figure 1.3: A representation of the two insulin peaks experienced during a typical insulin 
secretion (taken from Servier, 2001) 
 
(d) As controlled through a secondary messenger 
 
Cyclic AMP is also thought to be related to insulin secretion, not directly but rather 
by increasing the magnitude of the secretory response to glucose or other sugars 
which can enter the glycolytic pathway. It is likely that this effect is achieved by 
activation of cyclic AMP dependent protein kinase and phosphorylation of a protein 
involved in control of calcium transport, so that for a given concentration of glucose 
more calcium enters the cytosolic compartment of the cell, or phosphorylation of 
microtubules could increase their responsiveness to a given change in the calcium ion 
concentration  (Newsholme and Leech, 1994). 
 
1.2.5. Insulin: Hard at Work  
 
This polypeptide hormone is invaluable through its actions within the human body, as 
are many other hormones. Insulin’s sole function, however, is not only to decrease the 
concentration of circulating glucose in the blood through its conversion into glycogen 
and adipose tissue, but it has many other important tasks: 
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(a) Effects of insulin on carbohydrate metabolism 
 
 
1. Insulin increases transport of glucose across the cell membrane in adipose 
tissue and muscle, for storage when excess glucose is present and for the 
breakdown of glucose into ATP respectively (Montgomery et al., 1996). 
 
2. Insulin stimulates glycogen synthesis (to be discussed later in more detail) in 
a number of tissues including adipose tissue, liver, and muscle (Lehninger et 
al., 2000). 
 
3. Insulin increases glycolysis, indirectly, by stimulating other processes 
(triacylglycerol, glycogen, and protein synthesis) requiring increased rates of 
ATP formation (Montgomery et al., 1996). 
 
4. Insulin inhibits the rates of glycogenolysis, by inhibiting the glucagon 
hormone which promotes the breakdown of glycogen into glucose, and 
gluconeogenesis in the liver. Gluconeogenesis is inhibited due to the fact that 
the cellular uptake of glucose is promoted by insulin, thereby initiating the 
breakdown of the carbohydrate to produce energy for the body. If insulin is 
not present in a sufficient amount to promote the cellular uptake of glucose 
then there is no energy being produced and the body assumes that it is being 
starved. In such a case acetyl-CoA and oxaloacetate, from the citric acid 
cycle, are converted through the process of gluconeogenesis into glucose in 
an attempt to increase the blood glucose concentration so that the body may 
be able to once again produce sufficient energy for survival of important 
organs, including the most important of all the brain, which is only able to 
obtain its energy from glycolysis (Lehninger et al., 2000). 
     
5. Insulin increases the activity of the glucokinase enzyme in the liver. This 
enzyme is responsible for converting glucose into glucose-6-phosphate 
during glycogen synthesis. This may play an important part in decreasing the 
rate of glucose release and facilitating an increase in glucose uptake, by the 
liver, after a meal (Lehninger et al., 2000). 
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6. Insulin increases the rate of glucose oxidation by the pentose phosphate 
pathway in liver and adipose tissue, this is however secondary to the 
stimulation of fatty acid synthesis by this hormone (Newsholme and Leech, 
1994). 
 
Certain tissues, such as the kidney, brain, and intestine, are totally insensitive to the 
action of insulin on carbohydrate metabolism. This introduces a problem as to how to 
reduce glucose utilization in these tissues during starvation. The problem is however 
overcome through the mobilization of fatty acids from adipose tissue to the liver 
where ketogenesis is increased so that the oxidation of this fuel will reduce glucose 
utilization and oxidation (Newsholme and Leech, 1994).  
 
(b) Effects of insulin on lipid metabolism 
 
1. Insulin inhibits lipolysis in adipose tissue because it is involved in the 
activation of the pyruvate dehydrogenase complex and citrate lyase, both of 
which supply acetyl-CoA, thereby promoting fatty acid synthesis. If fatty acid 
synthesis and beta oxidation were to occur simultaneously, the two processes 
would constitute a futile cycle, wasting energy. Thus during fatty acid 
synthesis, the production of the first intermediate, malonyl-CoA, shuts down 
beta oxidation at the level of the transport system in the mitochondrial inner 
membrane (Lehninger et al., 2000).  
 
2. Insulin inhibits ketone body synthesis in the liver, by ensuring sufficient 
glucose is taken up by cells in the body. If insulin is not present in sufficient 
amounts, to promote the cellular uptake of glucose, then the citric acid cycle 
intermediates are used for glucose synthesis via gluconeogenesis. This causes 
the subsequent slowing of the oxidation of the citric acid cycle intermediates 
as well as the oxidation of acetyl-CoA. Moreover, the liver contains only a 
limited amount of coenzyme A, and when most of it is tied up in acetyl-CoA, 
beta oxidation of fatty acids slows for lack of the free coenzyme. However the 
production and export of the ketone bodies frees the coenzyme A, thereby 
allowing continued fatty acid oxidation (Lehninger et al., 2000). 
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3. Insulin also stimulates fatty acid and triacylglycerol synthesis in adipose 
tissue and liver (Newsholme and Leech, 1994). Insulin promotes the 
conversion of carbohydrates into triacylglycerols. The pyruvate 
dehydrogenase complex and citrate lyase, both of which supply acetyl-CoA, 
are activated by insulin. The acetyl-CoA then goes on to form malonyl-CoA 
which participates in the biosynthesis of fatty acids (Lehninger et al., 2000).  
 
(c) Effects of insulin on protein metabolism 
 
1. Insulin increases the rate of amino acid transport into the muscle, adipose 
tissue, and liver cells, so that amino acids may be used for protein synthesis 
rather than gluconeogenesis (MacSween and Whaley, 1992). 
 
2. Insulin increases the rate of protein synthesis in muscle, adipose tissue, liver 
and other tissues (MacSween and Whaley, 1992).  
 
3. Protein degradation in muscles is also decreased through the action of insulin                          
(Newsholme and Leech, 1994). 
 
(d) Effects of insulin and glucagon on metabolism in the liver 
 
Glucagon is responsible for increasing the rate of both glycogenolysis and 
gluconeogenesis, which thereby increases the rate of glucose release by the liver. This 
effect may however be reduced or abolished if the concentration of insulin is 
increased (Newsholme and Leech, 1994). 
 
1.2.6. Main Action of Insulin  
 
As mentioned earlier insulin stimulates glycogen synthesis, which is the main 
function of this polypeptide hormone, and will therefore be discussed in more detail 
in the section to follow. 
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In all animals excess glucose from carbohydrates in the diet or from gluconeogenesis 
is stored as glycogen in muscle or liver. The balance between glycogen synthesis and 
degradation in the liver is controlled by the hormones glucagon and insulin. The 
starting point for glycogen synthesis is glucose-6-phosphate, which is derived from 
free glucose by the hexokinase reaction: 
  
                            D-glucose + ATP ---> D-glucose-6-phosphate + ADP 
 
To initiate glycogen synthesis the glucose-6-phosphate is firstly reversibly converted 
into glucose-1-phosphate by phosphoglucomutase: 
 
                            Glucose-6-phosphate <---> glucose-1-phosphate 
 
This reaction is followed by the formation of UDP-glucose, a key reaction in 
glycogen biosynthesis, which is catalyzed by the enzyme, UDP-glucose 
pyrophosphorylase: 
                            
                            Glycogen-1-phosphate + UTP ---> UDP-glucose + PPi 
 
The energy produced in this reaction is -25kJ/mol, because the pyrophosphate is 
rapidly hydrolyzed  to orthophosphate by the inorganic pyrophosphatase (Lehninger 
et al., 2000).  
 
UDP-glucose is the intermediate donor of glucose residues in the enzymatic 
formation of glycogen by the action of glycogen synthase, which promotes the 
transfer of the glucosyl residue from UDP-glucose to a nonreducing end of the 
branched glycogen (Lehninger et al., 2000). Insulin controls glycogen synthesis by 
controlling the activation and deactivation of glycogen synthase, by indirectly 
initiating the phosphorylation (inactive form) and dephosphorylation (active form) of 
the enzyme. 
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1.2.7. Insulin Clearance 
 
The primary organs involved in the clearance of insulin from the circulation to the 
degradation of the hormone include the liver, kidney, and muscle (Duckworth et al., 
1998). Insulin uptake and degradation also occurs in adipocytes, fibroblasts, 
monocytes, lymphocytes, gastrointestinal cells, and all other tissues that contain 
insulin receptors. The liver is the predominant organ, for both normally secreted 
endogenous insulin, as well as exogenously administered insulin. Uptake is mediated 
primarily by the insulin receptor, at physiological concentrations, with a smaller 
contribution from nonspecific processes. However at higher concentrations 
nonreceptor processes assume greater importance. Insulin has a plasma half -life 
between 4 and 6 minutes due to the necessity for it to respond rapidly to changes in 
blood glucose. A brief summary of each of the major organs involved in insulin 
clearance follows:  
 
1.2.7.1. Liver   
 
The liver removes approximately 50% of portal insulin. Since most uptake is a 
receptor mediated process, very high concentrations of insulin (500-2000mU/ml) 
result in a decrease in the fractional uptake, although total uptake is increased. 
Removal of circulating insulin does not imply immediate destruction of the hormone, 
a certain amount of receptor bound insulin is released from the cell and re-enters 
circulation. The clearance rate of the liver is decreased in individuals who suffer from 
obesity and diabetes (Duckworth et al., 1998).  
 
1.2.7.2. Kidney  
 
Another important site of insulin clearance is the kidney, removing approximately 
50% of peripheral insulin. The kidney is also responsible for removing 50% of 
circulating proinsulin and 70% of C-peptide by glomerular filtration. Glomerular 
filtration and proximal tubular reabsorption and degradation are the two mechanisms 
for insulin clearance in the kidney. However during glomerular clearance more than 
99% of the filtered insulin is reabsorbed, primarily by endocytosis. Therefore very 
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little insulin is ultimately excreted in the urine. Insulin degradation by kidney cells is 
carried out by the same process as that of the liver. Insulin is internalized into 
endosomes where degradation is initiated (Duckworth et al., 1998). Some insulin may 
be released by retroendocytosis, from the cell. Lysosomes play a greater and earlier 
role in kidney insulin degradation, unlike liver. In the kidney most insulin and 
partially degraded insulin are delivered directly to lysosomes where degradation takes 
place (Duckworth et al., 1998). 
 
1.2.7.3. Other tissues    
 
All insulin sensitive tissues remove and degrade insulin which is not cleared by the 
liver or kidney. The muscle also plays a large role in the removal of this hormone, the 
mechanism includes insulin binding to its receptor, internalization, and degradation. 
As already mentioned earlier adipocytes, fibroblasts, monocytes, lymphocytes, and 
gastrointestinal cells also degrade insulin. In short all cells that contain insulin 
receptors and internalization mechanisms can degrade insulin (Duckworth et al., 
1998).     
 
1.2.8. Insulin receptor 
 
The insulin receptor is a protein kinase, which transfers a phosphate group from ATP 
to the hydroxyl group of Tyr residues. The receptor consists of two identical alpha 
chains protruding from the outer face of the plasma membrane, and two 
transmembrane beta subunits, with their carboxyl termini on the cytosolic face 
(Lehninger et al., 2000). The insulin binding domain is found on the alpha chain, and 
the beta chains contain the tyrosine kinase domain see figure 1.4.  
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Figure 1.4: A schematic representation depicting the functional characteristics of the insulin       
receptor (taken from Lehninger et al., 2000) 
 
1.2.8.1. The Insulin Signalling Pathway 
 
It seems as if the insulin receptor consists of two routes of signalling. Once the 
insulin binds to the receptor the tyrosine protein kinase activity is enhanced 10-fold, 
thereby causing the beta chains to bind to neighbouring adaptor proteins and 
phosphorylate the tyrosine residues. The two important adaptor proteins, IRS (insulin 
receptor substrate), and Shc, are found at the head of the two major insulin responsive 
signal transduction pathways, as can be seen in figure 1.5.  
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Figure 1.5: A schematic diagram displaying the two routes of insulin signalling (taken from 
Gibson and Harris, 2002). For abbreviations refer to text. 
 
The pathway on the left is labelled PI-3-K (phosphatidyl inositol-3-kinase) pathway 
and the pathway on the right is designated MAPK (mitogen activating protein kinase) 
pathway. It has recently been proposed that the MAPK pathway of liver and adipose 
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tissue terminates in the nucleus with the induction or repression (transcription) of a 
set of genes of key enzymes involved in insulin-glucagon sensitive (long term) 
control of metabolic pathways. The PI-3-K pathway signals an increase in protein 
synthesis through the promotion of translation and may also be responsible for the net 
dephosphorylation of key enzymes in the liver, adipose, and muscle which promote 
the formation of glycogen and triglycerides (Gibson and Harris, 2002). 
 
· The PI-3-K pathway 
 
IRS binds reversibly to the activated insulin receptor beta domains to initiate the 
first pathway. Once the insulin receptor tyrosine kinase is phosphorylated the 
bound IRS undergoes a conformational change and attracts a specific recognition 
site, the SH2, on the PI-3-K through its p85 regulatory subunit. The specificity of 
the protein-protein interactions depends not only on the SH2 domains, but also on 
adjacent amino acid sequences (Gibson and Harris, 2002), as can be seen in figure 
1.6. 
 
Figure 1.6: Molecular mechanism of insulin-stimulated transport. The insulin-dependent 
glucose transporter 4 (GLUT4) is translocated by a phosphatidylinositol 3-kinase (PI 3K)-
dependent pathway including PKB/AKT and PKC stimulation downstream of PI3K. PI3,4,5P, 
Phosphatidylinositol 3,4,5-phosphate; PDK, phosphatidylinositol (3 4 5 )-phosphate-dependent 
kinase; IRS, insulin receptor substrate (taken from Matthaei et al., 2000) 
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The PI-3-K, located near the cytosolic surface of the plasma membrane, catalyses  
the phosphorylation of inositol at position 3 of 4,5 diphosphophophatidyl inositol 
ring producing phosphatidyl inositol 3,4,5-triphosphate (PIP3). PIP3 is embedded 
in the plasma membrane and is elevated during insulin signalling. It is clear that 
PI-3-K is able to control several signal pathway outcomes depending on the cell 
type: enhancement of transcription and translation, impairment of apoptosis, or 
the terminal dephosphorylation state of enzymes that are crucial for metabolic 
control (Gibson and Harris, 2002). 
 
PI-3-K then catalyses the phosphorylation of PKB (protein kinase B), thereby 
activating it, which in turn catalyses the binding of PIP3 to the protein kinase B 
and initiates PKB and phosphatidyl inositol dependent kinase (PDK-1) to move 
along side one another in the plasma membrane. PKB and PDK-1 are responsible 
for inactivating glycogen synthase kinase (GSK-3), which normally 
phosphorylates and inactivates glycogen synthase. However with the GSK-3 
enzyme activity decreased, the opposing glycogen synthase-1G takes over. The 
protein phosphatase (PP1G), which is bound to glycogen through a regulatory 
protein (RGL) brings about dephosphorylation of glycogen synthase, 
phosphorylase kinase, and glycogen phosphorylase in opposing the action of 
protein kinases, and thereby promoting glycogen synthesis. This insulin pathway 
is also involved in recruiting GLUT4 glucose transporters in skeletal muscle and 
adipose tissue (Gibson and Harris, 2002). 
 
· The MAPK pathway 
 
In this pathway the insulin activated receptor tyrosine kinase phosphorylates the 
tyrosines on the adaptor protein Shc, thereby activating it and catalysing the 
binding to SH2 domains on a second adaptor protein called Grb-2. The Grb-2 
protein amino acid sequence domain, SH3, binds to the proline rich regions of the 
next signal transduction protein Sos, thereby activating it. Sos is a guanosine 
nucleotide exchange protein (GEP) which continues the cascade of activation by 
converting a monomeric small G protein called Ras from its GDP-inactive mode 
to its GTP-active mode (Gibson and Harris, 2002).  
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In the presence of Sos bound GDP is replaced by the insertion of GTP from the 
cytosol. In the opposite direction are GAPs (GTPase activating proteins), which 
hydrolyse the bound GTP to GDP returning the system to a ground state. Ras is 
therefore an important regulatory protein (Gibson and Harris, 2002).  
 
The now active Ras binds to the first of a series of linked protein kinases that 
phosphorylate (activate) and are themselves phosphorylated (activated) on 
specific serine, threonine, or tyrosine residues. Figure 1.5 indicates Raf-1, Mek 
and MAPK (ERK-endocrine receptor kinase) which are activated in response to 
insulin. They are representatives of three large families of kinases found in the 
various differentiated cells: MKKK (mitogen activating protein kinase-kinase-
kinase), MKK (mitogen activating protein kinase-kinase), and MAPK (mitogen 
activating protein kinase), respectively. These three interlocked kinases are 
usually grouped together by scaffolding proteins, constituting a Raf-MAPK 
pathway module, and all of which are opposed by protein phosphatases. The final 
linkage to gene expression is through transcriptional factors which bind to the 
insulin responsive elements. This pathway is concerned with the transcription of 
enzymes catalysing glycolysis and the formation of fatty acids, as well as 
repression of liver enzymes catalysing gluconeogenesis (Gibson and Harris, 
2002). 
 
1.2.8.2. Internalisation and Degradation of Insulin 
 
 
Binding of the hormone to the cell membrane receptor is the initial step in the 
degradative process (1 in Fig. 1.7). Once bound, the insulin receptor, serves as a 
reservoir that can return intact insulin into circulation (2 in Fig. 1.7) or deliver it to an 
intact site. However for degradative purposes clustering of the receptor-ligand 
complexes occurs (3 in Fig. 1.7), followed by invagination of the coated pits (4 in 
Fig. 1.7), and pinching off of the pit to form an intracytoplasmic vesicle or a 
endosome (5 in Fig. 1.7). Degradation is initiated in these vesicles by the insulin 
degrading enzyme (IDE) prior to acidification of the vesicle and dissociation of the 
receptor-insulin complex (Duckworth et al., 1997). The internal pH, of the endosome, 
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then rapidly falls to pH6, resulting in the dissociation of the insulin- receptor complex 
(6A in Fig. 1.7). Further degradation to fragments can then occur, and intact insulin, 
partially degraded insulin, and insulin fragments can then be translocated to various 
cellular sites (cytoplasm, nucleus, endoplasmic reticulum, lysosomes) (7A and 7B in 
Fig. 1.7) (Duckworth, 1988).  
 
The insulin may also be delivered to lysosomes from certain subcellular sites such as 
the Golgi (8 in Fig 1.7). Some of the degraded insulin from the endosome as well as 
some intact insulin may cycle back to the membrane and fragments and intact insulin 
can be released (6B in Fig 1.7). In this case the receptor would be recycled back to 
the plasma membrane (9B in Fig 1.7).  
 
 
Figure 1.7: A model of cellular handling and insulin degradation (taken from Duckworth, 1988). 
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1.2.9. Insulin Degrading Enzyme (IDE) 
 
IDE is the primary insulin degrading enzyme in tissues and is a neutral thiol 
metalloproteinase (Duckworth, 1988). It has been difficult to obtain a stable enzyme 
preparation to study the properties of the enzyme. However the characteristics of the 
enzyme have now been studied in detail after investigators purified to homogeneity 
an IDE from human red blood cells in 1988 (Duckworth, 1988). The enzyme showed 
inhibition by both sulfhydryl inhibitors, such as N-ethylmaleimide or p-
chloromercuribenzoic acid as well as by chelators, such as EDTA, EGTA, and 
phenanthroline and therefore has a metal requirement. However which metal is 
involved is still unclear. Bacteriocin has also been proven to inhibit the enzyme.  
 
The enzyme was also found to have an optimum pH of 7, and an isoelectric pH of 5.2. 
The enzyme has a molecular weight of 300 000 (Lehninger et al., 2000). The 
substrate specificity is not only to insulin, but it has been shown that glucagon and 
insulin growth factor II are also degraded by the enzyme, while proinsulin and insulin 
growth factor I inhibit the enzyme, but are poor substrates (Duckworth, 1988). 
 
The major portion of insulin degradation in tissues is cytosolic (Duckworth, 1988). 
However membrane degrading activity is also present with characteristics similar to 
that of the soluble enzyme. IDE also has regulatory functions for the activity of 
steroid receptors and proteasomes. Also the insulin control of cellular protein 
degradation and fat oxidation may be due to intracellular interactions of insulin with 
IDE (Duckworth et al., 1998).       
 
1.2.9.1. Degradation products 
 
The degradative products which are produced are a result of the action of the insulin 
degrading enzyme (IDE), which is the primary insulin degrading enzyme. The 
enzyme cleaves two peptide bonds in the A chain of intact insulin and seven bonds in 
the B chain with four major and three minor sites. The nature of the bonds cleaved do 
not allow a simple classification of peptide bond specificity for the enzyme, but all 
the sites except B24-B25 and B25-B26 are in close proximity in the three 
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dimensional structure of insulin, suggesting that the specificity is to the molecule 
itself rather than specific amino acid residues (Duckworth et al., 1998), see figure 1.8.  
 
 
 
Figure 1.8: Cleavage sites of insulin for the insulin degrading enzyme (taken from Duckworth et 
al., 1998) 
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1.3. DIABETES MELLITUS: CLASSIFICATION, SYMPTOMS, 
PREVENTION, AND TRREATMENT OF THIS FAST GROWING 
PANDEMIC 
 
1.3.1. Introduction  
 
Diabetes mellitus usually falls into one of two classes, which have been known for 
many years as juvenile onset and maturity onset diabetes, or the more commonly 
termed, type I and type II diabetes, respectively. The disease is characteristic of a 
state of extreme hyperglycemia within the body, resulting from internal or external 
events which may take place in the life of an individual. 
 
Diabetes, particularly type II diabetes, is becoming a serious problem in developed 
counties worldwide. Traditionally the median age at diagnosis for type II diabetes 
was around about sixty, but recent surveys have shown that the entire age distribution 
curve has shifted to the left. The United States boasts the worst statistics in which 
type II diabetes is now being reported in children under the age of ten. At such a 
young age the disease often goes undiagnosed for long periods of time, which allows 
considerable damage to occur to the pancreas. It is also expected that the earlier the 
onset of the disease the higher the rate of complications are liable to result  (Dyer 
2002). The incidence of type II diabetes is thought to be parallel with the growing rate 
of childhood obesity, a sad statistic considering the disease is easily preventable by 
following a healthy diet and by exercising regularly. 
 
The graph, in figure 1.9, illustrates the strain obesity and insulin resistance place on 
the pancreas. The figure displays the hypothetical situation for an obese, insulin 
resistant individual after a 75g slow intravenous glucose tolerance test. It is clear that 
there is a progressive disappearance of the first peak of plasma insulin levels (green 
line), in comparison to the normal glucose response. In order for the body to maintain 
accurate plasma glucose levels, the pancreas compensates by over producing insulin 
in the second peak/phase (green line). This procedure will however eventually 
exhaust the pancreas and over a period of time the second peak will also disappear, 
leading ultimately to a state of hyperglycemia (red line) and severe type I diabetes 
(Servier, 2001). 
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Figure 1.9: A representation of the progression of hyperglycemia (IVGTT= Intravenous 
Glucose Tolerance Test) (taken from Servier, 2001) 
 
1.3.2. Diagnosis for Diabetes Mellitus  
 
The cardinal clinical feature of diabetes mellitus is glucose intolerance, therefore 
clinical diagnosis depends upon tests to demonstrate such intolerance (Tortora and 
Grabowski, 2000). An elevated blood glucose concentration together with an elevated 
blood ketone body concentration and ketonuria may be sufficient to diagnose diabetes 
mellitus. In addition, the oral glucose tolerance test (oral GTT), which is designed to 
test the ability of the patient’s beta cells to secrete insulin, may also be used 
(Newsholme and Leech, 1994).  
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Table 1.1: Blood glucose concentration criteria for diabetes mellitus (taken from 
Newsholme and Leech, 1994) 
 Glucose concentration (mM) 
Condition Venous whole blood Capillary whole 
blood 
Venous plasma 
Patient fasted 
overnight 
7.0 7.0 8.0 
120 min after oral 
glucose 
10.0 11.0 11.0 
Any intervening time 
after glucose 
ingestion 
10.0 11.0 11.0 
 
Table 1.1 shows concentrations of glucose, put forward by The European Association 
for the Study of Diabetes, at or above which diabetes is indicated. Diabetes mellitus 
will be diagnosed if the fasting blood glucose concentration, at 120 minutes and one 
other concentration at an earlier time interval are at or above those given in table 1.1. 
However if only one or two are at, or above, the given concentration, impaired 
glucose tolerance is indicated and further tests are carried out to investigate the cause 
(Newsholme and Leech, 1994). Diabetes can then be diagnosed after a complete 
clinical examination under one of the following categories:  
 
(a) Clinical diabetes 
 
The patient has a diabetic glucose tolerance response together with the symptoms and 
clinical features of diabetes. 
 
(b) Chemical diabetes 
 
The patient has a diabetic glucose tolerance response but has no clinical 
abnormalities.  
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(c) Latent diabetes 
 
The patient has normal glucose tolerance response but has had either a previous 
abnormal response to tolbutamide or steroid tests. 
 
(d) Potential diabetes 
 
A patient with a normal glucose tolerance response but with higher than normal 
chance of developing the disease due to family history, or presence of another disease 
associated with diabetes (e.g. acromegaly) (Newsholme and Leech, 1994). 
 
Most of the patients who suffer from non-insulin dependent diabetes mellitus are 
obese and suffer from insulin resistance. The disease may also stem from a genetic 
background, however negligence to follow a healthy diet and exercise regularly are 
often the most common causative agents for insulin resistance, which in time can lead 
to type II diabetes as displayed in figure 1.10. 
. 
 
Figure 1.10: Pathogenesis of skeletal muscle insulin resistance. Schematic presentation of 
factors involved in the pathogenesis of skeletal muscle insulin resistance in prediabetes and 
type 2 diabetes (taken from Matthaei et al., 2000).   
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The monocytes and adipocytes isolated from patients suffering from type II diabetes 
mellitus have fewer insulin receptors having the same affinity as those from normal 
cells. Non-insulin dependent diabetes is basically a further pathological development 
of obesity. In obese individuals the changes in glucose concentration are within the 
normal range whereas those of insulin are greatly in excess of the normal, as can be 
seen in the following figures: 
 
 
 
 
Figure 1.11: A representation of insulin secretion in response to an increased blood glucose 
concentration in non diabetic obese patients. Shaded areas represent the normal ranges for 
insulin and glucose levels (taken from Newsholme and Leech, 1994) 
 
It is clear from the preceding figures, that the beta cells of the pancreas can secrete 
sufficient insulin thereby maintaining the blood glucose concentration within the 
normal range, despite the cells resistance to insulin. However, if the resistance is too 
severe and the pancreas is unable to secrete sufficient insulin to overcome the 
resistance, the blood glucose concentration will not be maintained within the normal 
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limits, despite the high levels of circulating insulin, and diabetes results (Newsholme 
and Leech, 1994). Proinsulin concentrations are increased relative to insulin 
concentrations in individuals with type II diabetes (Mykkanen, et al., 1999). It can 
therefore be summarised that if there is a sufficient insulin secretory reserve in the 
beta cells, the individual will remain obese, while with a small reserve the patient 
usually becomes diabetic. 
 
Several theories exist as to why insulin resistance is present: 
 
· Increased levels of free fatty acids in the blood which coats the insulin 
receptor and leads to decreased insulin binding (Servier, 2001). 
 
· Overweight causes a relative reduction in the number of insulin receptors 
(Servier, 2001). 
 
· Poor quality of insulin being produced, i.e. immature or pre-proinsulin 
(Servier, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Type II diabetes mellitus: the tip of the iceberg  (taken from Matthaei et al., 2000) 
 
The simplified schematic presentation in figure 1.12 illustrates the evolution of type 
II diabetes mellitus. Type II diabetes mellitus represents the end stage of long lasting 
 - - 48
metabolic disturbances caused by insulin resistance associated with 
hyperinsulinemia, obesity, dyslipoproteinemia, arterial hypertension, and 
consequently premature atherosclerosis. Since this detrimental metabolic milieu is 
present for many years before plasma glucose levels (as our diagnostic indicator) are 
elevated, it is not surprising that type II diabetic patients have already micro- and/or 
macrovascular complications at the time of the initial diagnosis. Subjects in stage I 
have normal glucose tolerance due to the ability of their ß-cells to compensate for the 
insulin-resistant state. At this stage elevated triglyceride levels and reduced HDL 
levels as well as an increased waist to hip ratio may indicate insulin resistance and 
should lead to therapeutic action. In stage II, glucose tolerance after an oral glucose 
load (75 g) is impaired due to developing insulin-secretory deficiency. To avoid 
progression to clinically overt type II diabetes (stage III), these IGT subjects must 
receive treatment options to reduce insulin resistance, such as dietary advice and 
increase of physical activity. The stage model of the pathophysiology of type II 
diabetes is adopted from Matthaei et al., 2000. 
 
Evidence also exists that an elevated concentration of glucose may cause changes in 
the structure of protein, namely haemoglobin. Chromatography of haemolysates of 
erythrocytes resolves four minor haemoglobin forms from the main HbA1 fraction. 
These minor fractions are collectively referred to as HbA1 components and constitute 
approximately 7% of total haemoglobin in normal persons. They result from 
nonenzymatic posttranslational modifications of haemoglobin (Tortora and 
Grabowski, 2000). Several unusual haemoglobin molecules are present in the blood 
of diabetics, such as haemoglobins A1a, A1b, and A1c. The structure of haemoglobin 
A1c has been established as follows: the N-terminal valine of the haemoglobin beta-
chain has reacted with a glucose molecule to form a stable ketoamine linkage (see 
figure 1.13) (Newsholme and Leech, 1994; Montgomery et al., 1996). Some assays 
measure HbA1 and others measure HbA1c, specifically, but either can be used. The 
level of the HbA1 is however dependent on the lifespan of the red blood cell and on 
the prevailing blood glucose concentration. The results will give an indication of the 
glycemia from the preceding two months, provided the red blood cell’s lifespan is 
normal. False results can however be obtained from individuals suffering from 
haemolytic anemia or haemoglobinopathy (Benn and Sonksen, 1993). 
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Figure 1.13: Changes which occur in the structure of haemoglobin associated with diabetes  
(taken from Newsholme and Leech, 1994) 
 
The reaction occurs spontaneously in the erythrocyte after haemoglobin has been 
synthesized and the rate is increased by an elevated blood glucose concentration. This 
process is also irreversible (Newsholme and Leech, 1994). 
 
Other serum proteins are glycosylated and may be assayed for. The assay reflects 
control over a shorter time span (2-3 weeks) and is generally been found to be less 
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useful than HbA1, even though it is cheaper and more rapid (Benn and Sonksen, 
1993). 
 
1.3.3. ‘Misguided’ Genes  
 
It is of common knowledge that even the most basic forms of life are dependent on 
some form of genetic material for survival from generation to generation. Genes 
differentiate between individuals and code different sequences for important 
hormones, proteins and enzymes within the body which are essential for life. 
However errors may exist in the genetic code of some individuals, leading to the 
formation of certain constituents with some form of functional error. This can be 
detrimental to the individual’s health and could even lead to death. Many genetic 
disorders have been linked with type II diabetes, but at the same time genetic 
manipulation is being used as a cure in some cases. 
 
Mutations of several genes encoding transcriptional regulators (HNF-alpha, HNF-
beta, HNF4-alpha, IDX1, and NEUROD/BETA2) cause autosomal dominant 
diabetes. The most prevalent form results from defective HNF1-alpha. Although 
HNF1-alpha is known to regulate the transcription of liver, kidney, and intestinal 
genes, the human phenotype is essentially insulin secretory dysfunction, suggesting 
that this factor must be critically involved in beta cell specific transcription (Parrizas 
et al., 2000).     
 
Genome wide screening procedures have identified several susceptibility loci for non-
insulin dependent diabetes within the human genome. The human proto-oncogene 
PBX1 codes for a homeodomain containing protein that modulates expression of 
several genes, including those contributing to regulation of insulin action and glucose 
metabolism. PBX1 is located on chromosome Iq22, a region linked with type II 
diabetes, and is composed of nine exons spanning approximately 117kb and is located 
within 300kb of microsatellite DIS1677, which marks the peak linkage to diabetes 
susceptibility. Sixteen single nucleotide polymorphisms were also located in PBX1 
including one which causes a glycine to serine substitution at position 21 (Thameem 
et al., 2001).  
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Another two regions were found to be linked to type II diabetes and insulin 
resistance, namely a location on chromosome 2q, near marker D2S141, and another 
location on chromosome 6q, near marker D6S264. A positional candidate gene for 
insulin resistance in this chromosomal region is the plasma cell membrane 
glycoprotein PC-1 (6q22-q23) (Duggirala et al., 2001). 
 
A gene conferring susceptibility to type II diabetes has also been located on 
chromosome 18p11. There is also evidence for linkage of chromosome I, near marker 
D1S3462; chromosome 4; near marker D4S2361; chromosome 5, near marker 
D5S1505; and chromosome 17, near marker D17S1301 (Parker et al., 2001). 
 
A putative sugar transporter has been localized to human chromosome 20q12-q13.1, 
one of the genomic loci associated with type II diabetes. This protein has a strong 
resemblence to members of the mammalian facilitative glucose transporter family 
(GLUT), and this protein is therefore known as GLUT10. GLUT10 contains 541 
amino acids with several glucose transporter sequence motifs and amino acids 
essential for glucose transport function (McVie-Wylie et al., 2001).  
 
Genetic susceptibility also exists for type I diabetes. For Asians, the human major 
histocompatibility complex (MHC) locus (HLA region), especially the class two 
region, is the major susceptibility interval. The role of insulin dependent diabetes 
locus has been questioned in Asia, because in contrast to Caucasians, Asian 
populations have a very low incidence of type I diabetes. This may be due to the 
population frequency distribution of susceptible type I genes, especially of HLA. The 
overall risk for type I diabetes from HLA DR and DQ is determined by alleles and 
particular combinations of alleles in a given individual. In Asians it is very common 
that a protective DR4 allele is associated with susceptible DQ alleles while 
neutral/protective DQ alleles are associated with DR4 alleles. The theory therefore 
stands that the counterbalance between susceptible DRB1 and protective DQB1, and 
visa versa, is a factor that may contribute to the low incidence of diabetes in Asians 
(Park and Eisenbarth 2001). 
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1.3.4. Sub Groups of Type II Diabetes 
 
Several forms of type II diabetes may exist which may not necessarily be permanent, 
and may be alleviated once the individual is removed from that environment or 
situation.  
 
· Malnutrition related diabetes mellitus or tropical diabetes is divided into 
fibrocalculous or protein deficient pancreatic diabetes. In both cases the 
patients are usually inhabitants of poor tropical countries, are underweight, 
and have clinical signs of present or past malnutrition and other dietary 
deficiency states (Benn and Sonksen, 1993). 
 
· Gestational diabetes is restricted to women in whom the onset of diabetes 
occurs first during pregnancy, and is only associated with approximately 3% 
of pregnancies. Women who show impaired glucose tolerance during 
pregnancy are included in this class, but it excludes diabetic women who 
become pregnant. The clinical recognition of gestational diabetes mellitus is 
important because the baby is at increased risk of macrosomia, though rates of 
perinatal mortality and congenital anomalies are no greater than in pregnant 
women who have normal glucose tolerance. The glucose tolerance often 
becomes normal after the birth of the child, however there remains a lifetime 
risk of developing non insulin dependent diabetes later in life (Benn and 
Sonksen, 1993). 
 
· Diabetes may be associated with various other conditions and syndromes. 
This group is usually very small and diverse and may be secondary to certain 
specific endocrine diseases or certain genetic syndromes (Benn and Sonksen, 
1993). 
 
· Impaired glucose tolerance is not always associated with diabetes. Some 
individuals may suffer from glucose in tolerance and still show no signs of 
microangiopathic renal and retinal complications associated with the classical 
diabetes diagnosis. Individuals suffering from impaired glucose tolerance 
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have shown an increased prevalence to atherosclerotic disease and 
associations with other known cardiovascular disease risk factors including 
hypertension, dyslipidemia, and central obesity. Individuals who suffer from 
impaired glucose tolerance do of course stand a higher chance of developing 
diabetes than normal individuals. It has been estimated that approximately 
33% of individuals diagnosed with impaired glucose tolerance will develop 
diabetes, while a similar percentage will return to a normal glucose tolerance, 
and the others will remain in the impaired glucose tolerance group, after 
approximately 5-10 years (Benn and Sonksen, 1993). 
 
1.3.5. Current Treatment for Diabetes Mellitus  
 
Type II diabetes is best treated by a change in lifestyle combined with medication. 
Lifestyle changes include weight loss, exercise and dietry changes. Medications 
include sulphonylureas, thiazolidones, biguanides and insulin. 
 
(a) Weight Loss 
 
Many diabetic patients need to lose weight. A reduction in energy intake reduces 
blood glucose concentrations as well as reducing the risk factors associated with 
obesity. Even modest weight loss is usually associated with a reduction of insulin 
resistance and a fall in the accelerated rate of glucose production in the liver. Weight 
loss can produce a decrease in low density lipoprotein and very low density 
lipoprotein levels, an increase in high density lipoprotein levels and a reduction in 
blood pressure. Thus, the overall cardiovascular risk profile can be improved (Benn 
and Sonksen, 1993). 
 
(b) Exercise 
 
Exercise is beneficial in many aspects to the body, and has been shown to be effective 
in the treatment of diabetes mellitus. Glucose, ketone bodies, and fatty acids in the 
blood are used up at a faster rate due to exercise. The glycogen content of the liver 
and muscle will also be reduced, thereby increasing the activity of glycogen synthase 
and reducing the requirement for insulin in the stimulation of glycogen synthesis after 
 - - 54
a meal. It has also been shown that endurance training in healthy individuals increases 
insulin sensitivity so that lower insulin concentrations are required to control the 
blood glucose concentration after an oral glucose load (Newsholme and Leech, 1994). 
 
(c) Dietary fiber 
 
The faster the rate of digestion and absorption of food the greater the change in the 
blood fuel concentrations and therefore the greater the requirement for insulin. It is 
therefore important that the diabetic patient realises that the ingestion of glucose and 
sucrose should be avoided and only slow digesting carbohydrates should be ingested, 
such as starchy foods. A natural agent such as fibre should be taken in with each meal 
to further increase the time of digestion. Fibre has been shown to reduce the rate of 
absorption of glucose and hence the peak concentrations of this sugar in the blood in 
both normal and diabetic patients, and reduces urinary excretion of glucose and 
ketone bodies in diabetic patients. Dietary fibre has also proven to improve the 
control of the blood glucose concentration and reduce the peak concentration of 
insulin in non insulin dependant diabetics (Newsholme and Leech, 1994).     
 
(d) Insulin administration 
 
This is the most common form of treatment for insulin dependent and sometimes non 
insulin dependent diabetic patients. The insulin is usually administered in the form of 
injections consisting of either a mixture of long and short lasting insulin twice a day, 
or short acting insulin before each main meal plus an injection of long lasting insulin 
in the evening to provide basal insulin levels throughout the night. The maximum 
concentration of insulin in the blood occurs 30-60 minutes after a meal, in normal 
individuals, which coincides with the period of rapid glucose absorption (Newsholme 
and Leech, 1994). 
 
However, subcutaneous injections of short acting insulin results in the maximum 
blood insulin concentration only 2-3 hours after injection, which does not coincide 
with the maximum blood glucose concentration, which as a result will be much 
higher than normal. Hypoglycemia may also be experienced 2-3 hours after a main 
meal (Newsholme and Leech, 1994). It is therefore concluded that this form of 
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treatment may inhibit extreme variations in the blood glucose concentration, but it 
does not maintain it within the narrow limits found in healthy individuals.  
 
In an attempt to eliminate this problem biomedical researchers have been trying to 
develop an artificial pancreas, but have failed to produce one small enough to be 
inserted inside the patient. Transplanting islets and the tail of a healthy pancreas is 
another alternative researchers are looking into, however there is always the problem 
of adequate sources of islet tissues and rejection of the tissue (Newsholme and Leech, 
1994).  
 
(e) Sulphonylurea drugs 
 
Sulphonylurea drugs are hypoglycemic drugs used to lower the blood glucose 
concentration in non-insulin dependent diabetics. It was initially thought that they 
caused an increase in the secretion of insulin from the pancreas, thereby lowering the 
circulating glucose concentration, this however was later found not to be their sole 
mode of action. The way in which these drugs function is through some way 
increasing the number of insulin receptors, which has proven to be a safe and long 
lasting effective process of lowering the concentration of circulating insulin 
(Newsholme and Leech, 1994). 
 
The main action of these drugs is however by the inactivation of the sulphonylurea 
receptor causing the subsequent opening of the voltage dependent calcium channels, 
thereby promoting insulin secretion. More information about these channels can be 
found in section 1.4.6. 
  
(f) Thiazolidinediones 
 
The thiazolidinediones are an exciting new class of insulin sensitising drugs used in 
the treatment of type II diabetes. The molecular target for these compounds is the 
nuclear hormone receptor, peroxisome proliferator-activated receptor ? (PPAR ?), 
which is predominantly expressed in the adipose tissue (Reginato and Lazar, 1999).  
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The thiazolidinediones, which include troglitazone, pioglitazone, and rosiaglitazone, 
are thought to sensitise tissues to the action of insulin and are effective in lowering 
serum glucose levels in the absence of insulin (Reginato and Lazar, 1999). These 
drugs act as high affinity ligands for the PPAR ?. The PPAR ? plays a role in 
adipocyte differentiation, in the adipose tissue, and therefore brings about an 
induction of small adipocytes through the subsequent conversion of larger adipocytes. 
This process is then able to lower insulin resistance because large adipocytes produce 
such insulin resistant related substances as tumour necrosis factor and non-esterified 
fatty acids whereas small ones do not (Suzuki et al., 2002). 
 
Thiazolidinediones have also been shown to increase the expression of the lipoprotein 
lipase gene via the PPAR ? or to enhance lipoprotein lipase activity, thereby causing 
triglyceride levels to decrease. These drugs are also associated with a decrease in 
plasma ketone body levels, however a side effect is weight gain in accordance with 
the adipocyte differentiation (Suzuki et al., 2002). 
 
(g) Biguanides 
 
Biguanides are guanide derivatives in which two molecules of guanidine are linked 
together with the elimination of an amino group. Guanidine itself has been shown to 
lower plasma glucose levels in animals, but its toxicity prevents its clinical use. In the 
1950s, three major biguanides became available for clinical use, phenformin 
(phenethylbiguanide), metformin (N,N-dimethylbiguanide), and buformin (N-
butylbiguanide). Phenformin was used successfully in the United States but was 
withdrawn because of associated cases of lactic acidosis, metformin does not have 
this problem and is widely used as a hypoglycaemic agent (Vigneri and Goldfine, 
1987).  
 
(h) Alternative medicines 
 
Despite the impressive technical advances made in the diagnosis and therapy of 
diabetes many individuals still use alternative forms of therapy due to cost, religious 
or traditional reasons. Plants such as garlic and onion bulbs, karela (bitter melon) and 
Indian cluster bean (guar galactomannan), aloe and fenugreek seeds have all been 
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studied and shown some benefit in lowering plasma glucose levels, but overall, there 
is little information about herbal remedies (Ryan et al., 2001).  
 
Some trace elements may improve glycaemic control, such as chromium, zinc, 
magnesium, manganese, molybdenum and vanadium, which could prove beneficial in 
certain circumstances such as parental nutrition therapy (Mooradian et al., 1994). 
Certain minerals may, however, be present in excess in diabetes causing more harm 
than good, such as copper and iron (Walter et al., 1991; Cutler, 1989). Certain 
vitamins and micronutrients have been proposed as nutriceutical interventions in 
diabetes and these may be present in medicinal plants. Fish oil supplementation has 
been suggested for diabetes complications and L-carnitine in type II diabetes, folic 
acid and vitamin B6 improve homocystein levels and may reduce the risk of 
cardiovascular complications (Ryan et al., 2001). 
 
Many plants are used by traditional healers around South Africa as a substitute for 
western medication. The fact that local tradition as well as lack of sufficient funding 
encourages many individuals to turn to their traditional healers for treatment results in 
many premature deaths or increased advanced diabetic associated complications. Not 
enough information is available for these alternative forms of diabetic medication, 
and one should not substitute any of the above mentioned alternative medicines for 
that which is subscribed by a health care professional. It is also important to 
remember that toxicity studies are essential before taking any form of medicinal plant 
or herb.   
 
1.3.6. Review of Medication to be used Throughout the Project 
 
As two hypoglycaemic agents are to be used throughout the duration of the project it 
is important to understand the mechanism of action of these drugs and any side 
effects that they may have. The drugs which will be used is the biguanide, metformin, 
and a traditional medicinal plant Sutherlandia frutescens (kankerbos). 
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(a) Metformin 
 
Despite the fact that this drug has been around since the 1950s, for the treatment of 
type II diabetes, its mechanism of action still remains unclear and controversial. 
Biguanides are not truly hypoglycaemic agents as they lower the blood glucose levels 
in non-insulin dependent diabetic patients but do not lower the glucose values in 
nondiabetics, unless there has been prolonged fasting. Metformin is not metabolised 
in the liver, is not bound to serum proteins, and has a mean plasma half -life of 1.5-2.8 
hours (Vigneri and Goldfine, 1987). 
 
The blood glucose lowering effect of metformin is not caused by increased insulin 
secretion, although the presence of some insulin is a prerequisite for a therapeutic 
response, but is postulated to be due to a multifactorial mode of actions involving 
decreased intestinal glucose absorption, decreased gluconeogenesis, and increased 
glucose uptake by muscle (Klip and Leiter, 1990).  Nosadini et al. (1987) 
demonstrated that it is not possible for metformin to act as effectively independently 
of insulin. In an in vivo glucose disposal experiment, using the euglycemic clamp 
technique, it was demonstrated that metformin increased glucose utilization of 
peripheral tissues by 50% at a high insulin infusion rate and by 25% at a low infusion 
rate. 
 
In the past it was believed that metformin’s main site of action was the fat however it 
seems that the muscle is the more favoured tissue. The cellular mechanism of action 
could involve any of the rate limiting steps in glucose metabolism, either basal 
(insulin independent) and/or insulin stimulated. These include insulin receptor 
binding and signals derived from it, glucose transport across the cell membrane, 
glucose oxidation at the level of pyruvate dehydrogenase, and glycogen synthesis at 
the level of the glycogen synthase complex (Klip and Leiter, 1990). 
 
Early studies undertaken by Lord et al. (1983) showed convincing evidence that 
metformin increased the number of insulin receptor binding sites on erythrocytes in 
type II diabetes. However many others have followed this path, using different cell 
models, and have shown conflicting results, even in instances when metformin was 
shown to increase insulin binding to cells, this effect did not appear to be directly 
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related to the subsequent metabolic and clinical effects of the drug (Klip and Leiter, 
1990). Therefore the ability of metformin to increase insulin receptors and insulin 
binding cannot be consistently demonstrated. It was therefore suggested that 
metformin may be acting at a post insulin binding level (Vigneri and Goldfine, 1987; 
Klip and Leiter, 1990). 
 
One way in which metformin acts on post receptor insulin binding is through the 
insulin receptor kinase activity and receptor internalisation. Circulating cells and 
cultured fibroblasts from insulin resistant patients have abnormal insulin receptor 
kinase activity, as do muscle cells from diverse diabetic animal models (Klip and 
Leiter, 1990). The insulin receptor kinase forms an important part of the insulin 
signalling process, including stimulation of glucose transport. It has been 
demonstrated in the past that a decrease in kinase activity associated with 
streptozotocin induced diabetic rat muscle is increased to supranormal levels in 
response to metformin treatment (Rossetti et al., 1990). Benzi et al. (1988) also found 
that insulin receptor internalisation, after ligand binding, is diminished in monocytes 
from obese non-insulin dependent diabetics in comparison to control subjects. This 
reduction was however corrected for after in vivo metformin treatment. These 
responses to metformin treatment may however not be a direct result of the 
medication but may be a consequence of improved glycemic control or a lower body 
mass index. It has been proven that improving glycemia and insulin receptor kinase 
activity is possible through weight loss alone in obese individuals (Klip and Leiter, 
1990). 
 
Metformin also has the ability to decrease excess weight in obese individuals, which 
is advantageous as this helps in the lowering of insulin resistance (Faghanel et al., 
1996). The drug is thought to decrease the desire for food intake through one of the 
following three hypotheses:  
 
· The concentration of the hypothalamic neuropeptide Y is thought to be 
directly associated with food intake. Acute and chronic injection of 
neuropeptide Y into paraventricular nucleus elicits a long lasting hyperphagic 
effect. An anorectic effect of metformin has been shown to be associated with 
an increase in neuropeptide Y content of the paraventricular nuclei and 
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arcuate nuclei without affecting preproneuropeptide Y mRNA expression in 
the arcuate nuclei, in obese rats. Similar findings were found in food deprived 
lean rats (Paolisso et al., 1998). 
 
· Another hypothesis states that the insulin action in the brain participates in 
body weight regulation. Various studies have shown that chronic 
intracerebroventricular administration of insulin in different animals led to a 
dose dependent reduction in food intake. The possible relationship between 
the insulin action and the anorectic effect is thought to be through the plasma 
insulin like growth factor, a proxy of insulin action. This suspicion was 
confirmed when the results of the experiment showed that before starting and 
after metformin treatment plasma insulin like growth factor was significantly 
associated with food intake (Paolisso et al., 1998). 
 
· A further mechanism by which metformin may affect food intake is through 
the improvement in energy production. With regard to such 
pathophysiological mechanism, it has been proposed that a decline in ATP 
synthesis is a metabolic stimulus that triggers feeding behaviour. Because 
ATP is a final end product of the oxidation of both glucose and fatty acids, 
changes in the amount of ATP in hepatocytes could provide an integrated 
signal for feeding behaviour. It is therefore assumed that overeating is a result 
of fuels that would be otherwise oxidized to produce ATP in a detectable 
manner being redirected into fat stores. It therefore seems that overeating 
appears to be an appropriate response to a need for energy created not by the 
lack of food inside the body but rather by the sequestration of energy stores 
within the body (Paolisso et al., 1998). 
 
Metformin has also been shown to have an effect on lipid metabolism, significantly 
reducing hepatic triglyceride synthesis  (Vigneri and Goldfine, 1987). However these 
results prove to be controversial according to papers published by Suzuki et al. 
(2002). Metformin has been shown to affect glucose metabolism through action on 
glycogen synthase a and glycogen phosphorylase a. It seems that the drug stimulates 
both glycogen phosphorylase a and synthase a in the liver, thereby increasing the 
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turnover of hepatic glycogen metabolism resulting in no net accumulation of 
glycogen. The muscle, on the other hand shows an increase in glycogen synthase a 
only, associated with metformin treatment. This allows for an accumulation of 
glycogen in the muscle (Reddi and Jyothirmayi, 1992). The increase of these enzymes 
allows for glucose to rather be converted into glycogen than into lipids, this alteration 
in glucose metabolism may also play a role in the reduction of body fat in obese 
individuals (Suzuki et al., 2002). 
 
Another way by which metformin improves glucose metabolism is by increasing the 
glucose transporters in the plasma membrane, namely GLUT-4 (Klip and Leiter, 
1990). The number of transporters have been shown to be diminished in 
streptozotocin diabetic rats. Metformin has, however, been shown to enhance basal 2-
deoxyglucose and 3-O-methylglucose uptake by muscle cells in culture through 
stimulation of GLUT-4 glucose transporters (Reddi and Jyothirmayi, 1992). 
 
There are not many side effects to report with metformin therapy. DeFronzo et al. 
(1995) did however report nausea, diarrhoea, and a decreased vitamin B12 in patients 
receiving metformin treatment. The dosage was however extremely high, 2550mg per 
day, and these symptoms subsided when the dosage was lowered. The normal dosage 
is in the range of 500mg every 8 hours, 850mg twice daily, or 3g daily if needed 
(Cooper and Gerlis, 1997). It is also evident that metformin does not cause lactic 
acidosis, as phenformin does, due to a difference in lactate metabolism. Metformin 
has been found to reduce lactate use for gluconeogenesis without altering the plasma 
lactate concentration or the plasma lactate turnover, but by increasing lactate 
oxidation (Stumvoll et al., 1995). 
 
All in all metformin seems to be an extremely effective drug for non-insulin 
dependent diabetic therapy, displaying few side effects, and producing 
normoglycemic levels effectively. However to increase the effectiveness of this drug 
combination therapies are being used with sulphonylurea receptor drugs (Hermann et 
al., 1994) and with thiazolidinediones (Suzuki et al., 2002). 
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(b) Sutherlandia frutescens 
 
The genus Sutherlandia, commonly known as the cancer bush or kankerbos 
comprises six species, all of which are endemic to Southern Africa. These six species 
can be reduced to two, namely S frutescens and S tomentosa, the former is further 
divided into three subspecies, namely subsp. frutescens, subsp. microphylla, and 
subsp. speciosa. The species are distinguished from one another from their habitat, 
the shape of the pods, and the shape and pubescence of the leaflets (Moshe, 1998). A 
typical S frutescens flower is shown in figure 1.14. 
 
 
Figure 1.14: Example of a typical S frutescens flower (taken from Seier et al., 2002). 
 
This plant has been used for its medicinal purposes for many years. It is thought that 
the Khoi and Nama people were the first to use it against fevers and a variety of other 
ailments including cleansing of open wounds (van Wyk et al., 1997). The plant has 
been used as a remedy for stomach problems and even internal cancers, the virtues of 
the plant, however, extend beyond this as it has also been used as remedies for colds, 
influenza, chicken pox, diabetes, varicose veins, piles, inflammation, liver problems, 
backache, and rheumatism. The leaves are the main portion of the plant used for 
medicinal purposes, however the stems are often also included (van Wyk et al., 
1997). Sutherlandia is available in tablet form, for which the recommended dosage is 
300mg twice daily. Patients on antihypertensive or diabetic medication may need the 
doses reduced while taking Sutherlandia (Gericke, 2001). 
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Three important compounds, which are of medicinal value, are associated with the 
Sutherlandia species:  
 
1. Triterpenoids 
 
Triterpenoids are compounds which are biologically active against various 
diseases and even display anticancer activity. These compounds inhibit cancer 
cell proliferation by acting as spindle poisons, for example lymphocytic 
leukaemia cells P-388 and L-1210 and human lung carcinoma cells A-549 
displayed a decreased rate of proliferation in the presence of ursolic acid. Some 
examples of medicinally important triterpenoids include oleanic acid putranoside, 
swartziasaponin, asiaticoside, soyasapogenol, and medicagenic acid (Moshe, 
1998).  
 
Moshe was able to isolate two triterpenoids from Sutherlandia, however 
identification and purification proved to be difficult and was therefore not 
undertaken. 
 
2. Amino acids 
 
Canavanine: L-canavanine, 2-amino-4 (guanidinooxy) butyric acid is a structural 
analogue of arginine and is a common seed metabolite of most legumes but is also 
stored in vegetative organs and vacuoles in leaves where it acts as a nitrogen store 
and an insecticide (Moshe, 1998). Canavanine has been used effectively against 
cancer, colds, and flu viruses. The anti-cancer activities of this amino acid have 
been demonstrated when mice bearing L1210 leukemic cells were treated with 
canavanine, and lived longer than mice that were not treated. Canavanine also 
inhibited rat colon carcinoma and pancreatic cancer cell proliferation (Moshe, 
1998). Various hypotheses have been put forward as to the biochemical nature of 
the anticancer and medicinal effects associated with canavanine. 
 
· Canavanine is substituted for arginine in most metabolic reactions, as 
canavanine is a structural analogue of arginine, resulting in structural 
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and functional protein aberrations occurring in canavanine sensitive 
organisms (Moshe, 1998). This process can cause the inhibition of 
tumour growth resulting from the incorporation of canavanine into 
tumour proteins, causing the production of aberrant macromolecules 
which exhibit impaired function. These proteins are then degraded 
more rapidly than their normal counterparts (Moshe, 1998). 
 
· Canavanine also interferes with RNA synthesis and disrupts DNA 
replication and transcription. This has been demonstrated when 
canavanine prevented RNA polymerase synthesis in Semilik Forest 
virus, and reduced DNA synthesis in the herpes simplex virus (Moshe, 
1998). 
 
Arginine and nitric oxide: Nitric oxide is formed from arginine by nitric oxide 
synthase, and is a messenger molecule in living organisms. Other functions of this 
compound include smooth muscle relaxation, platelet aggregation, 
neurotransmission, immune cell activation, tumour cell killing, protection against 
damage to cardiac myocytes, protection of endothelial cells and maintainance of 
vascular wall integrity, prevent intestinal ischaemia and induce intestinal fluid 
secretion into the jejunum (Moshe, 1998). 
 
L-Arginine is a common substrate in many metabolic reactions and is essential in 
the regulation of cell growth and differentiation. Arginine has also displayed 
anticancer activities by shortening tumour regression and retarding tumour growth 
(Moshe, 1998). 
 
GABA: Glutamate decarboxylation gives rise to ?-aminobutyrate (GABA), an 
inhibitory neurotransmitter. Its underproduction is associated with epileptic 
seizures, and is used pharmacologically in the treatment of epilepsy and 
hypertension (Lehninger et al., 2000). GABAA and GABAB are the two GABA 
receptors which mediate messages to the brain via ion channels (Moshe, 1998). 
The smoking of Sutherlandia seeds has been recorded to be associated with high 
levels of GABA, which could prove beneficial to the treatment of epilepsy 
(Moshe, 1998). 
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3. Pinitol 
 
Pinitol, derivatives, and metabolites thereof are useful in nutritional and medicinal 
compositions for lowering plasma free fatty acid levels, for treating conditions 
associated with insulin resistance, such as diabetes mellitus and its chronic 
complications (hyperlipidemias, dyslipidemias, atherosclerosis, hypertension, and 
cardiovascular disease), AIDS, cancer, wasting/cachexia, sepsis, burn wounds, 
malnutrition, stress, lupus, endocrine diseases, hyperuricemia, polycystic ovary 
syndrome and complications arising from athletic activity (Ostlund and Sherman, 
1998). 
 
Pinitol is very effective in lowering blood glucose levels, and is claimed to have 
insulin like effects (Ostlund and Sherman, 1998; Bates et al., 2000; Davis et al., 
2000). Bates et al. (2000) reported that pinitol can exert an insulin like effect to 
improve glycemic control in hypoinsulinaemic streptozotocin diabetic mice, and it 
is proposed that it acts via a post receptor pathway. The structure of pinitol is 
shown in figure 1.15. 
 
 
Figure 1.15: The chemical structure of D-Pinitol (3-O-methyl-D-chiro-inositol) (taken from 
http://www.irl.cri.nz/carbo/products/inositols.html) 
 
The dosage of pinitol, metabolite or derivative thereof, ranges from 0.1 to 1mg 
per day, per kilogram body weight of a mammal. This can be administered orally, 
enterally, or intravenously (Ostlund and Sherman, 1998). The exact biochemical 
action associated with the hypoglycaemic effects of pinitol is still not clearly 
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understood and further investigation into this compound is necessary. The 
concentration of pinitol, in Sutherlandia, has been calculated through HPLC 
analysis to be approximately 14mg/g of dry leaves. This concentration may 
however differ between seasons and varying geographical locations of the plant 
(Moshe, 1998). 
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1.4. ATP SENSITIVE POTASSSIUM (KATP) CHANNELS: STRUCTURE, 
FUNCTION, AND REGULATION THEREOF 
 
1.4.1. Introduction  
 
ATP-sensitive potassium channels represent a family of potassium channels inhibited 
by intracellular ATP, and have been found in many tissues including the heart, 
pancreatic beta cells, skeletal muscles, smooth muscle, and the central nervous 
system. They have been associated with diverse cellular functions, such as shortening 
of action potential duration and cellular loss of potassium ions that occur during 
metabolic inhibition in heart, insulin secretion from pancreatic beta cells, smooth 
muscle relaxation, regulation of skeletal muscle excitability, and neurotransmitter 
release (Isomoto et, al., 1996). 
 
As already discussed in 1.2.4(b) an increased concentration of ATP and certain 
glycolytic cycle intermediates initiate the clos ing of the ATP sensitive K+ plasma 
membrane channels. This results in the subsequent decrease of K+ conductance 
leading to depolarization with subsequent opening of the voltage dependant calcium 
channels. This process then ultimately leads to the secretion of insulin from the 
pancreatic beta cells. The ATP sensitive K+ plasma membrane channels are therefore 
important and crucial for the release of insulin, and any form of mutation to these 
channels could effect insulin secretion. This entire process can better be described or 
rather better understood by studying figure 1.16, which is a summary of insulin 
secretion in response to an elevated blood glucose concentration. The figure includes 
the KATP and calcium channels, and how they work together to bring about the 
exocytosis of insulin.    
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Figure 1.16: A diagrammatic summary of glucose induced insulin secretion (taken from Miki et 
al., 1999) 
 
1.4.2. KATP Channel Structure  
 
As already mentioned these channels are present in most, if not all, excitable tissues 
and are all inhibited by cytoplasmic ATP, thereby coupling cell metabolism to 
electrical activity and thus play an important role in the physiology and 
pathophysiology of many tissues. An example of functioning of the KATP channel is 
insulin secretion from pancreatic beta cells in response to glucose uptake. These 
channels must be able to respond to changes in ATP in the lower millimolar range 
(Baukrowitz and Fakler, 2000). 
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The molecular identity of the KATP channels has recently been elucidated: they are 
formed from an ATP binding cassette protein with several isoforms, the 
sulphonylurea receptor (SUR1, SUR2) which have two nucleotide binding folds 
(NBF-1 and NBF-2) in the cytoplasmic side, and a two segment type or Kir 
potassium channel (Kir6.2, Kir6.1) (Babenko, et al. 1999; Uhde et al., 1999). There 
are Walker A and B motifs in both NBFs which are important for the functional 
activity of many ATP binding cassette proteins (Miki et al., 1999). After much 
experimentation it was found that the main constituents allowing this channel to 
function are SUR1and Kir6.2, a member of the inwardly rectifying potassium channel 
family (Miki et al.,1999). Both subunits assemble in a 4:4 stoichiometry, with four 
SUR1 and four Kir6.2 subunits required to form functional KATP channels, as 
illustrated in figure 1.17. 
 
 
Figure 1.17: A structural representation of the KATP channel (taken from Miki et al., 1999) 
 
While Kir6.2 acts as the pore forming subunit of the channel complex that determines 
its single channel conductance, its blockade by polyamines, and its inhibition by 
ATP, SUR1 has been identified as the regulatory subunit that confers sensitivity to 
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sulfonylureas, channel openers and Mg-ADP, through the use of the two NBFs 
(Baukrowitz and Fakler, 2000). SUR1 also acts as a chaperone on the Kir6.2 subunits 
thereby allowing processing and transport of these proteins to the surface membrane 
(Ueda et al., 1997). 
 
The essential role of both subunits in regulating insulin secretion is supported by the 
characterization of mutations in either subunit that abrogate channel activity and 
cause persistent hyperinsulinemic hypoglycemia of infancy characterized by 
constitutive insulin secretion despite severe hypoglycemia (Hernandez-Sanchez et al., 
1999). A biochemical purification and amino terminal microsequencing of SUR1 
indicates the presence of a glycosylation site near the amino terminus. It is also 
thought that the glycosylated form of the SUR1 protein is physically associated with 
Kir6.2, suggesting an extracellular localization for the amino terminus of the SUR1 
subunit in the KATP channel (Raab-Graham et al., 1999). 
 
Mutations have also been identified in Walker A (K719R and K719M) in NBF-1 and 
Walker B (D854N) in NBF-1 of SUR1 which severely impair Mg2+ independent high 
affinity ATP binding. MgADP antagonizes ATP binding at NBF-1, and a mutation at 
NBF-2 reduces MgADP antagonism. Mutations in the KATP channel also exist which 
bring about hyperinsulemia and hypoglycemia (Miki et al.,1999).  
 
1.4.3. Control of ATP Inhibition of KATP Channels by Phospholipids  
 
Another important discovery involving the KATP channel has recently come of light: it 
has been shown that phospholipids such as phosphatidylinositol-4,5-biphosphate 
(PIP2) and phosphatidylinositol-4-phosphate (PIP) are able to shift ATP sensitivity of 
KATP channels from the micro- into the millimolar range and thus provide a 
mechanism for physiological activation of the channels (Baukrowitz and Fakler, 
2000). 
 
It was shown that the removal of the PIP2 phospholipid, in excised membrane 
patches, through the action of phospholipase C resulted in a loss of channel or 
transporter activity, which could be reversed with PIP2 and PIP (Baukrowitz and 
Fakler, 2000). 
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Two properties were found to be important for the functioning of the phospholipids, 
namely: (1) the negatively charged head group of the phospholipid, as it was found 
that PIP2 mediated shifts in ATP sensitivity could be abolished by the application of 
positively charged compounds such as poly-l-lysine, and  (2) the requirement for the 
phospholipid is its insertion into the plasma membrane mediated by the lipid tail of 
the PIPs. It was found that PIPs are only effective when inserted into the inner leaflet 
of the membrane bilayer, application of PIPs to the extracellular side of the 
membrane fails to affect channel properties (Baukrowitz and Fakler, 2000). 
 
1.4.4. Control of KATP Activity on an Enzymatic Level  
 
From the above information it can basically be concluded that PIPs are able to control 
ATP inhibition of KATP channels under cellular conditions. The entire process is 
certainly not as simple as it seems and involves a number of enzymes of the PIPs 
metabolism such as the phosphoinositide-kinases (PI-kinase), PIPs-phosphatases, and 
phospholipases. The activity of these enzymes is known to change in response to a 
multitude of biological responses such as activation of heteromeric G-proteins and 
protein tyrosine kinase receptors (Baukrowitz and Fakler, 2000). 
 
1.4.5. Control of KATP Activity on a Genetic Level  
 
Regulation of transcriptional activity of either SUR1 or Kir6.2 genes is important for 
determining the level of expression and therefore the activity of KATP channels. The 
mouse SUR1 gene proximal promoter region has recently been characterized. The 
study revealed that there are no CAAT and TATA boxes or initiator elements that 
may mediate the initiation of transcription. Multiple transcription start sites do 
however exist, with the major site located 54 base pairs 5' -upstream of the 
translational start site (Hernandez-Sanchez et al., 1999). 
 
Transient transfection experiments were run, with different constructs of the SUR1 
promoter region, in the aid of determining where the basic elements required for 
significant basal transcriptional activity are located. The study revealed that these 
elements are found within the first 140 base pairs of the 5'-flanking region. There are 
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multiple SP1 binding sites that are responsible for SP1 activation of SUR1 
transcriptional activity in this particular region. Experiments have also shown that 
glucocorticoids down regulate the KATP channel levels by decreasing the SUR1 and 
Kir6.2 gene expression (Hernandez-Sanchez et al., 1999). 
 
1.4.6. Drug Action on the Sulfonylurea Receptor  
 
A common finding in individuals suffering from type II diabetes is variations 
occurring in the SUR1 gene. The nucleotide binding fold regions of the SUR1 gene 
were amplified with polymerase chain reaction and screened by the single strand 
conformational polymorphism analysis in 40 subjects with type II diabetes. The 
findings showed that there was one amino acid change, four silent substitutions, and 
three intron variants present in the nucleotide binding fold regions of the SUR1 gene 
(Rissanen et al., 2000). 
   
The sulfonylurea class of drug, such as tolbutamide and glibenclamide, inhibit the 
activity of the channel, and are therefore important agents acting against type II 
diabetes. Evidence has accumulated that activation of the receptor by ADP and 
inhibition by the sulfonylurea class of drug is a property conferred by the 
sulfonylurea receptor on the channel complex, while the site for ATP inhibition 
resides on the pore forming Kir6.2 subunit. Furthermore, the combined expression of 
the two proteins is required to generate current (Giblin et al., 1999). 
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1.5. DEPRESSION AND AMITRIPTYLINE: THE IMPORTANCE OF 
BIOGENIC AMINES AND THEORIES OF EXCESS WEIGHT GAIN 
ASSOCIATED WITH AMITRIPTYLINE COMPLIANCE 
 
1.5.1. Introduction  
 
Many drugs, including tricyclic antidepressants, cause undesired increases in body 
weight (Rigler et al., 2001). Common symptoms of depression include anorexia and 
weight loss, and yet some patients receiving antidepressant therapy complain of an 
excess of unwanted weight gain, leading ultimately to obesity, associated with these 
drugs. This unwanted side effect is described with tricyclic antidepressants. 
Undesirable weight gain may jeopardize patient compliance with antidepressant 
therapy (Garland et  al., 1988; Hinze-Selch et al., 2000). Both dose and therapy 
duration are related to the degree of weight gain in the individual.  
 
The average weight gain reported for the tricyclic antidepressants is in the range of 
0.57 to 1.37kg/month, with an average dose of 100-150mg/day, of the drug, over a 
time period of three months (Garland et al., 1988). Investigators also reported that 
patients that were withdrawn from taking any form of the tricyclic antidepressant 
ceased to gain weight, after three months. A follow up study of these individuals was 
then made six months later, and it was found that they had lost almost all of the 
weight gained during the treatment. This evidence can therefore confirm the 
suspicions that tricyclic antidepressants cause an unwanted weight increase. In fact 
the tricyclic antidepressant, amitriptyline, has been used in the past to treat anorexia 
nervosa (Gottfries, 1981). 
 
1.5.2. Reason for Depression States 
 
The drug reserpine (which inhibits the storage of norepinephrine and serotonin 
thereby lowering the level of both neurotransmitters) has been shown to deplete 
intracellular norepinephrine levels and induce vital depressive states, including 
suicidal tendencies. It can therefore be concluded that a decrease in the amine 
neurotransmitter levels can be directly related to depression (Becker, 1974). 
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The aim of antidepressants is to increase the amine neurotransmitter levels in the 
brain. The effects of antidepressants are not exclusive to the brain, but are able to 
influence other organs in the body as well. 
 
1.5.3. Tricyclic Antidepressants and How these Drugs Work  
 
These drugs gain their name from their characteristic three ring nuclear structure. 
Tricyclic antidepressants are very lipophilic substances and are highly bound to 
plasma proteins especially to albumin, alpha1-acid glycoproteins, and lipoproteins. 
Since only free drug is diffusible, variations in plasma protein binding may affect 
tricyclic antidepressant distribution and their concentration at receptor sites, thus 
conditioning the antidepressant response. They bind to extravascular tissues, which 
accounts for their generally large distribution volumes and low rates of elimination. 
They follow two main routes of metabolism in the liver, namely N-demethylation, 
whereby tertiary amines are converted to secondary amines and ring hydroxylation 
(Rang and Dale, 1991). 
 
Tricyclic antidepressants are useful in the treatment of acute depression, maintenance 
of remission once it is established, and prophylaxis against recurrence (Griest and 
Griest, 1979). The classic tricyclic antidepressants increase the synaptic availability 
of catecholamines and of 5HT by blocking neuronal reuptake, thereby prolonging 
their physiological action at corresponding receptor sites (Hieble et al., 1995). 
 
Some tricyclic antidepressants appear to increase transmitter release indirectly by 
blocking presynaptic alpha 2 adrenoreceptors (Gram, 1983; Rang and Dale, 1991). 
The alpha-2 receptor is overactive in depressed patients in that this inhibitory receptor 
closes down the noradrenergic pathway by its continuous blocking of the function of 
the presynaptic cell (Kwok and Mitchelson, 1981; Ransford, 1982; Gram, 1983; 
Shaw, 1984). 
 
Therefore specific tricyclic antidepressant drugs block this hypersensitive or 
overactive alpha 2 receptor, thereby allowing the neuron to work again (blocking a 
receptor whose function is to stop the neuron working, allows it to start up again) 
(Ransford, 1982; Gram et al., 1983; Shaw, 1984). 
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Even though blockade of amine uptake is established promptly, the appearance of 
antidepressant effects typically requires administration of the drugs for several weeks. 
Thus, it is clear that potentiation of monoaminergic neurotransmission may be only 
an early event in a potentially complex cascade of events that is linked to a down 
regulation of beta adrenoreceptors (Baldessarini, 1991) (Hieble et al., 1995). 
 
It was then proposed that these drugs enhance the receptivity of depressives to their 
environment, which in turn has an effect with the drugs on improving mood (Becker, 
1974). However endogenous depressives tend to be unresponsive to this.  
 
For this study the tricyclic antidepressant amitriptyline was used. This is one of the 
oldest and most prescribed drugs and has been shown to be significant ly associated 
with weight gain. The metabolite is nortryptyline and the therapeutic plasma 
concentration is 80-200ng/ml with a half-life of 31-46 hours (Holister 1995).   
 
1.5.4. Tricyclic Antidepressants are they Necessary? 
 
With the emergence of selective serotonin reuptake inhibitors (SSRI) the use of 
tricyclic antidepressants is not as common as it once was. Many physicians prefer to 
prescribe selective serotonin reuptake inhibitors to their patients, as they seem to be 
more effective. Individuals taking the selective serotonin reuptake inhibitors generally 
suffer fewer side effects in comparison to individuals taking tricyclic antidepressants 
(Gallo, 1999; Tan, 1999). 
 
Despite the popular use of selective serotonin reuptake inhibitors, tricyclic 
antidepressants are still used as an effective medication in certain cases. Selective 
serotonin reuptake inhibitors are often associated with increased anxiety, this is either 
remedied by lowering the dose or changing to a tricyclic antidepressant instead. 
Tricyclic antidepressants may also be used in the case of treatment failure or adverse 
side effects associated with selective serotonin reuptake inhibitors (Gallo, 1999). 
 
The cost of tricyclic antidepressants is somewhat lower in comparison to selective 
serotonin reuptake inhibitors (Gallo, 1999). This appeals to the lower income class 
and the elderly. Tricyclic antidepressants are also effective in controlling the pain 
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arising in postherpetic neuralgia and peripheral nerve injuries (Nowak and Handford, 
1999). Although tricyclic antidepressants are not as commonly prescribed, as they 
were in the past, many individuals still rely on them. 
 
1.5.5. Mechanisms of Tricyclic Antidepressant Weight Gain         
 
There are many theories as to why these drugs cause such a fluctuation in body 
weight, but it is still not clear which of these theories are correct. Some hypotheses 
are listed bellow: 
 
· Hypoglycemia-induced hunger was proposed, however contradictory results 
have been reported. Specific experiments to test this hypothesis in healthy 
volunteers and depressed patients have shown that neither hyperinsulinemia 
nor hypoglycemia occurs during tricyclic antidepressant treatment  (Garland 
et al., 1988). However other studies have shown an increase in plasma insulin 
levels in rats and humans, after administering a course of tricyclic 
antidepressants (Hurr, 1996). 
  
· It was also proposed that amitriptyline, a tricyclic antidepressant, might alter 
the hypothalamic sensitivity to a given level of glucose, thereby causing an 
excessive craving for sweets, leading to weight gain (Garland et al., 1988; 
Fava, 2000). 
 
· The increased appetite could be the result of the antidepressant action on                                   
neurotransmitter systems at the hypothalamic level. A relative increase in 
alpha-noradrenergic activity could, for example, inhibit satiety and promote 
carbohydrate craving. This hypothesis has also been proved false (Garland et 
al., 1988 Rigler et al., 2001). 
 
· The antihistaminic effects of tricyclics, which they sha re with the structurally 
related phenothiazines, which also promote weight gain, have been proposed 
as responsible for increased appetite (Garland et al., 1988). However this 
hypothesis remains to be proven. 
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· Evidence has been provided that tricyclic antidepressants may cause a 
decrease in energy expenditure, thereby contributing to induced weight gain. 
It was observed that a 17% to 24% decrease in basal metabolic rate occured 
in three female patients after the drug was administered to them. The net 
effect of a decrease of this magnitude could account for a weight gain of up to 
1.3kg/month, an increase of this magnitude ranges within the documented 
average gains with tricyclic antidepressants (Garland et al., 1988). 
 
Many of these hypotheses have already been proven false or are yet to be proved true. 
In the proposed research project, the hypothesis that antidepressants can cause 
hyperinsulinemia will be tested, specifically by decreasing insulin degradation. 
 
None of the above mentioned theories fully explain the weight gain of 1.3kg/month 
as found by Garland (1988). Walker (2000) proposed that tricyclic antidepressants 
may bind to the sulphonylurea receptors, stimulating the pancreas to secrete more 
insulin. The hypoglycemia following may increase carbohydrate craving which may 
lead to an increased weight gain. This still, however, needs to be tested. This 
hypothesis is supported by the fact that heart muscle has SUR2 receptors and tricyclic 
antidepressants cause arrythmia in some patients. 
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1.6. TISSUES CONCENTRATED ON THROUGHOUT THE PROJECT: 
LIVER, MUSCLE, AND ADIPOSE TISSUE 
 
1.6.1. Introduction 
 
Three tissues were to be used during the glucose uptake experiments namely adipose, 
muscle and liver tissue. As the main aim of the project was to test the effectiveness of 
an anti diabetic remedy, it is necessary to know whether, and if, there is an 
accelerated glucose uptake occurring for a specific tissue. Each of the three tissues 
has a specific function in the body, expressing relevant biochemical pathways, as well 
as regulating these respective pathways. 
 
1.6.2. Muscle  
 
Skeletal muscle accounts for over 50% of the total oxygen consumption in a resting 
human being and up to 90% during very active muscular work. Skeletal muscle 
metabolism is primarily specialized to generate ATP as the immediate source of 
energy. Depending on the degree of muscular activity, skeletal muscles can use free 
fatty acids, ketone bodies, or glucose as fuel (Lehninger et al., 2000) 
.  
Muscle is an efficiently controlled fuel driven machine, which is able to convert free 
energy, extracted by oxidation of organic nutrients into motion. In muscle several 
vital biochemical pathways are regulated, enabling muscle to meet its energy needs 
through a combination of aerobic glycolysis, fatty acid oxidation and oxidative 
phosphorylation (Gibson and Harris, 2002). 
 
Glycolysis is arguably one of the most important biochemical pathways found in 
higher organisms, as it is responsible for producing energy in the form of ATP from a 
six carbon glucose molecule. The ATP produced is necessary to facilitate all energy 
driven reactions within the body. Other resources, such as fatty acids, may also be 
used by the body as a source of fuel, however these fuels are not suitable for the brain 
or erythrocytes which require glucose as an energy source. Glycolysis is a very 
delicate pathway, which consists of two phases, the preparatory phase and the payoff 
phase. The preparatory phase consumes two ATP’s while the pay off phase produces 
 - - 79
four ATP’s per glucose molecule. The end products of anaerobic glycolysis are two 
pyruvate molecules for every glucose molecule oxidized (Lehninger et al., 2000; 
Montgomery et al., 1996).  
 
The two pyruvate molecules produced during this process are transported to the 
mitochondria were they take part in the citric acid cycle (Krebs cycle). Under aerobic 
conditions pyruvate is first oxidized to acetyl coenzyme A which then enters the citric 
acid cycle, and with the participation of the mitochondrial electron transport system is 
fully oxidised to carbon dioxide and water.  
 
Once the entire process for a single glucose molecule is completed, under aerobic 
conditions, a total net yield of 36 or 38 ATP molecules is achieved. This is, however, 
not necessarily the fate of glucose in muscle. Under aerobic conditions glucose is 
converted to two molecules of lactate per molecule of glucose in muscle, through the 
cytosolic process of anaerobic glycolysis. A nett yield of only two molecules of ATP 
per molecule of glucose is achieved, while lactate accumulates, enters the blood 
circulation and is transported to the liver for further oxidation. Muscle is also able to 
convert glucose into glycogen, for energy storage, once the body’s ATP levels are 
saturated. Muscle is, however, unable to release glucose into the circulation as it lacks 
glucose 6-phophatase (Gibson and Harris, 2002). 
 
These biochemical pathways are very well coordinated, for example, during exercise 
AMP concentrations are elevated which serves as a signal for increased glucose 
uptake, glycolysis and glycogen breakdown through positive effects on GLUT4 
transport, 6-phosphofructo-1-kinase and glycogen respectively (Gibson and Harris, 
2002).  
 
1.6.3. Adipose tissue 
 
Adipose tissue, which consists of adipocytes, is amorphous and widely distributed in 
the body: under the skin, around the deep blood vessels, and in the abdominal cavity. 
It makes up about 15% of a young adult human being’s mass, with approximately 
65% of this mass being in the form of triacylglycerols. Adipocytes are metabolically 
very active, and are fast to respond to hormonal stimuli (Lehninger et al., 2000). 
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Adipocytes have an active glycolytic metabolism, oxidizing pyruvate and fatty acids 
via the citric acid cycle, and carrying out oxidative phosphorylation (Lehninger et al., 
2000). The principle flux of fatty acids and glucose is, however, directed towards the 
synthesis of triacylglycerols, during periods of high carbohydrate intake. 
Triacylglycerol synthesis is supported by the auxiliary flow of glucose through the 
pentose phosphate pathway, glycerol 3-phosphate synthesis, and through ATP 
synthesis, discussed in the preceding section (Gibson and Harris, 2002).  The first 
step in fatty acid synthesis involves the enzyme, acetyl-CoA carboxylase, which 
catalyzes a 2-step reaction carboxylating acetyl-CoA to form malonyl-CoA.  
The remaining reactions in the synthetic process are catalyzed by fatty acid synthase, 
which is a multienzyme complex consisting of seven enzymatically active sites 
(Lehninger et al., 2000). The main final product of the fatty acid synthase system is 
palmitate (C16), which is the starting point for further modification reactions leading 
to the whole spectrum of fatty acids encountered in the adipose depots. 
Fatty acids are in turn converted into triacylglycerides through the acylation of two 
free hydroxyl groups of glycerol-3-phosphate by two molecules of fatty acyl-CoA to 
yield diacylglycerol-3-phosphate. This in turn is hydrolysed by phosphatidate 
phosphatase to form 1,2-diacylglycerol, which is converted into triacylglycerols by 
transesterification with a third fatty acyl-CoA. The adipocytes behave more as a 
storage site for the triacylglycerides, which may also arrive from the liver or from the 
intestinal tract, usually after a meal rich in fat.  
 
Excess fatty acids and carbohydrates obtained in the diet are converted into 
triacylglycerols in the liver and packaged with specific apolipoproteins into VLDL 
for export. In addition to triacylglycerols, VLDL,s also contain some cholesterol and 
cholesteryl esters, as well as the apolipoproteins apoB-100, apoC-I, apoC-II, apoC-
III, and apo-E. These lipoproteins are transported in the blood from the liver to 
muscle and adipose tissue, where activation by lipoprotein lipase by apoC-II causes 
the release of free fatty acids from the triacylglycerols of the VLDL. The adipocytes 
take up these fatty acids, resynthesize triacylglycerols from them, and store the 
products in intracellular lipid droplets, whereas the myocytes oxidise them for an 
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energy supply. Hepa tocytes are responsible for removing most of the VLDL remnants 
from circulation through receptor mediated uptake and lysosomal degradation 
(Lehninger et al., 2000).  
 
Lipid stores in the form of triacylglycerides are important sources of energy, as they 
produce energy of complete oxidation (~38kJ/g) more than twice that for the same 
weight of carbohydrate or protein (Lehninger et al., 2000).  
 
Lipogenesis is very tightly regulated; during elevated plasma glucose and insulin 
levels, which accompany feeding, lipid synthesis is activated. However without 
further consumption of food plasma insulin levels fall as glucagon levels rise. The 
synthetic flux to triacylglycerides diminishes as glucagon signals the opening of the 
adipose hormone-sensitive lipase vents coincident with the down regulation of the 
activities of the lipogenic enzymes. The signal transduction circuitry for the insulin 
and glucagon hormones is directed towards a specific set of end point effector 
molecules (Gibson and Harris, 2002). 
 
The leptin hormone mediates a negative feedback circuit that arises from adipose 
tissue as triacylglycerol stores accumulate. During starvation the dampening of the 
leptin signal promotes food consumption and conserves initial energy stores thereby 
minimizing uncoupled metabolism (Gibson and Harris, 2002). 
 
1.6.4. The Liver 
 
The liver is an extremely versatile organ, carrying out a number of tasks in the body 
and controlling many of the metabolic pathways:  
 
· It synthesizes fat and cholesterol and ships them to peripheral tissues.  
· It stores glycogen for later use by other tissues. 
· It synthesizes bile acids and excretes them into the gut for lipid absorption. 
· It synthesizes urea thereby preventing the build up of toxic levels of ammonia. 
· The liver is glycogenic, glycolytic, and lipogenic in the fed state and 
glycogenolytic, gluconeogenic, and ketogenic in the starved state. 
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It is also of great importance that the liver has well developed regulatory mechanisms 
enabling it to switch rapidly between opposing metabolic pathways. Glukokinase 
serves as a glucose sensor enabling the liver to buffer the blood glucose 
concentration. Fructose 2,6-bisphosphate regulates flux from fructose 6-phosphate to 
fructose 1,6-bisphosphate by exerting opposite effects on the activities of 6-
phosphofructo-1-kinase and the fructose 1,6-bisphosphatase (Gibson and Harris, 
2002). 
 
Fatty acid oxidation promotes gluconeogenesis by providing ATP for energy 
requiring steps and acetyl-CoA for activation of pyruvate carboxylase and inhibition 
of pyruvate dehydrogenase. The capacity of the liver for gluconeogenesis is 
dependent upon increased expression of the gene encoding phosphoenolpyruvate 
carboxykinase by glucagon and glucocorticoids. Malonyl-CoA inhibits fatty acid 
oxidation at the level of carnitine palmitoyltransferase I, this prevents futile cycling 
between fatty acid oxidation and synthesis (Gibson and Harris, 2002). 
 
The liver is also able to produce ketone bodies from fat, as a source of energy for 
peripheral tissues during starvation. The synthesis of cholesterol is, in part, controlled 
by the end product negative feedback at the level of 3-hydroxy-3-methylglutaryl-CoA 
reductase expression. Bile acid synthesis is, in turn, controlled by end product 
negative feedback at the level of cholesterol 7 alpha-hydroxylase expression (Gibson 
and Harris, 2002).  
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CHAPTER 2 
 
INTRODUCTION TO THE PRESENT STUDY 
 
Obesity is among the more serious health care problems facing the westernised world 
to date, placing enormous economic and health costs on the government. This 
disorder is the gateway to many metabolic disorders including cardiovascular disease, 
type II diabetes, hypertension, gallbladder disease and stroke. The trends of obesity 
are expected to increase throughout the next half century if serious actions are not 
undertaken (Case et al., 2002). Although many cases of obesity are a result of a lack 
of excersise and bad eating habits, other factors are to blame such as environmental 
and physiological factors, as well as genetic and hormonal factors (section 1.3.). 
However certain forms of prescription medication may be the culprit for excessive 
weight gain, leading ultimately to obesity and the side effects thereof. 
 
The tricyclic antidepressant, amitriptyline, is one such form of medication, which in 
many cases, has been accused of promoting excessive weight gain. Although many 
physicians are preffering to prescribe alternative forms of antidepressants, such as 
selective serotonin reuptake inhibitors, tricyclics are still favoured by many due to 
their low cost and ability to be used as pain killer (Nowak and Handford, 1999) (see 
section 1.5.4.). 
 
Many theories exist as to why amitriptyline is associated with excessive weight gain, 
shown in section 1.5.5, however many of these theories have since been proven false 
and many are still speculative. This project was therefore designed to determine the 
causative agent of the weight gain, if any, through the use of an animal model, in this 
case the male Wistar rat. 
 
As previously mentioned, in section 1.3.1, type II diabetes is fast becoming a serious 
problem in developed counties worldwide, with children under the age of ten being 
diagnosed with the disease (Dyer 2002). The incidence of type II diabetes is thought 
to be parallel with the growing rate of childhood obesity, a sad statistic considering 
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the disease is easily preventable by following a healthy diet and by exercising 
regularly. 
 
Various treatments are presently available for the type II diabetes, as displayed in 
section 1.3.5, however these various forms of medication are expensive. It is also 
important to note that the medication is not a once off affair but instead is a daily 
necessity, thereby increasing the economic burden placed on the individual. It is 
therefore necessary to discover alterna tive forms of medication against type II 
diabetes. Through the use of an animal model, in the male Wistar rat, the alternative 
medication which was tested was an indigenous plant, Sutherlandia frutescens, which 
is believed to be a hypoglycaemic agent by traditional healers. If this plant is indeed a 
hypoglycaemic agent then it will certainly bring hope for the future of those 
individuals suffering with type II diabetes. 
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CHAPTER 3 
 
METHODOLOGY: PILOT AND MAIN STUDY 
 
3.1 INTRODUCTION 
3.2 PILOT STUDY 
3.3 MAIN STUDY 
 
3.1. INTRODUCTION  
 
This study was aimed at designing an animal model to investigate the metabolic 
effects of a particular medication, amitriptyline, often associated with excessive 
weight gain, and of certain hypoglycemic agents for type II diabetes. An animal 
model was decided upon because of the advantage of measuring more than one 
metabolic parameter in a single living organism. An animal model also allows for the 
measurement of certain plasma constituents thereby giving an indication of whether 
there is a shift in the metabolic homeostasis of the animal, in response to the 
medication. Rats are relatively inexpensive, in terms of housing and feeding, and are 
easy to handle, it was for this reason that they were chosen as the model of 
preference.    
 
3.2. PILOT STUDY 
 
This study was approved by the animal ethical committee of the University of Port 
Elizabeth. 48 male Wistar rats, 2 months of age and with an average weight of 370g, 
were obtained from the animal unit of the University of the Western Cape. The rats 
were divided into 12 cages, with 4 rats to a cage for the purpose of 4 rats being 
sacrificed at a time. They were housed in an animal room with a constant temperature 
(25oC) and lighting (08h00-20h00). Table 3.1 shows how the rats were divided into 
their relative groups according to the medication they received. 
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Table 3.1: Medication and time during which various groups of rats received 
treatment prior to sacrifice 
 
Time:  2 weeks  6 weeks  11 weeks  
Control  4 rats 4 rats 4 rats 
Amitriptyline  4 rats 4 rats 4 rats 
Kankerbos  4 rats 4 rats 4 rats 
Metformin  4 rats  4 rats 
 
The cages were cleaned once a week, and the rats were fed dog pellets ad lib, and 
received their various medication in their drinking water on a daily basis. The rats 
were weighed on a weekly basis. 
     
3.2.1. Preparation of medication  
 
3.2.1.1. Sutherlandia frutescens (kankerbos)  
 
Sutherlandia frutescens subsp. microphylla was collected on a farm in the 
Murraysburg district. The kankerbos infusion was prepared by weighing off 2.5 
grams of dried, crushed leaves, adding 100 ml boiling water and allowing this tea to 
brew overnight. The extract was then filtered through a sieve consisting of pores of 
approximately one millimetre in diameter. The rats received a dose concentration of 
0.01 ml per gram rat weight, of the 100 ml tea extract, in their drinking water. The 
kankerbos medication was made up freshly on a daily basis to prevent any fungal or 
bacterial growth in the tea. Water bottles were also washed daily. 
 
3.2.1.1.1. Bacterial identification of contaminants in Sutherlandia frutescens extract 
 
Bacterial identification of contamination in Sutherlandia frutescens infusion was 
done according to the method of Gehringer et al. (1998). The bacterial identification 
was necessary as bacterial growth could be seen in the infusion after more than a day 
of standing at room temperature. 
 
 - - 87
(a) Spread plate and streak plate 
 
100ml of 0.025g/ml Sutherlandia frutescens infusion, as prepared in section 3.2.1.1. 
was transferred onto a petri dish containing nutrient agar. An L-shaped glass rod was 
placed into a beaker with 70% ethanol, covering the bent portion of the rod. The rod 
was then passed through the flame of a bunsen burner for sterilization, allowing the 
ethanol to burn off completely. The Sutherlandia extract was then spread over the 
entire surface of the agar and the plates incubated in an inverted position at 37oC 
overnight. 
 
The following day colonies of different morphologies were picked off with a flamed 
sterilized inoculation loop and each was streaked onto a fresh nutrient agar plate. 
Only one sector of the plate was initially streaked. The plates were then incubated in 
an inverted position at 37oC overnight. Now that individual pure colonies were 
available identification of the bacteria could proceed. 
 
(b) Preparation of a bacterial smear  
 
Clean slides are essential for microbial smear preparations, and were therefore 
cleaned with 95% ethanol before use. An individual colony of bacteria was placed in 
a small drop of water on the slide, with a sterilized inoculation loop. The bacteria 
were slowly mixed with the water to create a milky suspension, which was allowed to 
air dry. Once dried the slides could be used for various stains to aid identification. 
 
(c) Gram Stain Procedure  
 
The smear was first covered with crystal violet for 30 seconds before being rinsed 
with distilled water. Then the smear was covered with Gram’s iodine for 30 seconds, 
and then decolourized with 95% ethanol. The slide was then washed with distilled 
water, covered in safranin for 30 seconds and allowed to air dry before viewing under 
a microscope. Purple stained bacteria indicates gram positive bacteria, while red 
stained bacteria indicates gram negative bacteria. 
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(d) Endospore Stain Procedure  
 
Small pieces of tissue paper were torn and placed on fresh bacterial smears to reduce 
evaporation of the malachite green. The paper should be smaller than the stain. The 
slide and stain were then steamed for five minutes in order to drive the stain into the 
impermeable endospore. It was essential that the slide remained moist throughout the 
steaming process by adding more stain if necessary. The paper was then removed and 
the slides washed with distilled water and counter stained with safranin for 30 
seconds. Thereafter the slides were again washed with distilled water, blotted dry and 
examined under the microscope. This technique yields a green endospore resting in a 
pink to red cell. 
 
(e) Anaerobic growth 
 
This procedure determines whether a bacterium is able to grow under conditions 
where no oxygen is present. For this process the Sutherlandia frutescens infusion was 
streaked out, onto nutrient agar as previously mentioned and placed into an anaerobic 
container with a specialized GasPak. The GasPak is a sealed bag containing 
chemicals which remove oxygen from a sealed environment. The GasPak was then 
opened, 10ml of water was added to it and all was sealed in the anaerobic container. 
The palladium catalyst in the chamber lid catalysed the formation of water from 
hydrogen and oxygen, thereby removing oxygen from the sealed container. If growth 
is present on the agar dishes after one day’s growth then the bacteria tests positive for 
anaerobic growth. 
   
(f) Growth on 10% NaCl 
 
Isolated bacterial colonies were picked off, with a sterilized inoculation loop, and 
streaked on specialized nutrient agar containing 10%NaCl. The plates were then 
incubated overnight at 37oC in an inverted position. Any sign of growth was reported. 
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(g) Oxidase Test Procedure 
 
In aerobic bacteria, cytochromes carry electrons to oxygen. The ability of bacteria to 
produce cytochrome oxidase can be determined by the addition of the test reagent 
tetramethyl-p-phenylenediamine dihydrochloride to colonies grown on a plate 
medium. This light pink reagent serves as an artificial substrate, donating electrons 
and thereby becoming oxidised to a blackish compound in the presence of the oxidase 
and the free oxygen. Following the addition of the test reagent, the development of 
pink, then maroon, and finally black colouration on the surface of the colonies is 
indicative of cytochrome oxidase production and represents a positive test. No colour 
change or a light pink colouration on the colonies is indicative of the absence of 
oxidase activity and is a negative test.  
  
A streak plate of individual colonies, grown from the Sutherlandia frutescens 
infusion, was made and incubated overnight, as already mentioned. To test for 
cytochrome oxidase a drop of oxidase reagent was added to the colonies. A colour 
change to pink within one minute, then blue to black indicates a positive result. 
Negative results will have no colour change. 
 
(h) Motility test 
 
Petroleum jelly was placed on all four corners of a cover slip with a drop of water 
placed in the center. A single bacterial colony was then picked, from a streak plate 
made from the Sutherlandia frutescens infusion, and mixed in with the water. A 
sterile microscope slide was then placed on top of the petroleum jelly, taking care that 
there was no contact between the slide and the droplet. The slide was then inverted 
forming a hanging drop from the cover slip. Bacterial motility could now be 
examined under the microscope.    
 
3.2.1.2. Amitriptyline  
 
25 mg amitriptyline tablets were employed throughout the experiment. The tablets 
were crushed with the aid of a pestle and mortar and stored in a dry environment. The 
dose was worked out relative to that prescribed to humans as per ‘A consumers guide 
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to prescription medicines’ (Cooper and Gerlis, 1997) which states that the normal 
dose of amitriptyline is 75 mg per day. The doses were then worked out assuming 
that an average adult human weighs approximately 75 kg: 
 
Amitriptyline: 
 
75 mg amitriptyline /day / 75 kg body weight 
= 1 mg amitriptyline / 1000g body weight/day 
= 0.001mg amitriptyline /g body weight/day 
Each tablet has a mass of 0.11g containing 25mg amitriptyline, therefore 
25mg/0.11g / 0.001mg/x 
= 0.0044mg amitriptyline tablet /g body weight/day 
 
The dose was then dissolved in 1 ml of a 0.1 M HCl solution. This step was 
necessary, as the medications do not dissolve to form a homogenous solution with 
pure distilled water. The dissolved medicine was then made up to 200 ml with 
distilled water, in the water bottles, and were added to the relevant cages. Doses were 
worked out with accordance to four rats per cage. As with the kankerbos, the amount 
of medication consumed was monitored on a daily bases.    
 
3.2.1.3. Metformin 
 
500 mg metformin tablets were employed throughout the experiment. The tablets 
were crushed with the aid of a pestle and mortar and stored in a dry environment. The 
doses were worked out relative to those prescribed to humans as per ‘A consumers 
guide to prescription medicines’ (Cooper and Gerlis, 1997), which states that the 
normal dose for metformin is 500 mg every 8 hours or 850 mg twice daily. The doses 
were then worked out assuming that an average adult human weighs approximately 
75 kg: 
 
Metformin: 
 
850mg metformin / 75kg body weight 
= 11.33mg metformin / kg body weight/day 
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= 0.01133mg metformin / g body weight/day 
Each tablet has a mass of 0.55g and has a concentration of 500mg, therefore 
500mg/0.55g / 0.01133mg/x 
= 0.012mg metformin tablet /g body weight/day 
 
The relevant dose was then dissolved in 1 ml of a 0.1 M HCl solution. This step was 
necessary, as the medication does not dissolve to form a homogenous solution with 
pure distilled water. The dissolved medicine was then made up to 200 ml with 
distilled water, in the water bottles, and was added to the relevant cages. Doses were 
worked out with accordance to four rats per cage. The amount of medication 
consumed was monitored on a daily bases.    
 
3.2.2. Metabolic rate  
 
The experiment was run over a two week period using an electric oxygen controller. 
This apparatus consists of an electronic reader connected by an outflow tube to a 
4680 cm3 chamber, which is tightly sealed with the aid of vaseline. This chamber also 
contains an inflow tube through which air can move freely.  
 
The oxygen controller was calibrated for a day before each experiment, to determine 
the initial oxygen percentage in the air. Thereafter the rats were individually placed in 
the chamber for 10 minutes, allowing for their oxygen consumption to be determined. 
The air flowing to the reader was set to 0,2 litres / minute for this particular 
experiment. As temperature fluctuations can give deceiving results in such 
experiments, the entire chamber was partially submerged in a water bath, keeping the 
temperature at approximately 22oC throughout the procedure. The temperature inside 
the chamber remained at approximately 24oC for the experiment.  
 
3.2.3. Food intake  
 
The rats received dog pellets ad lib. The amount of food consumed was monitored on 
a daily basis four weeks into the experiment. At a set time in the morning 333g of dog 
food pellets was provided to the four rats per cage. The next day the remaining food 
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was weighed back and the food consumed by the four rats was calculated and 
recorded. 
 
3.2.4. Glucose standard curve  
 
Firstly serial dilutions of a 2.5mM glucose concentration were made up, using 
Dulbecco’s modified Eagles medium (DMEM) without glucose, to dilute the 
samples.  50ml aliquots of these glucose concentrations were then added, in triplicate, 
to wells in a 96 well plate and 200ml of a glu-cinet® reagent was added to each of the 
glucose concentrations. The wells were mixed and incubated at 37oC for 30 minutes. 
The absorbance was read at 492 nm, using a microtitre plate reader. A standard curve 
was run with each set of samples.  
 
3.2.5. Sacrifice of rats 
 
Rats were sacrificed after 2 weeks, 6 weeks and 11 weeks. The rats were starved 12 
hours prior to the experiment, to ensure the blood glucose concentration to be at a 
fasting level. On the day of the experiment the rats were sacrificed by placing them in 
a dessicator containing cotton wool soaked in diethyl ether, for approximately 5 
minutes. The rat’s weights were recorded. It is also of great importance that the place 
of sacrifice be situated in another room, which is isolated from where the live animals 
are kept. 
 
3.2.6. Glucose uptake experiment  
 
The liver and both testicular fat pads were immediately removed, after death, and 
washed thoroughly with PBSA, pre-warmed to 37oC, to remove all the blood. The 
hind leg thigh muscle was also removed, with 11 week treatment exposure 
experiment, and was treated in the same manner as described for the other two 
organs. PBSA was also passed through the inferior vena cava of the liver several 
times using a 2 ml syringe to ensure that all the blood had been removed from the 
blood vessels.  
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Half the liver (the other half is stored in PBSA at 37oC for insulin degradation 
experiments), the fat tissue and the muscle tissue were then finely sliced, using sharp 
scalpel blades, and again washed with PBSA. Fat and muscle tissue at 0.4g each per 
ml of media and 0.5g of liver was used per ml of media. The experiment was run in 
duplicate, and consisted of a basal (control) and a test. The test tube contained 900ml 
of DMEM, 10mM of glucose and 600mU/ml of, lyophilised, human insulin. This was 
then made up to 1ml by adding 100ml of a 20 x diluted Sigma protease inhibitor 
cocktail solution. The basal tubes contained the same reagents, except that the insulin 
was replaced with PBSA.  
 
The relevant tissues were then added to the various tubes and the stop watch started. 
Medium (20ml aliquots) was removed, while working in a 37oC walk in incubator, at 
times 10, 20, and 60 seconds, and kept on ice until needed. These samples were then 
diluted 5 x with glucose free DMEM, so as to compensate for the glucose standard 
curve as the standard curve no longer follows a straight line after a glucose 
concentration of 2.5ml. The aliquots were then read as in section 3.2.4. It is essential 
to include a zero reading as well as a blank reading. It is also of great importance that 
any reagent coming into contact with the tissue be pre warmed to 37oC so as to keep 
the tissue at one temperature throughout the experiment. 
 
3.2.7. Blood collection 
 
Immediately after death the rat’s chest cavity was opened and blood removed from 
the heart using a 2ml syringe. The blood was then added to 2.5mg sodium fluoride 
and 2mg potassium oxalate, per ml of blood, in a polypropylene tube. The reagents  
prevent blood clotting. The blood was then kept on ice and centrifuged at 2000g for 
20 minutes and the plasma collected for blood glucose analysis. The glucose analysis 
was performed by adding 50ml of a 5x diluted sample to 200ml of a glu-cinet® 
solution and read as in section 3.2.4.   
 
 
 
 
 - - 94
3.2.8. Insulin degradation 
 
The degradation of [125I] insulin was followed by using an adaptation of the method 
of Powers et al., 1980 and Duckworth, 1979. 10mCi of [125I] insulin labelled at 
Tyrosine A14 was reconstituted in 100ml distilled water, according to manufacturers 
instructions (AEC-Amersham®) this yields an insulin concentration of 5 x 10-8M. Of 
this 2.5ml aliquots were stored at –20oC.  
 
A 7.5ml [125I] insulin aliquot was used per 4 rats during each degradation experiment. 
To dilute the insulin 1.87 ml degradation buffer (Minimal essential medium 
containing 0.5% bovine serum albumin) was added to the 7.5ml [125I] insulin. The 
remaining liver from each rat was finely sliced, washed with PBSA, and 0.5 g added 
to each of the tubes, making up 8 tubes in total, plus a control tube, which did not 
contain any tissue. To each tube 200ml of  [125I] insulin and 800ml degradation buffer 
(pre-warmed to 37oC) was added. Aliquots (100ml) were then taken at times 0, 5, 15 
and 30 minutes, while at 37oC. The aliquots were added to 100ml of cold 10% 
trichloroacetic acid (TCA) solution, vortexed and kept on ice for 5 minutes, thereby 
ensuring the completion of the reaction and precipitation of undegraded insulin. The 
samples were then microfuged for 5 minutes and 175ml of each supernatant added to 
a pony vial containing 3 ml Beckman ready gel® liquid scintillation cocktail, for 
aqueous samples. Each of the samples was then counted, for 15 minutes, using the 
scintillation counter. 
   
 3.3. MAIN STUDY 
 
For the main study a larger number of rats were used per group to allow for statistical 
analysis. The groups remained unchanged from the pilot study except that each group 
consisted of ten rats. The rats were also fed dog pellets ad lib and received their 
various medications on a daily basis, in their drinking water. The rats were weighed 
weekly throughout the experiment. All rats were housed in an environmental room 
with controlled temperature (22oC±1oC) and lighting (08h00 to 20h00). Cages were 
cleaned three times a week. Approval for this study was also obtained from the 
animal ethical committee of the University of Port Elizabeth. 
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3.3.1. Preparation of medication 
 
All medication was prepared and administered in the same way as described in 
section 3.2.1.1, 3.2.1.2 and 3.2.1.3. 
 
3.3.2. Metabolic rate 
 
The experiment was run at three time intervals: 6, 8 and 19 weeks. It was also decided 
to increase the time the rat was in the metabolic chamber thereby bringing about a 
more accurate reading. The ten minutes used previously may have been too short, the 
animal may still have been under some stress at this time which could reduce the 
accuracy of results.  
 
In order to increase the time spent by the animal in the chamber the flux of the 
oxygen had to be increased so as to prevent the oxygen in the chamber dropping to 
bellow 18% which could induce stress in the animal, therby lowering accuracy again. 
Due to limitations of the pump of the oxygen controller, the flux could only be 
increased to 0,5 litres/minute, and the time the animal spent in the chamber 
consequently could be increased to only 20 minutes, instead of a preferred 30 
minutes.   
 
A final metabolic reading was taken just prior to the sacrifice, at 18 weeks. This 
reading was done using the amitec which is much more sensitive than the oxygen 
controller, used previously.  The rats are placed in the same chamber as before, which 
is submerged in water in order to keep the temperature stable, and this apparatus runs 
on the same principle as the oxygen controller. The flow rate is set at 3 litres/minute 
allowing the rats to stay in the chamber for 40 minutes. All results were stored on a 
computer in volts and were interpreted from a standard curve obtained using pure 
oxygen, a 50/50 oxygen/nitrogen mixture, and pure nitrogen.  
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3.3.3. Food intake  
 
The amount of food consumed by the rats was monitored throughout the experiment 
the same way as described in section 3.2.3. The food consumed by each group of rats 
was weighed every morning, at the same time, for a period of 18 weeks and was 
recorded.  
 
3.3.4. Collection and analysis of urine and faeces samples 
 
After 18 and 19 weeks of treatment the rats were housed, individually, in specialised 
metabolic cages for a period of seven days. These cages allowed for the separate 
collection of urine and faeces samples, and also allowed for the accurate 
determination of the volume of fluid consumed by the animal and the volume spilt. 
Urine and faeces were collected on a daily basis. The amount of fluid consumed was 
also monitored.  
 
3.3.4.1. Analysis of urine samples 
 
The urine was collected on a daily basis every morning at the same time. The amount 
of urine produced by each rat was measured and its colouration noted. The urine was 
tested using Bayer® biostix, which allows for the determination of various compounds 
in urine.  
 
As the glucose concentration in the rat urine was too low to be detected with the aid 
of the biostix the glu-cinet® method was employed. This method entailed the addition 
of 200ml of glu-cinet® to 50ml of the urine sample, in a microtitre plate. The sample 
was then read at 492nm after a 30 minute incubation period, at 37oC, with the aid of a 
microtitre plate reader. This was then read against a glucose standard curve prepared 
in the same way as described earlier (see 3.2.4).  
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3.3.4.2. Analysis of faeces samples 
 
The faeces were collected, over the same time as the urine, on a daily basis and were 
weighed and stored at -80oC until all sampling was complete. The faeces were then 
freeze dried, and ground into a fine powder. The faeces powder (0.5g) from each rat 
was then accurately weighed off and the energy contained within the faeces was 
determined through the use of a bomb calorimeter.  
 
3.3.5. Sacrifice of rats 
 
The rats were starved 12 hours prior to sacrifice. The rats were weighed and 
sacrificed by issuing a sharp blow to the back of the head thereby rendering them 
unconscious instantaneously. This method was preferred over the ether method used 
in the pilot study (see 3.2.5.), which inevitably induced more stress in the animals 
being sacrificed.  
 
3.3.6. Blood collection 
 
3.3.6.1. Pre-sacrifice 
 
The blood was collected after the rats had been on medication for 12 weeks. The rats 
were starved for12 hours, before, and blood was collected from the tail through a 
small incision made with the aid of a scalpel. A blood droplet was collected with a 
pasteur pipette and added to an Accu-Chek® glucose sensor strip which was read with 
a glucometer. It is essential that the same glucometer be used throughout the entire 
experiment, thereby eliminating any ‘outside’ variation. The incision was then 
cleaned with 70% ethanol to prevent any infection. 
    
3.3.6.2. Post-sacrifice 
 
Immediately after death the rat’s chest cavity was opened and blood removed from 
the heart using a 2 ml syringe. A drop of blood was immediately added to the 
glucometer strip and the blood glucose concentration determined from the 
glucometer. The remaining blood was not added to sodium fluoride and potassium 
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oxalate, but was stored on ice in polypropylene tubes until needed. The blood was 
then centrifuged at 2000g for 20 minutes and the serum collected for blood insulin 
analysis. The insulin was assayed using a rat insulin enzymeimmunoassay kit from 
Amersham®. Serum was also sent for high density lipoprotein, low density 
lipoprotein, cholesterol, and triglyceride analysis. These assays were done by Drs. 
Swart, Mare` and partners pathology laboratories in Port Elizabeth. 
 
3.3.7. Glucose uptake 
 
This experiment was run using the same principles as for the pilot study (see 3.2.6.) 
However certain changes were necessary in order to reduce the very high standard 
deviations which were encountered in the pilot study results.  To this end a single 
sacrifice, after 16 weeks including ten rats per group was used. With the increased 
number of animals per group, the possibility to detect statistically significant 
differences would be increased greatly. 
 
The thigh muscle tissue was also used throughout the entire experiment along with 
the testicular fat pads and the liver. The tissue was removed and treated in the same 
way as before (see 3.2.6.), making sure to minimize the time the tissue was out of the 
body after the time of sacrifice. Fat (0.4 g), liver (0.5 g), and muscle (0.7 g) was used 
per 1 ml DMEM, containing 10mM glucose and 100ml of a 10 x diluted Sigma 
protease inhibitor cocktail solution. Once again the test samples contained      
600mU/ml of human insulin, while the basal samples were insulin free. The insulin 
was kept on ice until needed, ensuring that it would remain intact. The experiment 
was also carried out in triplicate instead of duplicate and a 37oC thermostatic water 
bath replaced the 37oC walk in incubator, to achieve better temperature control during 
the experiment. Aliquots (30ml) were taken at times 20, 40, 60, and 120 seconds. It 
was difficult to always get reliable 10 second readings, due to time constraints during 
sampling. The samples were immediately spun down for 1 minute in a microfuge in 
order to pellet any cells or blood which may have been taken up during sampling. 
Immediately after spinning 20ul of each sample is removed and stored on ice until 
needed. Each sample is then read with the aid of glu-cinet® as described in the pilot 
study (see 3.2.6.). 
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3.3.8. Insulin degradation 
 
The same method described in section 3.2.8 was employed here with a few changes: 
the mass of liver used was changed from 0.5g to 0.25g which allowed for half the 
volumes to be used, in other words each tube contained 100ml of  [125I] insulin and 
400ml degradation buffer. The reason for this was purely to save on reagents. Because 
of the small volume in each tube a smaller aliquot had to be taken at each time 
interval. Therefore 50ml aliquots were taken at times 0, 2.5, 5 and 30 minutes. A 2.5 
minute sampling time was added as most of the insulin degradation was thought to 
occur within the first ten minutes, as indicated by results obtained during the pilot 
study.  
 
Due to the short half life of the [125I] labelled insulin it is of great importance that a 
fresh batch is ordered just prior to the experiment, so as to eliminate any natural 
degradation of the radiolabelled insulin which will take place over time. However, a 
problem was encountered with the supplier upon ordering of the sample. They stated 
that it would only be possible to obtain fresh [125I] labelled insulin a month too late, 
as they had unforseen ptoblems in importing stock. It was decided not to delay the 
project despite the unavailability of freshly labelled insulin. There were, however, 
some vials of radiolabelled insulin in storage, at –20oC, left from the pilot study. It 
was therefore decided to use this insulin despite its age and its unknown condition. 
Due to the small amount available it was decided that degradation studies would only 
be performed on the control and amitriptyline groups, as the amitriptyline group was 
the only group to show any difference in insulin degradation, according to what was 
found in the pilot study. Also due to the age of the radiolabelled insulin the samples 
were counted in the scintillation counter for 30 minutes instead of the 15 minutes 
used before. This would compensate, to some degree, for the low counts expected for 
the aged radiolabelled insulin.   
 
3.3.9. Statistical analysis 
 
All data, for the main study, are presented as the mean ± SD. Differences in mean 
values between the control group and all the other groups were analysed by Dunnett’s 
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test. All statistical analysis was done with the aid of ‘fundamentals of biostatistics’, 
Rosner (1995). 
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CHAPTER 4 
 
RESULTS AND DISCUSSION 
 
4.1 PILOT STUDY 
4.2 MAIN STUDY 
 
4.1. PILOT STUDY  
 
The pilot study was intended to design a later more definitive study. This preliminary 
study allowed for the use of new and adapted methods to be refined and perfected for 
the final study. The results obtained during the pilot study could indicate the success 
of the approach and whether it needed adjusting or not. 
 
It was not the primary intention to find any statistically significant differences 
between treatments, but rather to identify possible trends in the data. Four rats, 
instead of the recommended six or more needed for significance, were therefore used 
per group. This also limited the cost factor of the study, allowing for a bigger budget 
for the final study. 
 
4.1.1. Bacterial identification 
 
The total bacterial count was 88 000 colony forming units per ml of the Sutherlandia 
frutescens infusion, as determined from the spread plate. Three morphologically 
different colonies were identified, from the spread plate, and were isolated into single 
colonies through the streak plate technique. These individual colonies were then used 
for further identification of the bacteria. 
 
All three colonies stained purple for the gram stain, indicating they were all gram 
positive bacteria. The three different colonies also all contained endospores, were rod 
shaped, and were motile. The morphology of these bacteria under the microscope 
along with the above mentioned information allowed all three bacteria to be grouped 
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into the Bacillus genus. There have been more than sixty different valid Bacillus 
species identified in the past, and all except two are non-pathogenic (Barrow and 
Feltham, 1995). It was therefore decided not to identify the bacteria but to rather 
confirm that they are not of a pathogenic nature. As all the other Bacillus species are 
commonly found in the soil and do not have any pathogenic effects, it seemed 
rational to determine whether the bacteria in the infusion was a health risk or not, 
instead of going through the long tedious effort of identifying each one. 
 
The two pathogenic bacteria in the Bacillus group are B. anthracis and B. cereus. The 
simplest way of elimination was to determine whether the bacteria, isolated from the 
tea, grew on 10% NaCl and whether they grew under anaerobic conditions, as the 
pathogenic Bacillus species grew under both these conditions. After an overnight 
incubation, at 37oC for the relative growth conditions, all three bacteria from the tea 
were negative for anaerobic growth and growth on 10% NaCl. One species was 
oxidase positive, while the other two species were oxidase negative. These results 
suggested that none of the bacteria isolated from the tea was either B. anthracis or B. 
cereus and was therefore not of a pathogenic nature. All bacterial identification was 
determined with the aid of Cowan and Steel’s Manual for the Identification of 
Medical Bacteria (Barrow and Feltham, 1995). 
 
4.1.2. Blood glucose concentration 
 
Blood was drawn from the rat’s heart immediately after the sacrifice. Figure 4.1 is a 
comparison of the average blood glucose concentrations for each group of rats, at 
each time of sacrifice, for the entire pilot study. 
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Figure 4.1: Blood glucose concentration for each group throughout pilot study 
 
Each value represents the average of four rats and the error bars indicate the standard 
deviation. There was a slight decline in blood glucose values over the eleven week 
period for all rats excluding the amitriptyline group. Taking the standard deviations 
for the controls into account no difference seems apparent over the time period for 
this group.  
 
The blood glucose values of the rats treated with amitriptyline shows an initial drop 
to 5.38±0.63mM at two weeks, after six weeks the value was 6.13±1.08mM, and after 
eleven weeks the blood glucose value rose to 11.18±1.23mM. This trend of an initial 
drop in glucose levels followed first by a gradual increase in plasma glucose levels 
and a sharp increase after 11 weeks, may lead to speculation that amitriptyline 
stimulated insulin secretion resulting in insulin resistance at eleven weeks.   
 
The metformin group showed an initial drop, of the plasma glucose levels, to 
4.53±0.85mM bringing about an apparent state of hypoglycemia. The plasma glucose 
levels however increased to 7.07±1.2mM after 11 weeks of treatment. Reasons for 
this increase are not apparent as metformin is expected to increase insulin-receptor 
sensitivity thereby lowering the plasma glucose levels. Due to the tight budget, a 
metformin group was not included at the 6 week sacrifice time. 
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The blood plasma glucose values of the rats treated with the kankerbos infusion, in 
comparison with the controls, declined to 7.3±1.67mM after two weeks, 
5.45±1.16mM after six weeks and reached 4.2±3.22mM after 11 weeks. Although a 
declining trend was observed over the eleven weeks for this group, the large standard 
deviations prevented any definitive conclusions to be drawn. 
 
Blood glucose levels of the four different groups show certain trends, though results 
were compromised by large standard deviations. Stress before sacrifice could have 
differed between rats, which could have influenced blood glucose levels. The effect 
of ether could also have influenced results, since the time from when the rats were 
anaesthetized until blood could be drawn was not constant. 
 
4.1.3. Insulin degradation 
 
This procedure incorporates the use of  [125I] labelled insulin to determine the 
percentage of insulin degraded by the liver tissue. The principle is simple. Once the 
[125I] labeled insulin binds to insulin receptors on the liver, it is taken up and 
degraded by the cells, and then released as TCA soluble fragments into the 
surrounding medium (see 3.2.8.). These fragments, in the aliquots taken from the 
medium, are then detected by a scintillation counter. Therefore the amount of insulin 
being degraded should be directly proportional to the concentration of radiolabelled 
fragments in the surrounding medium.  
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Table 4.1: Degradation of insulin by rat liver tissue at different stages of the pilot study 
 
Stage Two Weeks Six Weeks Eleven Weeks 
Incubation 
time (min) 
0 5 15 30 0 5 15 30 0 5 15 30 
C 0 30.3
±6.2 
60.1
±11 
53.8
±11 
0 26.3
±2.2 
25 
±2.4 
23.5
±2.1 
0 20.1
±6 
40 
±1.3 
35.5
±2.4 
A 0 70.2
±6.7 
88.7
±6.7 
89.2
±6.4 
0 55.8
±15 
66.3
±4 
59.3
±13 
0 34.5
±2.4 
27.8
±6.2 
20.7
±3.8 
K 0 33.4
±15 
54.3
±8.5 
54  
±9 
0 15.5
±5.7 
26.5
±7.7 
24.8
±7.3 
0 19.1
±5.7 
29.3
±5 
30 
±3.6 
M 0 41.5
±7.5 
47 
±3.8 
44.8
±3.9 
0 - - - 0 29.5
±15 
35.3
±4.6 
32.5
±11 
Key: C- Control, A- Amitriptyline, K- Kankerbos, M- Metformin 
 
Degradation is expressed as the percentage of total radiolabelled insulin being 
degraded per 100ml incubation medium during three different incubation times. The 
results in table 4.1 indicate that the major insulin degradation occurred during the first 
fifteen minutes of incubation for all the groups. The fact that there is an apparent 
lower percentage of degraded insulin present after the thirty minute interval could 
possibly result from reuptake of the insulin fragments by the liver during extended 
incubation periods. 
 
A modest decrease, in the degraded product, can be observed for all the groups from 
the beginning until the end of the experiment. The reason for this is possibly due to an 
age effect. The rats at the beginning of the experiment were younger and therefore 
had a higher rate of insulin clearance when compared to the eleven week older rats.  
 
The amitriptyline group displayed the highest percentage of insulin degradation, 
particularly during the first two weeks, reaching a maximum of 89.2±6.4% insulin 
degraded after thirty minutes. Similar results were obtained by Chadwick (2001), who 
found that HepG2 cells increased insulin degradation in culture in the presence of 
amitriptyline. This implies that the amitriptyline has a local effect on the liver cells in 
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vitro as well as in vivo, and the higher rate of degradation is not only a result of 
presumed increased circulating insulin levels. Increased blood insulin was suspected 
since a clear drop in blood glucose levels was observed after two weeks (see fig. 4.1). 
If insulin degradation as well as blood insulin levels increased, then the re must have 
been a marked increase in insulin secretion by the pancreatic cells. Higher circulating 
insulin levels contribute towards insulin receptor insensitivity (Aspinwall et al., 
1998). That could explain the increase in blood glucose levels and a drop in insulin 
degradation after six weeks. Higher levels of circulating insulin may have caused 
insulin resistance after eleven weeks, which will explain the clear rise in blood 
glucose levels shown in figure 4.1 after eleven weeks on amitriptyline, and the drop 
in insulin degradation at eleven weeks. Note as well that at two weeks the insulin 
degradation process was still increasing during 30 minutes of incubation. At eleven 
weeks, however, the most net degradation occurred within the first five minutes and 
thereafter the removal of fragments from the medium exceeded the degradation 
process. At six weeks the degradation had already slowed down in some rats and not 
in others. That explains the big standard deviation at five and thirty minutes. At all 
stages the insulin degradation in the amitriptyline group is faster at five minutes than 
for the controls, but at fifteen and thirty minutes it is slower than the controls after 11 
weeks. 
 
The kankerbos group showed no significant differences in insulin degradation when 
compared to the control group. Both groups also seemed to have reached maximum 
degradation after fifteen minutes incubation, for the two, six and eleven week stages, 
suggesting that the half -life of insulin in circulation is not affected by kankerbos. 
These results imply that the blood glucose values, which displayed increased 
hypoglycemia throughout the experiment, may not be due to an increase in insulin 
sensitivity, as this would have favoured an accelerated rate of insulin clearance, 
which is not favoured by results in table 4.1. The hypoglycaemic trend observed may 
therefore be the result of the insulin-like actions of pinitol from the kankerbos extract 
(see 1.3.6. (b)3) which, in the present study, seems to have no effect on insulin 
degradation.   
 
The metformin group showed slightly lower values for degradation when compared 
to the control group. The maximum degradation seemed to be consistently at the 
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fifteen minute mark throughout the study. The values in table 4.1 suggest that 
metformin, like kankerbos, plays no significant role in increasing the half-life of 
insulin. 
  
Many of the results in table 4.1 are accompanied by rather large standard deviations. 
The reasons for the large standard deviations can be identified when studying the 
individual results (not displayed here). The livers used for the insulin degradation 
experiments, for all the rats in a particular group, were kept in PBSA at 37oC until the 
glucose uptake experiments, for that day, were completed. The liver of the first rat 
sacrificed therefore stood the longest, and because of this lost a large amount of 
cellular activity compared to the liver of the last rat sacrificed, leading to large 
standard deviations. At the end of the pilot study, when all the results were compiled, 
the large standard deviations raised concern. It was therefore decided to change the 
method for the main studyby decreasing the time between the sacrifice of the rats and 
the assay for insulin degradation. This was achieved by performing the insulin 
degradation experiments straight after each rat was sacrificed. This would allow fresh 
liver to be used for each degradation experiment, which is expected to lower the 
standard deviations. 
 
4.1.4. Glucose uptake by fat, liver, and muscle of male Wistar rats 
 
This particular method allowed for insulin receptor functionality to be determined, by 
comparison of glucose uptake by the tissue in the absence of insulin (referred to as 
basal) and in the presence of insulin (referred to as test). The results therefore gave an 
indication of whether any of the medication was affecting the insulin receptor 
complex system’s responsiveness. Once again for the sake of simplicity, the results 
are displayed in table form (table 4.2), and represent of the area (cm2) under the 
progress curve depicting the amount of glucose taken up with increasing time by a 
particular cell type. Examples of such uptake progress curves for individual rats are  
represented in figure 4.2 and figure 4.3. 
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Figure 4.2: Example of individual glucose uptake progress curves for the basal groups after 11 
weeks of exposure to amitriptyline, each data point represents the mean of duplicate 
determinations for a single rat. 
 
 
 
 
Figure 4.3: Example of individual glucose uptake progress curves for the test groups after 11 
weeks of exposure to amitriptyline, each data point represents the mean of duplicate 
determinations for a single rat. 
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Table 4.2: Glucose uptake in the absence (basal) and the presence (test) of insulin by 
adipose and liver tissue of male Wistar rats after different periods of treatment  
 
Short time interval - 2 Weeks 
Control Amitriptyline  Kankerbos Metformin 
Fat Liver Fat Liver Fat Liver Fat Liver 
B T B T B T B T B T B T B T B T 
34 
±8.4 
41 
±22 
28 
±11 
14 
±13 
28 
±21 
44 
±4.6 
24 
±7.9 
30 
±14 
24 
±18 
37 
±15 
18 
±18 
27 
±10 
19 
±9 
43 
±4.4 
25 
±15 
47 
±9 
Intermediate time interval – 6 Weeks 
Control Amitriptyline  Kankerbos Metformin 
Fat Liver Fat Liver Fat Liver Fat Liver 
B T B T B T B T B T B T B T B T 
18 
±8.4 
41 
±22 
33 
±5.3 
38 
±6.1 
27 
±14 
32 
±6.6 
36 
±15 
38 
±4.6 
31 
±4 
24 
±15 
25 
±8.3 
16 
±13 
- - - - 
Long time interval – 11 Weeks 
Control Amitriptyline  Kankerbos Metformin 
Fat Liver Fat Liver Fat Liver Fat Liver 
B T B T B T B T B T B T B T B T 
27 
±9.3 
32 
±13 
26 
±13 
34 
±8.6 
47 
±2.1 
42 
±9.2 
38 
±3.4 
41 
±9.7 
40 
±5.3 
26 
±3.9 
25 
±8.6 
35 
±14 
19 
±17 
32 
±14 
21 
±11 
33 
±13 
All values shown in the table were measured in cm2 and represent the average areas and srandard 
deviations under the four respective progress curves. 
Key: B- Basal, T- Test 
 
The results in table 4.2 are best analyzed seperately for each treatment group. The 
identification of definitive trends is complicated by the large standard deviations 
noted in many cases. 
 
Amitriptyline: in comparing the basal fat tissue with the control group it is evident 
that the amitriptyline group shows a higher uptake of glucose as time passes. After six 
and eleven weeks the fat basal reading for amitriptyline is 27±14cm2 and 47±2.1cm2  
compared to the 18±8.4cm2 and 27±9.3cm2 , respectively, for the control groups. The 
amount of glucose, taken up by the test samples, also seem to be higher than that of 
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the control. These results seem to remain stable over the eleven week period for 
amitriptyline in comparison to 41±22cm2 , 41±22cm2 and 32±13cm2 for the control 
groups over two, six and eleven weeks respectively. These values may suggest that 
amitriptyline is promoting glucose uptake in the presence and absence of insulin over 
the eleven weeks, however the standard deviations are extremely large and do not 
allow any conclusions to be drawn at this point. 
 
The glucose uptake in the liver samples seemed to be similar to that of the fat 
samples, for amitriptyline. No difference was observed between the control and 
amitriptyline liver samples over the first six weeks. However an increase in glucose 
uptake could be observed at eleven weeks for the basal and test values of the 
amitriptyline samples, 38±3.4cm2 and 41±9.7cm2 respectively, when compared to 
those of the control, 26±13cm2 and 34±8.6cm2 respectively. Once again the standard 
deviations are high and no conclusions can be drawn. These results do however 
coincide with the theory that amitriptyline, and other tricyclic antidepressants, cause 
weight gain only after a period of three months (Garland et al., 1988).  
 
Kankerbos: the fat, basal samples, in table 4.2, seem to have a higher glucose uptake 
as time increases, contrary to its test counterpart, which seems to display a decreased 
uptake with time: test values for two, six, and eleven weeks respectively, 37±15cm2 , 
24±15cm2 and 26±3.9cm2 ; basal values for two, six and eleven weeks respectively, 
24±18cm2 , 31±4cm2 and 40±5.3cm2. It seems as if the kankerbos is itself assuming an 
insulin-like role whereby it promotes glucose uptake. However, if this was the case 
then the test samples should not show a decrease in glucose uptake as time increased. 
In fact the adipose test samples for kankerbos are also found to be lower than those of 
the corresponding control test samples. A reason for this could be that the kankerbos 
is in fact assuming the role of insulin, facilitating glucose uptake. The biochemistry of 
this process is still not fully understood. This process could allow for a decrease in 
insulin receptors on exposure to kankerbos, as glucose clearance was occurring at a 
fast rate even in the absence of insulin. However the fact that the test samples are 
lower could be that when insulin is present it has a higher affinity for the insulin 
receptors than pinitol, thereby binding to them in competition with pinitol. This 
would therefore facilitate a lower rate of glucose uptake, assuming that the number of 
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receptors on each cell may have decreased even though the sensitivity to insulin 
remained unchanged.  
 
It appears as if the liver samples for kankerbos do not comply with above theory. The 
test liver samples do seem to be predominantly higher than those of the basal 
samples, implying that insulin is the primary agent promoting glucose uptake. At 
eleven weeks there is no difference between the liver basal (25±8.6cm2) and test 
samples (35±14cm2) when compared with those of the control group’s basal 
(26±13cm2) and test (34±8.6cm2) samples. From these results it is assumed that the 
liver is not affected by the kankerbos in the same way as the fat tissue, however 
further studies involving cell lines can possibly clarify this point. It is also important 
to keep in mind that liver cells do not contain GLUT 4 transporters whereas the 
muscle and fat cells do.  
 
Metformin: as mentioned earlier this drug is to act as the positive control, as it is 
known to increase the sensitivity of the receptor, towards insulin, on the cell 
membrane. In table 4.2, a large difference in the rate of glucose uptake can be seen 
between the basal and test samples after metformin treatment, thus confirming the 
potential of the drug in both tissue types. The rate of glucose uptake is initially high 
and then decreases at eleven weeks for both tissues, reaching values similar to those 
shown for the control group, at this time. The reason for this decrease, with 
metformin, cannot solely be attributed to insulin resistance with age as this particular 
drug is intended and believed to combat this ailment in humans.    
 
Table 4.3: Glucose uptake in the absence (basal) and presence (test) of insulin by 
muscle tissue after 11 weeks of treatment 
 
Long interval – 11 Weeks  
Control Amitriptyline  Kankerbos Metformin 
Basal Test Basal Test Basal Test Basal Test 
22 ±16 20.7 ±10 11.9 ±11 36.4 ±13 37 ±10 36 ±9.3 24 ±14 27 ±15 
All values shown in the table were measured in cm2 and represent the areas under the respective uptake 
progress curves and the standard deviations 
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The glucose uptake experiment, with muscle, was only performed at the eleven week 
interval as its relevance was only decided on once the project was already underway. 
In comparing table 4.3 with table 4.2 it can be clearly seen that both the basal and the 
test results for the muscle are generally lower than those of the fat and the liver. 
Reasons for this could be related to the fact that different tissues display varying 
degrees of insulin sensitivity. For example the adipocytes respond to an extremely 
low concentration of insulin, as does the liver. The muscle on the other hand responds 
to a serum insulin concentration twice that needed to stimulate fat or liver tissue 
(Stumvoll and Jacob, 1999). 
  
Amitriptyline: the basal glucose uptake in table 4.3 appears to be low, 11.9±11cm2 , 
when compared to the control group’s basal value, 22±16cm2, for the muscle. The test 
group does however seem to be substantially higher, 36.4±13cm2 for amitriptyline 
and 20.7±10cm2 for the control group, thereby implying that amitriptyline is probably 
increasing the sensitivity of the receptors for insulin. 
 
Kankerbos: there is no difference between the test, 36±9.3cm2 , and basal, 37±10cm2 , 
muscle values for kankerbos. Both values, test and basal, do however seem to be 
higher than that of the control’s test, 20.7±10cm2, and basal, 22±16cm2 , values 
thereby implying that the kankerbos is promoting glucose uptake. Once again the 
basal levels seem to be rather high, in comparison to the other basal results in the 
table, which may again support the notion that the kankerbos is assuming the role of 
insulin, in its absence. Glucose uptake seems to be higher than that of the metformin 
group, 24±14cm2 and 27±15cm2 , for basal and test respectively. This seems 
promising for the potential use of kankerbos as a future hypoglycemic agent.  
 
Metformin: no difference can be seen between the basal and test samples for this 
group. Both results appear slightly higher than that of the control group, showing that 
metformin does promote glucose uptake. These values are, however, less convincing 
than the kankerbos and amitriptyline results already discussed.   
 
At the end of the pilot study it was clearly evident that a larger number of rats should 
be used per group to allow for statistical significance to be evaluated. It was also 
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decided to try to reduce standard deviations by adding an extra step in the 
methodology. It was suspected that some cells may have been removed with the 
medium when aliquoting. Such cells may have continued taking up glucose after the 
intended sampling time. This may have increased the standard deviation of the mean 
values, as the aliquots stood for quite some time before being assayed. Transferred 
cells may have also interfered with the subsequent absorbance, readings. To limit this 
problem it was decided to microfuge the aliquotes, after each sampling time, thereby 
removing any cells or cell debris.    
 
4.1.5. Weight of rats throughout the pilot experiment in relation to the amount of food 
consumed and resting metabolic rate 
 
The rats, in each cage, were weighed on a weekly bases and an average for each 
group was recorded. The weighing of the rats and recording of their food intake did 
not however begin at the start of the experiment. All weights were only recorded 
approximately four weeks into the experiment and then at weekly intervals. 
Figure 4.4: Weight of male Wistar rats followed over an eleven week period of treatment 
 
Adult male rats, weighing more than 280g, were assigned to the different groups in 
such a way that the average weight for the different groups were the same (370±10g), 
at the beginning of the experiment. Figure 4.4 shows that after four weeks the 
metformin group’s average body weight was the second highest but dropped at the 
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fifth week. From week seven to eleven this group recorded the lowest average weight 
of all the groups, these results are parallel to those obtained by Uehara et al., (2001), 
who showed that metformin treatment is associated with weight loss. 
 
Inspection of figure 4.4 shows that the amitriptyline group outweighed the control 
group significantly (P<0.05), particularly during the first seven weeks. The kankerbos 
group also displayed a considerable increase in weight, relative to the control group. 
However the onset was slightly delayed, occurring only after about seven weeks.  
 
All the cages received the same amount of food (333g) on a daily basis, at the same 
time of day. The next day left over food was weighed, calculated and recorded. 
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Figure 4.5: Average weight of food consumed per gram rat weight over the period 4-11 weeks 
 
Figure 4.5 clearly shows that the metformin group consumed the most food over the 
period 4-6 weeks. However, as already stated, on average they were the lightest group 
especially towards the end of the experiment. This group also consumed slightly more 
food than the control group from week eight onwards. Considering this for the whole 
experimental period, it is clear that this group was consuming the most food on 
average. 
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The opposite was, however, true for the kankerbos and amitriptyline groups, which 
were on average the heaviest, despite them consuming slightly less food than the 
controls for most of the measuring period (fig. 4.5).  
 
These results implied that some factor, other than simply food consumption, must 
also be involved in the weight changes experienced within the different groups. For 
this reason the metabolic rate was measured, for the different groups, as this was 
considered to be the most likely other factor contributing to the results recorded in 
figures 4.4 and 4.5. This procedure was only carried out during the final few weeks of 
the experiment therefore the long exposure (11 weeks) group were the  only to 
participate.  
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Figure 4.6: Oxygen consumed per ml over 10 minutes per gram rat body weight, each value 
represents a mean of 4 rats and the standard deviation for those four rats 
 
Figure 4.6 may give an indication as to why the kankerbos and amitriptyline groups 
displayed an increased weight gain even though they were eating less. After nine 
weeks the amitriptyline and kankerbos groups have a slightly lower metabolism of 
0.09±0.017ml O2/g/min and 0.1±0.013ml O2/g/min, respectively, compared to the 
control group (0.11±0.008ml O2/g/min). The metabolic rate seemed to remain the 
same, after eleven weeks for these groups, with only the kankerbos group’s metabolic 
rate decreasing from 0.1±0.013ml O2/g/min to 0.09±0.012ml O2/g/min. It seems 
likely that the decrease in the metabolic rate for the amitriptyline and kankerbos 
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groups could be the causative agent for the greater weight gain experienced in these 
groups. 
 
The metformin group’s metabolic rate seems to be equivalent to that of the control 
group, even though the metformin group appeared to have consumed on average 
more food per gram body weight than any other group. It would therefore be expected 
that this group have an elevated metabolism. However, it is evident from figure 4.5 
that the major food intake occurred within the first 6 weeks and thereafter the eating 
habits of this group did not diverge far from that of the control group. This also 
applied at the time (9 and 11 weeks) when metabolic rates were measured. 
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4.2. MAIN STUDY 
 
The main study consisted of four groups of male Wistar rats with each group 
consisting of ten rats. As with the pilot study the four groups were seperated from one 
another in accordance to the type of medication they received: amitriptyline, 
metformin, kankerbos or none as was the case with the control group. 
 
4.2.1. Food intake, body mass and oxygen consumption throughout experiment 
 
4.2.1.1. Food consumed per gram body weight 
 
Figure 4.7: Amount of food consumed, by male Wistar rats in grams, per gram body weight 
over a period of 18 weeks 
 
The food consumption was measured on a daily basis and plotted as the amount of 
food consumed per gram body weight for each week, as seen in figure 4.7. Although 
the metformin group consumed the most food over the first five weeks, there was no 
statistical significant difference over this time period (see fig. 4.8). After ten weeks 
there was a difference (P<0.1) for kankerbos in comparison to the control group (see 
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fig. 4.9). After fifteen weeks and eighteen weeks statistical differences, was also 
apparent, as can be seen in figures 4.10 and 4.11 respectively.  
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Figure 4.8:  Average amount of food consumed by male rats per gram body weight after 5 
weeks of treatment. Data are the mean ± SD (n = 10) 
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Figure 4.9:  Average amount of food consumed by male rats per gram body weight after 10 
weeks of treatment. Data are the mean ± SD (n = 10). # P < 0.1 compared with the Wistar rat 
control group by Dunnett’s test 
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Figure 4.10:  Average amount of food consumed by male rats per gram body weight after 15 
weeks of treatment. Data are the mean ± SD (n = 10). + P < 0.02 compared with the Wistar rat 
control group by Dunnett’s test 
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Figure 4.11:  Average of the amount of food consumed by male rats per gram body weight 
after 18 weeks of treatment. Data are the mean ± SD (n = 10).  * P < 0.05, o P < 0.005, and + 
P < 0.02 compared with the Wistar rat control group by Dunnett’s test 
 
The control group began to show significantly higher food consumption from week 
fifteen (see fig. 4.10), although generally significant differences seem to appear only 
after 18 weeks of medication; 0.099±0.031g/g rat weight for the control compared to 
the kankerbos group, 0.072±0.011g/g rat weight (P<0.005), the metformin group, 
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0.073±0.0075g/g rat weight (P<0.05) and the amitriptyline group, 0.071±0.0033g/g 
rat weight (P<0.02) (see fig. 4.11).  
 
It has been reported that metformin inhibits food intake. Kaiyala et al. (1995) found 
evidence that insulin action in the brain is able to regulate body weight. It was 
discovered that intracerebroventricular administration of insulin in different animals 
led to a dose dependent reduction in food intake. Hypothalamic pathways involved in 
food intake are likely targets for insulin action because the intrahypothalamic 
administration of insulin at doses 100-fold lower than those required during 
intracerebroventricular infusion is enough to elicit an inhibition of food intake 
(Paolisso et al., 1998). 
 
The effect that the kankerbos has on food intake may be similar to that displayed by 
the metformin group. The kankerbos may affect certain hypothalamic pathways, 
involved with food intake, in a similar fashion to that of metformin.  
 
The amitriptyline group started to show signs of a decreased food intake after fifteen 
treatment weeks, 0.074±0.0069g/g rat weight (P<0.02) compared to the control 
group’s 0.082±0.011g/g rat weight (see fig. 4.10). This trend continued after eighteen 
weeks, figure 4.11, where the amitriptyline group’s average food intake continued to 
decrease to 0.071±0.0033g/g rat weight and the control group’s intake continued to 
rise to 0.099±0.031g/g rat weight (P<0.02). A similar trend was observed during the 
pilot study (see figure 4.5). These results indicate that amitriptyline probably does not 
cause carbohydrate craving as was suspected in the past by Garland et al., (1988). 
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4.2.1.2. Body weight 
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Figure 4.12: Rat weight in grams measured over a period of 19 weeks of  medicational 
treatment. Data are the mean ± SD (n = 10) 
 
As can be seen from figure 4.12 the metformin group gained the most weight, 
followed by the kankerbos group. There seems to be no significant difference in 
weight between the amitriptyline and the control groups throughout the entire 
experiment. In order to further evaluate statistical significance, using Dunnett’s test, 
certain time interval periods were analysed throughout the experiment. The time 
periods used were after five, ten, and nineteen weeks of medication.  
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Figure 4.13: Rat weight in grams after five weeks on medication. Data are the mean ± SD    (n 
= 10). # P < 0.1, * P < 0.05 compared with the Wistar rat control group by Dunnett’s test 
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Figure 4.14: Rat weight in grams after ten weeks on medication. Data are the mean ± SD      (n 
= 10). o P < 0.005 compared with the Wistar rat control group by Dunnett’s test 
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Figure 4.15: Rat weight in grams after nineteen weeks on medication. Data are the mean ± SD 
(n = 10). x P < 0.01 compared with the Wistar rat control group by Dunnett’s test 
 
The kankerbos and metformin groups show early signs of weight gain, 475±24.9g and 
483.4±44.7g, respectively, in comparison to the control group, 456±36.4g, at five 
weeks (see fig. 4.13). The finding that the metformin group displayed the highest 
weight gain is unexpected, as this medication is known to prevent any weight increase 
in humans, these results are also contrary to the findings of the pilot experiment (see 
4.1.5.). The metformin group continued to increase weight throughout the 
experiment, 543±47.9g compared to the control’s 488±27.5g at ten weeks (P<0.005) 
(fig. 4.14) and 603.9±47.4g in contrast to the control’s 545±46.6g at nineteen weeks 
(P<0.01) (fig. 4.15).  
 
Previous experiments have shown that metformin is successful in promoting weight 
loss in humans through inhibition of food intake and a reduction in the rate of glucose 
absorption through the intestine (Paolisso et al., 1998). However once again the 
subjects used for the experiment were obese and obese diabetics, which was not the 
case with the Wistar rats. Other work done by Suzuki et al., (2002), using Wistar rats, 
showed that they displayed a slight weight increase after being administered a dose of 
300mg/kg per day of metformin. Many studies have been undertaken involving 
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metformin, most of which show the drug promoting weight loss, however it is 
important to note that these studies involved obese subjects.  
 
The kankerbos weight increase is also significant throughout the experiment; 
538±25g compared to the control’s 488±27.5g after ten weeks (P<0.005) (see 
fig.4.14) and 599.4±35.3g in comparison to the control’s 545.4±46.6g after nineteen 
weeks (P<0.01) (see fig. 4.15). Photos of kidney fat pads were taken at the time of 
sacrifice in order to record any visible differences in fat distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: A kidney fat pad of a typical control rat after 19 weeks of medication 
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Figure 4.17: A kidney fat pad of a typical metformin rat after 19 weeks of medication 
 
 
Figure 4.18: A kidney fat pad of a typical kankerbos rat after 19 weeks of medication 
 
 
Figure 4.19: A kidney fat pad of a typical amitriptyline rat after 19 weeks of medication 
 
Figures 4.16 to 4.19 show the difference between typical kidney fat pads for the 
different treatment groups. As can be seen in figure 4.17 the kidney fat pad of the 
metformin rat is much larger than that of the control rat, seen in figure 4.16. The fat 
pads of the kankerbos rats were also larger than the control group as can be seen in 
figure 4.18, they were however not larger than the fat pads found in the metformin 
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rats. There was not a clear difference between the fat pads of the control and the 
amitriptyline group, shown in figure 4.19. 
 
 
Figure 4.20: Intestinal fat of a typical control rat after 19 weeks of medication 
 
 
Figure 4.21: Intestinal fat of a typical metformin rat after 19 weeks of medication 
 
The fat found between the intestines of the metformin group (fig. 4.21) also displayed a 
difference in comparison to the control group (fig. 4.20). There was no clear difference 
between the intestinal fat of the kankerbos and amitriptyline groups in comparison to the 
control group (photos not shown here). There seems to be an extremely large amount of fat 
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present for the metformin group, shown by the red arrows, for both the kidney and intestinal 
fat. The excessive weight gain displayed by this group is a result of the large fat 
accumulation, displayed in figures 4.17 and 4.21.   
 
4.2.1.3. Resting metabolic rate 
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Figure 4.22: Oxygen consumed per gram body weight, per minute after 6 weeks. The flow rate 
was 0.5L/min over a period of 10 minutes. Data are the mean ± SD (n = 10) 
 
The results obtained in figure 4.22 were unsatisfactory as the time the rats were in the 
chamber was too short. The rats may have still been under some stress during this 
time leading to incorrect results. It was therefore decided to increase the time the rats 
spent in the chamber to twenty minutes. 
 
 
 
 
 
 
 
 
 
 
 - - 128 
Figure 4.23: Oxygen consumed per gram body weight, per minute after 8 weeks. The flow rate 
was 0.5L/min over a period of 20 minutes. Data are the mean ± SD (n = 10) 
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Figure 4.24: Oxygen consumed per gram body weight, per minute after 19 weeks. The flow 
rate was 0.5L/min over a period of 20 minutes. Data are the mean ± SD (n = 10) 
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Figure 4.25: Oxygen consumed per gram body weight, per minute after 18 weeks. The flow 
rate was 3L/min over a period of 40 minutes. Data are the mean ± SD (n = 6) 
 
The above results (figs.4.22-4.24) revealed no clear differences between the groups, 
even at the 19 weeks exposure period. The resting metabolic rate of the amitriptyline 
group at the 19 weeks was 0.495±0.082ml O2/g/min and that of the control group was 
0.53±0.074ml O2/g/min. Based on the results from the pilot study a difference in the 
resting metabolic rate was anticipated for the amitriptyline group, however, no 
significant differences could be demonstrated through Dunnet’s test, in any of the 
above results, due to the high standard deviations present in the data. The 
amitriptyline group did not, however, show any of the features previously displayed 
by the rats involved in the pilot study. There was not even an excessive weight gain to 
report. Reasons for this could lie in the concentration of the amitriptyline 
administered being too low. Even though it was the same concentration the rats 
received during the pilot study the dose may be a threshold one, which may or may 
not cause weight gain in an individual animal.  
 
These findings may add to the controversy about whether or not tricyclic 
antidepressants are associated with weight gain, as many contradictory articles have 
been published on this topic. Benazzi (1998) states that weight gain may not 
necessarily be due to the pharmacological effects of antidepressants, but may rather 
be an effect of recovery from depression. Reports that amitriptyline causes 
carbohydrate craving and weight gain in humans conflict with other reports that it 
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causes anorexia and weight loss. The effects of such drugs on energy balance may 
differ between a lean subject and a subject with a predisposition to obesity (Dullo and 
Miller, 1987).  
 
In some cases antidepressants have been linked with treatment of obesity through the 
aetiology of obesity. It has been shown that obesity is a result of a faulty homeostatic 
system involving a metabolic defect. Since amitriptyline’s function is to increase the 
half-life of noradrenaline, at the sympathetic nerve terminals, it is generally thought 
that it would therefore contain thermogenic properties, and would thus be associated 
with weight loss (Dullo and Miller, 1987). It is also, however, important to keep in 
mind that thermogenic drugs are not likely to be as effective in the lean as they are in 
the obese and one should be careful when choosing a subject or model. This may be 
where Dullo and Miller (1987) have been misled by their results that amitriptyline 
promotes weight loss, as it was tested on MSG induced obese mice (obesity induced 
through chemical lesioning in the hypothalamus following injections of monosodium 
glutamate during the first week of life). Since a characteristic of obesity is a 
deficiency of sympathetically released noradrenaline rather than an insensitivity of 
the receptor, and amitriptyline promotes noradrenaline release, it is possible to see 
how the drug could have promoted weight loss in the obese mouse model. 
 
The results obtained in the sensitive amitec experiment (figure 4.25) still showed no 
difference between the amitriptyline group’s resting metabolic rate of 2.39±0.16ml 
O2/g/min and that of the control group’s, 2.48±0.46ml O2/g/min. Some data 
unfortunately had to be disregarded due to instrument failure on the day of the 
experiment.  
 
Despite the many contradictions found in the literature, the authour is still confident 
that the tricyclic antidepressant, amitriptyline, is associated with excessive weight 
gain when taken over a relatively long period (three months or longer). Even though 
the results obtained in the final study contradicted this view, a trend was present in 
the pilot study, implying that there was indeed some form of weight gain associated 
with this drug. The fact that two similar experiments were run back to back and 
contradictory results were obtained adds to the contrasting results reported by 
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different authors in the literature. The dose used in these experiments was 1mg per 
day per kg body weight, which is the lowest dose prescribed. This dose level is 
usually prescribed to patients, by their doctors, and is later increased to 2mg per kg 
per day. Individuals also receive a further 0.6mg or 1.3mg per kg per day at a later 
stage, which is administered before sleep (Cooper and Gerlis, 1997). The authour 
feels certain that if a higher concentration of amitriptyline was administered to the 
rats, that a significant weight increase would have been evident. Even though the 
increased concentration of noradrenaline, associated with amitriptyline therapy, 
should cause the metabolic rate to increase, thus promoting weight loss, there seems 
to be some other factors overriding the noradrenaline effect and allowing weight gain. 
The pilot study suggested that weight gain was associated with a decreased metabolic 
rate, however this could not be proved statistically. To resolve this issue, further 
testing, involving a wide range of dose levels, needs to be investigated on obese as 
well as lean rats over an extended time period such as 3 months.  
 
No change in the metformin group’s metabolic rate is evident over any of the time 
periods either: 0.12±0.015ml O2/g/min at 6 weeks, 0.541±0.09ml O2/g/min at 8 
weeks, 0.521±0.087ml O2/g/min at 19 weeks and 2.65±0.25ml O2/g/min at 18 weeks; 
when compared to that of the control group: 0.131±0.012ml O2/g/min at 6 weeks, 
0.528±0.06ml O2/g/min at 8 weeks, 0.53±0.074ml O2/g/min at 19 weeks and 
2.48±0.46ml O2/g/min at 18 weeks. The kankerbos group does seem to be decreasing 
slightly over time, 0.515±0.08ml O2/g/min at 8 weeks and 0.488±0.0532ml O2/g/min 
at 19 weeks in comparison to the control group, 0.528±0.06ml O2/g/min at 8 weeks 
and 0.53±0.074ml O2/g/min at 19 weeks. The values seem to be consistently lower 
than those of the control group’s throughout all sampling times including the final 
one at 18 weeks: 2.1±0.46ml O2/g/min for kankerbos in comparison to 2,48±0.46ml 
O2/g/min for the control group. The results are however not statistically significantly 
different. This trend may however be the reason that this group did pick up weight 
despite the fact that they consumed less food. 
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4.2.2. Volume of Fluid Consumed and Urine Analysis 
 
The amount of urine produced, by an individual, is of course, directly related to the 
amount of fluid consumed by that individual. The amount of fluid consumed (fig. 
4.26-4.27) and the amount of urine produced (fig.4.28-4.29) are therefore shown 
together in this section and will be dealt with as an integrated aspect.  
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Figure 4.26: Volume of fluid consumed, in millilitres, by male Wistar rats after 18 weeks of 
treatment. Data are the mean ± SD (n = 10). ). * P< 0.01 and o P < 0.001 compared with the 
control group by Dunnett’s test 
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Figure 4.27: Volume of fluid consumed, by male Wistar rats in millilitres, after 19 weeks of 
treatment. Data are the mean ± SD (n = 10). * P< 0.001 compared with the control group by 
Dunnett’s test 
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Figure 4.28: Volume of urine excreted, in millilitres, by male Wistar rats after 18 weeks of 
treatment. Data are the mean ± SD (n = 10).  * P < 0.1, and o P < 0.05 compared with the 
control group by Dunnett’s test 
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Figure 4.29: Volume of urine excreted, in millilitres, by male Wistar rats after 19 weeks of 
treatment. Data are the mean ± SD (n = 10). o P < 0.05  compared with the control group by 
Dunnett’s test 
 
The significance shown for the kankerbos group’s low fluid consumption, 
32.1±3.73ml, compared to the control’s 53.2±9.04ml (P<0.001) at 18 weeks (see fig. 
4.26) and 30.4±6.5ml compared to the control’s 49.2±8.8ml (P<0.001) at 19 weeks 
(see fig. 4.27), most likely may be a result of the bitter taste associated with the 
kankerbos tea.  
 
The fact that the metformin and amitriptyline groups also consumed less fluid, 
39.6±9.25ml (P<0.01) and 43.8±14ml, respectively, compared to the control’s 
53.2±9.04ml at 18 weeks (see fig. 4.26) and 43.6±6.9ml and 45.6±12.3ml, 
respectively, compared to the control’s 49.2±8.8ml at 19 weeks (see fig. 4.27), may 
be attributed to the amount of food consumed by the different groups. The food 
administered to the rats consisted of dry dog pellets, more water would therefore be 
needed to aid swallowing, and digestion. It is then to be expected that the more food 
being consumed, as was the case with the control rats (see fig.4.7), the more water 
would be needed as well.  
 
Very low levels of glucose were detected in the urine. There was however no 
significant difference between the different groups. 
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Figure 4.30: Glucose concentration in urine after 18 weeks of medication. Data are the mean ± 
SD (n = 10)  
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Figure 4.31: Glucose concentration in urine after 19 weeks of medication. Data are the mean ± 
SD (n = 10) 
 
The fact that glucose was found in the urine is not an unusual phenomenon as small 
amounts of glucose have been known to be excreted by the kidney. Furthermore the 
glucose found in the urine, in this case, was detected by the glucinet reagent as the 
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concentration was too low to be detected by the dip sticks, the concentrations were 
not at a level of clinical concern.  
 
4.2.3. Constituents found in urine 
 
Bilirubin: 
 
Bilirubin is not normally detected in a healthy individual’s urine, however certain 
metabolites of drugs can give false positives. When red blood cells are destroyed by 
reticuloendothelial cells, the globin portion of hemoglobin is split off and the heme is 
converted to biliverdin. Most of the biliverdin is in turn converted into bilirubin, 
which gives bile its major pigmentation (Tortora and Grabowski, 2000). None of the 
rats from any group showed any signs of bilirubinuria. 
 
Ketones: 
 
The test used is specific for acetoacetic acid, in the urine, and does not detect acetone 
or beta hydroxybutyric acid. No ketone bodies should be present in a healthy 
normally fed individual’s urine, as ketones represent an indication of diabetes, 
starvation or too little carbohydrate in the diet. None of the rats had detectable 
quantaties of acetoacetic acid in their urine, except for some of the amitriptyline 
treated rats, which showed trace amounts of ketones in their urine.  
 
However it has been found that amitriptyline metabolites associated with phenols, 
dihydrodiols, glycols, and ketones may appear in the urine (Prox and Breyer-Pfaff, 
1987). This false positive was, however, not observed with all the amitriptyline 
treated rats and was also not consistent in those who displayed it. The reason for this 
may be due to the relatively low concentration of amitriptyline used.  
 
Specific gravity:  
 
The specific gravity is the ratio of the weight of a volume of a substance to the weight 
of an equal volume of distilled water. For urine usually ranges from 1.001 to 1.035 
(Tortora and Grabowski, 2000). The higher the concentration of solutes in the urine 
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the higher the specific gravity of that urine. The results obtained from the rats, in the 
present study, displayed no extreme values for the specific gravity, and were constant 
throughout the experiment, ranging between 1.015-1.030. 
Blood: 
 
The detection of even trace amounts of blood in the urine often indicates a serious 
problem and is termed hematuria. A common cause of this could be acute 
inflammation of the urinary organs as a result of disease, or irritation from kidney 
stones. Other causes include tumours, trauma, and kidney diseases (Tortora and 
Grabowski, 2000).  
 
High concentrations of blood were consistently found in the kankerbos group’s urine 
samples. This is extremely alarming as this could possibly indicate kidney damage. 
At the time of sacrifice smaller amounts of blood were also associated with the urine 
of the other groups, including the control group. However these were trace amounts 
and were only revealed after four months of treatment, whereas the blood associated 
with the kankerbos group was visible in the urine with the naked eye, too high to read 
from the urine dipsticks, and was evident even from the first urine analysis (18 
weeks).  
 
Since the urine was not caught in free flow it was not possible to check for 
contaminating bacteria which may have been causing some of the hematuria. 
However, the blood would appear, at a high concentration (visible to the naked eye), 
for a few days and then would disappear overnight, only to reappear a few weeks 
later. It was therefore thought that the blood was the result of a bladder tumour and 
not due to the presence of bacteria. The continual appearance and disappearance of 
the blood in the urine could have been the result of excessive bleeding from the 
tumour, the formation of a scab, and then the removal of the scab to initiate more 
bleeding at a later stage.  
 
At the time of sacrifice the bladders of the control and kankerbos treated rats as well 
as the kidneys were carefully removed and stored in formalin, for analysis by a 
pathologist. As there were no tumours present the pathologist suspected that there 
was damage to the glomerular capillaries of the kidneys in the kankerbos group, 
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however electron microscopy work would be needed to confirm this. Glomerular 
filtration occurs in the renal corpuscles of the kidneys across the endothelial-capsular 
membrane. Blood pressure forces water and dissolved blood components through the 
endothelial fenestrations (pores) of the capillaries, basement membrane, and on 
through the filtration slits of the adjoining visceral wall of the glomerular capsule. 
The resulting fluid is called the filtrate. Damaged glomerular capillaries become so 
permeable that plasma proteins and blood enter the filtrate and are found in the urine 
(Tortora and Grabowski, 2000).   
 
Some substances within the kankerbos tea extract may therefore be causing kidney 
damage. The substances responsible may, however, be different from the antidiabetic 
agents in the plant. The compounds responsible for the hypoglycemia observed, 
therefore need to be identified and separated from substances affecting the kidneys, 
allowing clinical application in humans. 
 
pH: 
 
The pH found in the urine was consistent for all the rats throughout the sampling, and 
was in the range of approximately pH 7.5-8. 
 
Proteins: 
 
No protein is usually detectable in the urine of normal healthy individuals, however 
there may be minute amounts present, which is secreted from the kidney. Low 
concentrations of protein was detectable in the urine of many rats from all groups at 
the 19 week sampling time. It is thought that this may be an age related phenomenon. 
The kankerbos group was consistent in showing protein present in their urine, as early 
on as the first sampling time (18 weeks). However the presence of protein in this case 
is suspected to arise from the presence of blood. The concentration of protein in the 
blood was found to be about 100mg/dL in the kankerbos group’s sample. 
 
 
 
Urobilinogen: 
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The presence of urobilinogen (breakdown product of haemoglobin) in urine is called 
urobilinogenuria. Traces found in the urine is normal, but increased urobilinogen may 
be due to haemolytic and pernicious anemia, infectious hepatitis, biliary obstruction, 
jaundice, cirrhosis, congestive heart failure, or infectious mononucleosis (Tortora and 
Grabowski, 2000). The rat urine for all the groups displayed no traces of 
urobilinogen. 
 
Nitrite: 
 
Nitrite results from the conversion of nitrate (obtained through the diet) to nitrite by 
the action of principally Gram negative bacteria in the urine. The test is very specific 
for nitrite and will not detect any other substance normally excreted in the urine. A 
colour change associated with the urine dipstick suggests a positive result and implies 
105 or more organisms per ml of urine. Nitrite levels were found to be normal for all 
rats. 
 
Leucocytes: 
 
The detection of leucocytes in the urine is a significant result and further testing 
should be performed on the individual. The presence of these white blood cells and 
other components of pus in the urine, referred to as pyuria, indicates infection in the 
kidney or other urinary organs (Tortora and Grabowski, 2000). None of the rats from 
any group showed a positive result for pyuria. 
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4.2.4. Faeces Analysis 
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Figure 4.32: Energy associated with faeces production after 18 weeks of treatment. Data are 
the mean ± SD (n = 10) 
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Figure 4.33: Energy associated with faeces production after 19 weeks of treatment. Data are 
the mean ± SD (n = 10) 
 
The energy produced in the bomb calorimeter, by the faeces, displayed no significant 
difference between the metformin, kankerbos and amitriptyline groups at either 
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sampling time; 14.46±0.63MJ/kg, 14.54±0.64MJ/kg and 14.78±0.49MJ/kg, 
respectively, in comparison to the control group’s 14.65±0.58 at 18 weeks (see fig. 
4.32) and 14.66±0.84MJ/kg, 14.4±0.67MJ/kg and 14.71±0.66MJ/kg, respectively, in 
comparison to the control’s 14.73±0.55MJ/kg at 19 weeks (see fig. 4.33). The 
metformin and kankerbos groups would be expected to produce a lower energy yield 
in their faeces, in comparison to the other groups, as they consumed the least amount 
of food and yet gained the most weight towards the end of the experiment.   
 
4.2.5. Blood glucose levels before sacrifice 
 
Figure 4.34 illustrates the fasting blood glucose concentrations for the different 
groups of rats prior to sacrifice. In comparison to the control group, all the medication 
treatments lowered the blood glucose significantly after twelve weeks. 
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Figure 4.34: Fasting blood glucose concentrations, in male Wistar rats, as a result of a 12 
weeks treatment with the medication. Data are the mean ± SD (n = 10).  * P < 0.005, o P < 
0.001, and + P < 0.02 compared with the control group by Dunnett’s test 
 
Compared to the control group, significantly lower blood glucose levels were found 
for all the treatment groups here; 3.75±0.47mM (P<0.005) for metformin, 
3.46±0.34mM (P<0.001) for kankerbos and 3.73±0.35mM (P<0.02) for the 
amitriptyline group in comparison to the control group’s 4.16±0.27mM. The 
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amitriptyline result was in conflict with that found in the pilot study at the 11 week 
time interval (see fig. 4.1). The present results clearly demonstrate that the 
amitriptyline group is also hypoglycemic, with results similar to those of the positive 
control, metformin. The amitriptyline seems to be promoting glucose uptake either 
through insulin receptor sensitivity or through some other mechanism. This may play 
a role in the weight gain associated with this drug in humans, even though it was not  
demonstrated in the present study (fig. 4.12) as a opposed to the pilot study (fig. 4.4).  
 
The kankerbos group was found to be the most hypoglycemic in comparison to the 
other groups with a significance of P<0.001 as compared to the control group. The 
fact that the kankerbos displayed apparently even stronger hypoglycemic effects than 
metformin is promising for the fight against insulin resistance in type II diabetes. 
Furthermore the fact that pinitol, which is thought to be the main hypoglycemic agent 
in the plant, is insulin independent may mean that this plant can be used in the 
treatment of type I diabetes as well (see also 1.3.6(b)3). 
 
The mechanism by which metformin brings about a state of hypoglycemia is still not 
yet fully understood. The blood glucose results obtained at the time of sacrifice are 
not displayed as they were similar to the fasting blood glucose concentrations 
obtained prior to sacrifice (fig. 4.34).   
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4.2.6. Serum Triglycerides, Cholesterol, HDL and LDL Levels 
 
Figure 4.35 displays the plasma triglyceride concentrations, which seems to be 
normal for the control group according to work done on Wistar rats by Suzuki et al., 
(2002). 
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Figure 4.35: Plasma triglyceride concentration after 19 weeks of medication. Data are the 
mean ± SD (n = 10) 
 
Suzuki et al., (2002) tested various antidiabetic drugs, including metformin, on lean 
and fatty Wistar rats. Their findings suggested that metformin played no significant 
role in lowering the plasma triglyceride levels in the rats, which is in agreement with 
the present findings; 0.53±0.052mmol/L for metformin compared to 
0.52±0.13mmol/L for the control group. A contradictory article, by DeFronzo et al., 
(1995) has shown metformin to significantly lower plasma triglyceride, HDL, LDL, 
and cholesterol levels. However it is once again important to identify the subjects 
used in the experiment, which in DeFronzo’s case were obese non-insulin dependent 
diabetic humans.  
 
As shown in figures 4.36 to 4.38 no significant differences was found between the 
serum LDL, HDL, or total cholesterol levels in any of the groups.  
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Figure 4.36: Plasma cholesterol levels after 19 weeks of medication. Data are the mean ± SD 
(n = 10) 
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Figure 4.37: Plasma high density lipoprotein (HDL) levels after 19 weeks of medication. Data 
are the mean ± SD (n = 10) 
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Figure 4.38: Plasma concentrations of low density lipoprotein (LDL) levels after 19 weeks of 
medication. Data are the mean ± SD (n = 10) 
 
4.2.7. Glucose uptake 
 
The improvements introduced after the pilot study (see 3.2.6.) were very effective. 
The use of the thermostatic water bath, for better temperature control, and running 
each sample individually allowed for smaller standard deviations and more reliable 
results. As can be seen in table 4.4 no significant differences were found between the 
test (containing insulin) and the basal (insulin free) samples.  
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Table 4.4: Glucose uptake (mM) in the absence (basal) and presence (test) of insulin 
by rat tissues after 19 weeks of treatment 
20 Seconds incubation (37oC waterbath) 
 Control Metformin Kankerbos Amitriptyline  
 Basal Test Basal Test Basal Test Basal Test 
Liver 0.868 
±0.066 
0.867 
±0.065 
0.880 
±0.056 
0.883 
±0.057 
0.875 
±0.055 
0.876 
±0.054 
0.860 
±0.046 
0.870 
±0.045 
Fat 0.843 
±0.078 
0.845 
±0.075 
0.845 
±0.058 
0.838 
±0.056 
0.857 
±0.069 
0.845 
±0.059 
0.832 
±0.049 
0.836 
±0.044 
Muscle 0.930 
±0.049 
0.933 
±0.050 
0.961 
±0.053 
0.969 
±0.052 
0.925 
±0.036 
0.929 
±0.044 
0.958 
±0.048 
0.963 
±0.054 
40 Seconds incubation (37oC waterbath) 
 Control Metformin Kankerbos Amitriptyline  
 Basal Test Basal Test Basal Test Basal Test 
Liver 0.866 
±0.065 
0.872 
±0.066 
0.878 
±0.060 
0.884 
±0.058 
0.874 
±0.058 
0.873 
±0.055 
0.861 
±0.047 
0.864 
±0.049 
Fat 0.842 
±0.079 
0.843 
±0.079 
0.842 
±0.050 
0.841 
±0.056 
0.868 
±0.072 
0.855 
±0.058 
0.830 
±0.046 
0.835 
±0.044 
Muscle 0.937 
±0.050 
0.939 
±0.051 
0.964 
±0.055 
0.966 
±0.052 
0.931 
±0.037 
0.930 
±0.042 
0.961 
±0.047 
0.966 
±0.050 
60 Seconds incubation (37oC waterbath) 
 Control Metformin Kankerbos Amitriptyline  
 Basal Test Basal Test Basal Test Basal Test 
Liver 0.867 
±0.066 
0.878 
±0.067 
0.878 
±0.059 
0.882 
±0.059 
0.872 
±0.056 
0.875 
±0.055 
0.845 
±0.082 
0.867 
±0.049 
Fat 0.845 
±0.080  
0.845 
±0.078 
0.840 
±0.054 
0.842 
±0.055 
0.861 
±0.067 
0.855 
±0.061 
0.837 
±0.048 
0.835 
±0.038 
Muscle 0.942 
±0.051 
0.940 
±0.049 
0.968 
±0.054 
0.971 
±0.056 
0.934 
±0.038 
0.932 
±0.039 
0.966 
±0.048 
0.966 
±0.046 
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Table 4.4. Continued… 
120 Seconds incubation (37oC waterbath) 
 Control Metformin Kankerbos Amitriptyline  
 Basal Test Basal Test Basal Test Basal Test 
Liver 0.868 
±0.071 
0.875 
±0.070 
0.886 
±0.061 
0.891 
±0.059 
0.882 
±0.064 
0.877 
±0.054 
0.863 
±0.048 
0.870 
±0.045 
Fat 0.854 
±0.078 
0.855 
±0.079 
0.855 
±0.057 
0.856 
±0.054 
0.874 
±0.066 
0.872 
±0.059 
0.844 
±0.043 
0.845 
±0.042 
Muscle 0.952 
±0.052 
0.952 
±0.051 
0.981 
±0.045 
0.977 
±0.055 
0.945 
±0.036 
0.945 
±0.038 
0.975 
±0.048 
0.977 
±0.050 
Values represent the mean ± SD of ten rats, each done in triplicate. 
 
The following uptake progress curves represent the percentage of total glucose within 
the specific tissue. As the exact amount of glucose in the tissue, before the 
experiment, was unknown the graphs begin at the first sampling time (20 sec.) and 
not at time zero.  
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Figure 4.39: Glucose uptake progress curves in muscle tissue for control rats after 19 weeks of 
medication. Data are the mean ± SD (n = 10) 
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Figure 4.40: Glucose uptake progress curves in liver tissue for control rats after 19 weeks of 
medication. Data are the mean ± SD (n = 10) 
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Figure 4.41: Glucose uptake progress curves in fat tissue for control rats after 19 weeks of 
medication. Data are the mean ± SD (n = 10) 
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Figure 4.42: Glucose uptake progress curves in muscle tissue for kankerbos rats after 19 of 
weeks medication. Data are the mean ± SD (n = 10) 
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Figure 4.43: Glucose uptake progress curves in liver tissue for kankerbos rats after 19 weeks 
of medication. Data are the mean ± SD (n = 10) 
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Figure 4.44: Glucose uptake progress curves in fat tissue for kankerbos rats after 19 weeks of 
medication. Data are the mean ± SD (n = 10) 
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Figure 4.45: Glucose uptake progress curves in muscle tissue for metformin rats after 19 
weeks of medication. Data are the mean ± SD (n = 10) 
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Figure 4.46: Glucose uptake progress curves in liver tissue for metformin rats after 19 weeks of 
medication. Data are the mean ± SD (n = 10) 
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Figure 4.47: Glucose uptake progress curves in fat tissue for metformin rats after 19 weeks of 
medication. Data are the mean ± SD (n = 10) 
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Figure 4.48: Glucose uptake progress curves in muscle tissue for amitriptyline rats after 19 
weeks of medication. Data are the mean ± SD (n = 10) 
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Figure 4.49: Glucose uptake progress curves in liver tissue for amitriptyline rats after 19 weeks 
of medication. Data are the mean ± SD (n = 10) 
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Figure 4.50: Glucose uptake progress curves in fat tissue for amitriptyline rats after 19 weeks 
of medication. Data are the mean ± SD (n = 10) 
 
Figures 4.39 through to 4.50 suggest that insulin played no significant role in 
facilitating glucose uptake in any of the tissues tested. Reasons for this are still 
unclear as 10x the normal physiological level of insulin was used, during the 
experiment, which should have initiated some sort of response from the various 
tissues. The insulin was made up freshly every day and was stored on ice throughout 
the entire experiment. A certain percentage of the insulin receptors may have been 
damaged during the cutting up of the tissue, leaving the tissue to be more `insulin 
resistant`.   
 
On the other hand the problem may be with the insulin itself. The insulin used for this 
experiment was human recombinant insulin produced from yeast cells. It was 97% 
pure and had a specific activity of 26U/mg. This insulin is also said to be effective on 
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all mammalian cell lines. There is, however, an amino acid difference between the 
human and rat insulins, on the A chain where Glu has been replaced by Asp at 
position 4, for the rat insulin, while three changes are apparent on the B chain of 
human insulin at positions 3, 9, and 30, which are Lys replacing Asn, Phe replacing 
Ser, and Ser replacing Thr respectively (Beintema and Campagne, 1987). These 
changes may bring about a significant divergence in insulin specificity between 
species. Although it is not possible, at present, to purchase rat insulin commercially, it 
may be necessary to test this theory with insulin produced from the stimulated 
pancreas of a sacrificed rat or insulin secreted by INS-1 cells, on rat tissue, and 
compare its activity to the activity of human insulin on the same target tissue. Species 
specificity may however not be the culprit, as the human insulin clearly did bind to 
the rat insulin receptors during the insulin degradation studies (see 4.2.8). Although 
insulin is able to be taken up by the cell for degradation at the cell’s surface through 
non-receptor mechanisims. 
 
While analysing the results during the course of the experiment it was thought that the 
insulin may not have had a long enough time to interact with the specific tissues. 
Therefore on one day the experiment was allowed to run for an extended time, taking 
the last sample at fifteen minutes. The results observed at the fifteen minute mark 
showed that large amounts of glucose uptake had occurred for both the test and the 
basal samples, but there was still no significant difference found between the basal 
and test samples.  
 
Most of the glucose uptake, for all the tissue samples tested, seemed to occur between 
times 0 and 20 seconds, with relatively little further uptake at larger incubation times 
(figs. 4.39-4.50). This also suggests an insulin independent uptake system to be 
operating.  
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Figure 4.51: Percentage of total glucose taken up in the presence of insulin during a 120 
second incubation time interval. Data are the mean ± SD (n = 10) 
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Figure 4.52: Percentage of total glucose taken up in the absence of insulin during a 120 
second incubation time interval. Data are the mean ± SD (n = 10) 
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Figures 4.51 and 4.52 give a comparison of glucose uptake between the different 
tissues during a 120 second incubation interval. It seems that the highest glucose 
uptake occurred in the muscle, then the liver followed by the fat, for both the test and 
basal samples. Even though there is a slight increase in glucose uptake displayed by 
the metformin group there is no significant difference between this group and the 
controls. Metformin was expected to increase the sensitivity at the insulin receptor, 
thereby promoting glucose uptake. However this was not the case here. This may be 
due to the human insulin used not affecting the rat insulin receptors as a result of 
structural differences. The metformin nevertheless seemed to have worked 
effectively, when considering the blood glucose results. Although metformin has 
other modes of action besides increasing insulin sensitivity, inhibition of glucose 
uptake through the small intestine could not have been responsible for the extremely 
low blood glucose levels experienced with this group. The authour therefore suspects 
that the reason for the failure to demonstrate an insulin effect in this experiment, is 
most likely due to the human insulin which was used, not being able to react with the 
rat insulin receptors as effectively, due to structural differences with rat insulin. 
 
Although it was not clear from the results, the authour suspects that glucose uptake 
was indeed higher in the basal than in the test samples for the kankerbos group. 70% 
of the rats displayed this trend but it was not as evident when an average for all the 
rats was taken. A similar trend could be seen in the pilot study (see 4.1.4).  
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4.2.8. Insulin Degradation Experiment 
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Figure 4.53: Percent insulin degraded per 100ul degradation buffer for amitriptyline treated and 
control Wistar rat groups after a 19 week trial period. Data are the mean ± SD (n = 10).  * P < 
0.05 compared with the control group by Dunnett’s test 
 
Figure 4.53 shows a clear trend that amitriptyline promotes insulin degradation when 
compared to the control group. Significant differences (P<0.05) were found at 
incubation times of 2.5 minutes and 30 minutes; 7.4±2% and 22.4±3.3%, 
respectively, for amitriptyline in comparison to the control group’s 4±2.5% and 
18.1±3.6%, respectively. The lower results obtained here can almost certainly be 
attributed to insulin resistance related to an increased age of the rats. The results 
found in the pilot study’s long exposure results (11 weeks) supported this conclusion, 
when a decrease in insulin degradation was observed for all groups with increasing 
time from 2-11 weeks (table 4.1). It can be assumed that the amitriptyline treated rats 
also experienced a very much higher level of insulin degradation earlier in their lives, 
as did the amitriptyline treated rats in the pilot study. 
 
The reason for the accelerated rate of insulin clearance, for the amitriptyline treated 
group, is unclear. It can be speculated that there is an increased number of insulin 
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receptors present on the cell surface or that there is an increased sensitivity of the 
receptor for insulin. However this possibility seems remote, as an increase in glucose 
uptake would then have been expected for the amitriptyline group relative to the 
control group, which was not the case (see fig. 4.51 and 4.52). On the other hand, it is 
possible that human insulin binding and subsequent clearance by the rat tissues, may 
not necessarily be linked to glucose uptake, which involves post-receptor events, and 
which might not be triggered by human insulin in the rat. The amitriptyline treated 
group may also have experienced a higher activity of the insulin degrading enzyme, 
thereby promoting a higher rate of insulin clearance as compared to the control group.  
 
In conclusion, it is clear that the interpretation of the observed degradation data, in the 
absence of further definitive experiments, remain highly speculative at present. 
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CHAPTER 5 
 
CONCLUSIONS AND SUGGESTIONS FOR FUTURE 
RESEARCH 
 
5.1 CONCLUSIONS  
 
5.2 SUGGESTIONS FOR FUTURE RESEARCH 
 
 
5.1 CONCLUSIONS 
 
The primary aims of the study was to compare the hypoglycaemic effects of 
Sutherlandia frutescens (kankerbos) to a well known type II diabetes medication, 
metformin; and to determine whether the tricyclic antidepressant, amitriptyline, is 
associated with excessive weight gain. A further aim of the project allowed for the 
design of an animal model, which may be used as a research tool in the future, to 
determine the metabolic effects of certain medication or herbal remedies associated 
with insulin resistance. 
 
The animal model is, in the authour’s opinion, an effective one, allowing for 
determinations of the relative metabolic factors which may play a role in disrupting 
the glycemic homeostasis of an organism.  It may, however, be necessary to 
incorporate the analysis of certain other hormones and enzymes in order to have a 
more complete model. Such expansion of the model is, however, limited by 
budgetary and practical constraints, and therefore requires the identification of 
priorities at an early stage. 
 
As a toxicological study has already been performed on Sutherlandia by Seier et al. 
(2002), and no pathogenic complications were reported, no further investigations in 
this direction were undertaken for the present study. The results pertaining to S. 
frutescens were definitive in suggesting that the plant extracts indeed possess 
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significant hypoglycemic properties. The observed lowering of the fasting plasma 
glucose levels during the pilot and final studies confirmed this (see sections 4.1.2. and 
4.2.5.). The exact mechanism for this hypoglycemic effect are as yet not fully 
understood. Results obtained from the insulin degradation experiment, during the 
pilot study, suggested that the half-life of insulin is not increased (see section 4.1.3.). 
The likelihood of a prolonged plasma insulin half-life is therefore diminished by the 
present study as a potential mechanism for the observed hypoglycemic action of the 
Sutherlandia extracts. Nevertheless, irrespective of the mechanisims involved, the 
clear demonstration of the hypoglycaemic properties of the extracts, confirmed its 
potential as an alternative antidiabetic treatment. As such an important goal of the 
present study was achieved.  
 
The weight increases experienced, with kankerbos extracts, during both studies (see 
sections 4.1.5. and 4.2.1.2.) is a disturbing factor, as excessive weight gain is 
associated with an increased insulin resistance, and may also have an effect on the 
patient’s compliance to the drug. The results obtained during both studies suggested 
that the weight gain is probably not subject to a carbohydrate craving. The weight 
gain may, however, be due to the specific action of the hypoglycemic agents in the 
plant extract. One mechanism which may be causing the excessive weight gain, in 
parallel with the hypoglycemia, may be linked to interactions involving the 
peroxisome proliferator-activated receptor-g  (PPARg). Certain extractable 
compounds from the plant may be acting as ligands for the PPARg. 
Thiazolidinediones are type II diabetic drugs on the market, which interact with 
PPARg , the exact mechanisms of action still being uncertain. Suzuki et al., (2002) has 
recently shown that thiazolidinediones play a role in the induction of adipocyte 
differentiation thereby converting large adipocytes into smaller ones. This process is 
thought to be responsible for reducing insulin resistance as large adipocytes produce 
insulin resistant related substances such as tumour necrosis factor and non-esterified 
fatty acids whereas smaller ones do not. This may be one of the actions associated 
with the plant extract. However further investigations in this direction are needed. 
 
Another mechanism for weight gain may be due to a reduced metabolic rate. 
Although no significant differences were evident, a lower metabolic rate was evident 
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with the Sutherlandia treated groups throughout both the pilot and final studies (see 
sections 4.1.5. and 4.2.1.3.). However, whether such slight decreases in the metabolic 
rate would be able to induce a significant weight increase is debatable. 
 
No significant differences were found for any of the lipoproteins, cholesterol or 
triglycerides levels as compared to controls (see section 4.2.6.). The triglyceride 
levels did seem to be slightly higher in comparison to the control group, but the high 
standard deviations did not allow any definitive conclusions to be drawn. 
 
The glucose uptake experiment still needs perfecting, although positive advances 
were made to reducing the standard deviations from the pilot study (see sections 
4.1.4. and 4.2.7.). The fact that no differences could be detected between the test and 
basal samples with regards to glucose uptake, suggests a problem related to the 
insulin having been used. The insulin may have been inactive at the time of purchase, 
or, more likely the human insulin used may not be fully compatible to the rat insulin 
receptors. Further investigation is necessary to clarify these issues before further 
uptake studies can be undertaken.  
 
Unfortunately no clear comparisons could be made between the glucose uptake 
results from the pilot study (section 4.1.4.) and those of the final study (section 
4.2.7.), due to the standard deviations encountered in the pilot study. Such a 
comparison would have been advantageous as it could have indicated whether the 
insulin used during the later study was indeed active. Two different shipments of the 
human lyophilized insulin were used for the two experiments. The results obtained 
during the pilot study do suggest a difference between the test and basal samples 
however once again the high standard deviations left a large area of doubt. 
 
The results did, however, show that the basal glucose uptake was higher in the fat 
tissue at eleven weeks, for the pilot study (section 4.1.4.). This suggests that 
Sutherlandia acts independently of insulin to lower blood glucose levels. Bates et al., 
(2000) showed that pinitol, an active ingredient of Sutherlandia, exerts an insulin-like 
effect on glucose transport that is independent of insulin. This does not preclude the 
possibility that pinitol could interact with a pathway of insulin signalling. There is 
structural similarity between pinitol and inositol phospha tes involved in the post 
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receptor signalling of insulin via the phosphatidyl inositol-3-kinase and protein kinase 
B. If pinitol provided a substrate or surrogate signal for this pathway it might increase 
glucose transport independently of insulin (Bates et al., 2000). 
 
Another area of concern lies with the excessive blood associated with the urine of the 
Sutherlandia treated group, in the main study (section 4.2.3.). As no individual urine 
samples were taken during the pilot study it is uncertain whether the rats from this 
group suffered the same symptoms. As mentioned earlier the observed hematuria may 
be a result of a damaged glomerular filtration system. No form of Bacillus species, 
found in the Sutherlandia infusion, could be responsible for this effect, and it 
therefore must be the result of an active ingredient in the plant extract. The specific 
agent may not, however, be the same agent responsible for the proven hypoglycemic 
effects of the plant. One should, therefore not be deterred by this finding until further 
investigation into this problem brings greater clarification. 
 
The fasting blood plasma glucose levels for the metformin group, during the final 
study (section 4.2.5.), confirmed the basis for the popular use of this medication 
against insulin resistance. The high values obtained at two and eleven weeks for the 
pilot study was, however, unexpected for this drug (section 4.1.2.). These results 
seemed uncharacteristically high for fasting plasma glucose levels and might have 
been stress related. The method of sacrifice, through the use of ether anaesthesia, was 
not stress free, allowing stress hormones (such as adrenaline) to possibly be secreted, 
which in turn brings about a state of hyperglycemia. The control results confirmed 
this, with relative ly high blood glucose concentrations being evident (see fig. 4.1). 
Such complications were reduced by altering the method of sacrifice and thereby 
limiting any stress factors. The blood glucose values of the control animals confirmed 
this in the main experiment.  
 
The results for the insulin degradation experiment, obtained from the pilot study 
(section 4.1.3.), suggested that metformin, like kankerbos, did not increase the plasma 
half-life of insulin. The reasons for the induced hypoglycemia therefore lie in some 
other aspect of this medication.  The exact mechanisim of action of this drug is still 
not completely understood. Certain mechanisms of action have, however, been 
suggested: 1.) increased glucose uptake into muscle, 2.) decreased hepatic 
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gluconeogenesis, 3.) decreased intestinal glucose uptake and 4.) increased glycogen 
synthase activity (Vigneri and Goldfine, 1987; Suzuki et al., 2002). 
 
The metformin treated rats from the pilot study showed the lowest weight increase 
(section 4.1.5.) contradictory to the results obtained during the final study (section 
4.2.1.2.), where this group gained the most weight. The fact that metformin exerted 
an anorectic effect during the pilot study is comparable to results obtained by Paolisso 
et al. (1998). His results suggested that obese human subjects displayed excessive 
weight loss due to an inhibition of food intake. This does not, however, seem to be 
the case here, as the metformin treated rats from the pilot study consumed the most 
food, on average (section 4.1.5.). Some other reason must be responsible for this 
weight loss as an accelerated metabolism does not seem to be the culprit either. 
Suzuki et al., (2002) found contradictory results when working with Wistar fatty rats. 
They found that rats, treated with metformin, showed a significant body weight 
increase with a slight decrease in food consumption. The results obtained by Suzuki 
and his colleagues are similar to those obtained during the final study for the 
metformin group (section 4.2.1.). 
 
The glucose uptake experiment performed during the pilot study (section 4.1.4.) 
suggested a difference between the test and basal samples for the metformin group, in 
the fat and liver samples. No clear difference was evident for the muscle sample, 
which was unexpected, as this is where metformin is believed to exert a maximum 
effect on insulin receptors (Reddi and Jyothirmayi 1992). Once again the high 
standard deviations make it impossible to draw any final conclusions. There seemed 
to be no differences between the control groups and the metformin groups, in relation 
to the test samples for the pilot study. In the final study uptake experiments revealed 
no significant differences in either the test or basal values for any tissue sample for all 
the groups including the kankerbos treated group (section 4.2.7.). Reddi and 
Jyothirmayi (1992) did ,however, stress in their studies on KK and streptozotocin 
mice, that metformin has no effect on glucose metabolism in normal mice. This 
cannot, however, be true in the present study as the rats in the final study experienced 
a state of well established hypoglycemia (section 4.2.5.).  
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The amitriptyline groups showed an increased trend in the blood glucose values 
during the pilot study (section 4.1.2.). The increased trend may have been a result of 
an increased insulin secretion, over time, resulting in insulin resistance at the eleven 
week sacrifice time. The fact that insulin degradation was elevated during the pilot 
and final studies may confirm the suspicion of an increased rate of insulin secretion 
(sections 4.1.3. and 4.2.8. respectively). The fact that the insulin degradation 
decreased over time, for the pilot study, can be attributed to a loss of insulin-receptor 
sensitivity over time.  
 
The amitriptyline treated group displayed a significant increase in body weight, 
during the pilot study, which was not induced by elevated food intake. These results 
suggest that excessive weight gain associated with amitriptyline is not attributed to 
carbohydrate craving as hypothesized by Garland et al., (1988) and Rigler et al., 
(2001). This excessive weight gain seems to be associated with a decreased metabolic 
rate, as proposed by Fernstorm (1989). 
 
The fact that the rat weight results obtained from the final study (section 4.2.1.2.) are 
contradictory to the results from the pilot study (section 4.1.5.) may suggest that the 
concentration of the amitriptyline could have been a threshold dose. Further studies 
are however necessary to confirm and explain these unexpected results. 
 
The glucose uptake experiment, from the pilot study (section 4.1.4.), show the 
amitriptyline group to have a relatively high uptake of glucose both in the presence 
and absence of insulin in the fat and liver tissues, at the eleven week sacrifice. The 
glucose uptake in the presence of insulin in the muscle also seemed to be relatively 
high. This high rate of uptake may be the reason for the excessive weight gain 
observed, however as no significant differences were evident, due to the high 
standard deviations no final conclusions could be drawn. A high uptake theory, 
however, is difficult to reconcile with the high blood glucose values, noted at this 
time period, suggesting that the tissue was unable to take up glucose in vivo.   
 
It is clear from the results obtained in the final study (section 4.2.7.) that a closer look 
needs to be taken into the methodology of the glucose uptake experiment. Great 
advances were evident from the results obtained in the pilot study, with reference to 
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the reduction of the large standard deviations. The final method was tested before the 
last sacrifice and the results obtained did suggest a slight difference between the test 
and basal results (results not shown here). This difference may, however, not have 
been large enough to compensate for the average difference between ten rats per 
group and no change was therefore evident. Although various insulin concentrations 
were looked at, in order to obtain the most effective concentration, this may have to 
be revisited. Another option is using insulin which was obtained from stimulation of 
the rat’s pancreas, with 10mM glucose, for insulin secretion experiments (results not 
displayed in this manuscript). The insulin concentration could be determined and 
glucose uptake experiments could then be run, as before, and results compared to the 
lyophilised human insulin used for the present project. This could give an indication 
of how sensitive the rat insulin receptors are to human insulin.  
 
5.2. SUGGESTIONS FOR FUTURE RESEARCH 
 
Rodents are relatively inexpensive, easy to handle, house and feed and are therefore a 
practical animal model to use for experimentation. As this project focused on the 
design of an animal model for the measurement of certain metabolic parameters in 
response to medication certain adjustments have to be made to make future studies 
more applicable. For example, testing the hypoglycemic effects of Sutherlandia 
frutescens it would be advantageous if the animals are also known to be insulin 
resistant as a result of obesity, in line with the human condition which motivates this 
type of research. 
 
There are a variety of genetically modified rodents available for obesity related 
studies, such as the ob/ob, db/db, fa/fa, tub and the Ay models. The predisposition of 
these rodents to obesity is, however, on a genetic scale which is often not the case 
with obese human individuals. Another approach which could be employed, is 
feeding rodents a high fat diet from a young age as this will create an obese rat model, 
which ultimately may lead to insulin resistance related to the excessive weight gain. 
A simple way of determining insulin resistance in the obese animals would be by 
means of an oral glucose tolerance test. This is would be a more relevant model to use 
as it is related to the obesity associated with an unhealthy lifestyle found in today’s 
society, which results from an unhealthy diet coupled to lack of exercise. 
 - - 164 
 
As obese rats are to be employed it may be necessary to monitor the leptin hormone, 
as leptin is also involved in controlling body fat storage. Peroxisome proliferator-
activated receptor-g  (PPARg) should also be monitored in studies of the S. frutescens 
hypoglycemic activity, which may depend on a plant substance acting as a ligand for 
this receptor. It may also be necessary to include an alternative positive control such 
as a thiazolidinedione, which is a new class of insulin sensitizing drug, acting as a 
ligand for PPARg. Eventually it will be necessary to isolate and identify all 
hypoglycemic agents associated with S. frutescens, and to investigate their specific 
biochemical mechanisims of action, as well-defined compounds acting together in 
crude plant extracts. 
 
As weight gain is to be monitored lean rats should be included in future investigations 
of amitriptyline. Furthermore a wide range of prescribed amitriptyline concentrations 
should be used, and the rats should be fed ad lib, as before. In addition groups of rats, 
receiving different amitriptyline concentrations, should be allowed to exercise 
regularly on a treadmill. This will determine if any weight gain associated with the 
drug can be avoided by regular exercise. Monthly oral glucose tolerance tests will 
enable one to determine if insulin resistance developes in any of the rats gaining 
excessive weight. It would also be advisable to measure leptin hormone 
concentrations regularly, and to monitor the rate of insulin secretion. 
 
The use of 14C radiolabeled deoxyglucose has been suggested as an alternative 
method for glucose uptake measurements. This is an option but in the authour’s 
opinion is not necessary as the glucose oxidase reagent provides an extremely 
sensitive assay. The cost of radiolabeled glucose and accompanying reagents is also 
inhibitory. 
 
The measurement of plasma insulin levels is also necessary when working with 
insulin resistant obese subjects. A decrease in the plasma insulin levels in response to 
the insulin resistance treatment will provide a positive result in combating insulin 
resistance. Rat insulin ELISA kits are available for this purpose, they are however 
extremely expensive. 
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The suggestions put forward do seem to be extremely labor intensive. These 
parameters are however necessary in order to obtain a complete animal model and to 
better understand the biochemical mechanism(s) of action associated with the 
hypoglycemic effects of S. frutescens and the proposed weight gain accompanied by 
amitriptyline therapy. 
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